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A review of the body of knowledge has provided an insightful overview of the significant 
strides taken in the field of multiple sclerosis. For instance, the literature has made clear the 
considerable impact this autoimmune disease can have on an individual and how treatment can 
modulate the processes that underline this condition. However, this review equally highlighted 
an absence of literature exploring the experiences of both relapsing-remitting multiple sclerosis 
and disease-modifying treatment. It is in this context that this thesis is based. That is, this thesis 
sets out to address this gap in theoretical and clinical practice by employing a methodology 
and method that would discern individual accounts on the experience of being diagnosed with 
relapsing-remitting multiple sclerosis and the experience of taking disease-modifying 
treatment. 
 
Guided by a qualitative research design, semi-structured interviews were undertaken with six 
participants and analysed using Max van Manen’s hermeneutic phenomenological method. For 
participants diagnosed with relapsing-remitting multiple sclerosis, the analysis organised the 
discerned themes around four lifeworld existential elements: Bodily Interruption, Fatigue, and 
Psychological Distress (corporeality), Guilt and Power Imbalance (relationality), Secrecy 
(spatiality), and Death (temporality). Subsequent themes were discerned in relation to the 
experience of taking disease-modifying treatment: Body Object, Decision Dilemma, Pain, 
Reformulated Life, and Complementary and Alternative Medicine (corporeality) and Future 
Orientated (temporality). These themes, serving as navigators, discerned the manner in which 
a diagnosis permeated everyday living so that an individual’s experience of themselves, of 
others, and of the world became scientized. Equally, how this encounter with medical 
terminology influenced treatment decision making and views pertaining to the future. 
The discussion addressed the complexity associated to a diagnosis of relapsing-remitting 
multiple sclerosis (before, during and after) and provided an understanding as to why 
individuals supplement disease-modifying treatment with complementary and alternative 
medicine. With this in mind, specific recommendations were suggested: (i) clinicians should 
give more attention to relapsing-remitting multiple sclerosis as a relational and lived 
phenomenon, (ii) clinical practice should include discussions surrounding complementary and 
alternative medicine, and (iii) future research should be developed to the point that the 
principles of evidence-based disease-modifying treatment practice can be applied to 
complementary and alternative medicine treatment. 
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This chapter presents an overview of multiple sclerosis. The intent is to situate the reader into 
the complex nature of this autoimmune disease in a manner that is digestible. By developing 
an understanding, the reader is supported in appreciating the burden and consequences of the 
disease. To meet these endeavours, consideration is equally given to the evolution of treatment. 
At this point, a question around the effectiveness of treatment may arise in the reader. The 
answer is a simple one. There is no curative treatment owing to the heterogeneity, chronicity, 
and limited understanding of disease progression. The intention is to summarise treatment 
evolution so that an exploration of disease-modifying treatment and specific agents, namely, 
alemtuzumab, dimethyl fumarate, ocrelizumab, and peginterferon beta-1a can be pursued. The 
reason for specifying these agents is not arbitrary. It is important to point out here, and as shall 
be presented in chapter three, these agents were those which were prescribed and experienced 
by the research participants. 
 
1.1  Multiple Sclerosis 
1.1.1 Multiple Sclerosis  
 
“Multiple Sclerosis is what a good clinician would call Multiple Sclerosis.”  
John Kurtzke (1974) 
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The often-cited historical landmarks of multiple sclerosis (MS) resemble a tapestry interwoven 
by a sequence of observations, breakthroughs, and scientific developments. Whilst it is beyond 
the scope to present here the fabric of that tapestry from paralysis to paraplegia sclérose en 
plaque disseminée, a comprehensive history is provided by Murray (2005).  
 
The earliest recorded description of a case of MS dates back to 1421. Aged sixteen, Saint 
Lidwina of Schiedan (1380-1433) displayed a prognosis consistent with MS having fallen and 
broken a rib whilst ice-skating. Later, Sir Augustus d'Este (1794-1848) documented his own 
twenty-six-year undiagnosed experience of ill-health that emerged after a bout of measles. In 
his diary, he recorded experiencing fatigue, visual impairment, numbness below the waist, and 
a progressive loss of motor control (Milo & Miller, 2014). Shortly afterwards, the Scottish 
pathologist Robert Carswell (1793-1857) in the Atlas of Pathology (1838) identified lesions in 
the spinal cord but did not attribute the detected lesions to MS. As an early illustrator, he wrote 
“a peculiar disease state of the chord and pons varolii, accompanied with atrophy of the 
discoloured portions” (1838, p.110). In the same period, the French anatomist Jean Cruveilhier 
(1791-1874) put forward the pathological features of ‘disseminated sclerosis’ having studied 
the case of a female patient who presented with dysphagia, spasms, visual impairment and 
weakness in her limbs. However, according to Murray (2006), it is the German pathologist 
Friedrich von Frerichs who can be regarded as having made the first diagnosis of MS in 1849. 
This “brilliant correctness of diagnosis” (Reese, 1950, p.1471) was later authenticated by his 
student Valentiner in 1856. Most recognisably, it was Jean-Martin Charcot at the Salpétrière 
Hospital in Paris who embarked on the study of human demyelinating disease. Charcot made 
definite the association between symptomatology and the pathological changes in this disease 
through research published in 1868, and in later published lectures and clinical presentations. 
He understood this disease as “sclérose en plaques disseminées”, “la sclérose multiloculaire” 
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and “la sclérose generalisée” (Charcot, 1868a; 1868b; 1872; 1875; 1886; 1887). As these 
terms were translated, the German term multiplen sklerose arose. Translated into English, 
multiple sclerosis became widely accepted following the publication of the landmark text 
Multiple Sclerosis (McAlpine et al., 1955). Specifically, the term sclerosis means 
scars/scarring, and which denotes the damage inflicted onto the nerves by MS. Multiple refers 
to the frequency of occurrence in various areas of the central nervous system (CNS).  
 
Throughout this thesis and notwithstanding the rich history conceptualising MS (Talley, 2004), 
the term multiple sclerosis has been applied for continuity. This has been the case even in 
reference to the work of contributors who may themselves have adopted alternative terms.  
 
1.1.2 Pathophysiology, Symptoms and Classifications 
Pathophysiology 
MS is an autoimmune, inflammatory, demyelinating and neurodegenerative disease of the CNS 
(D’Amico et al., 2016; Reich et al., 2018). Why these characterizations transpire is a mystery. 
The general rubric that has pervaded literature is that “for some reason, the body fails to 
recognize the myelin [sheath] as its own and destroys it” (Beaumont, 2008, p.161). Myelin 
which is considered to be the protective coating around the nerve axon (part of a nerve cell 
which transmits nerve impulses away from the cell body) is damaged by autoreactive T-cells 
(a component of the adaptive immune system) (see Figure 1.) which cross the blood-brain-
barrier. The subsequent events culminate in demyelination which leads to the slowing, 
disruption and/or blockage of action potentials travelling through the nerve axon (Calabresi, 
2004; Compston & Coles, 2008). Another key element is the long-term level of demyelination. 
Subsequent remyelination is not uncommon and to a certain degree can explain the remission 
that may occur after a relapse. Yet, it is in this respect that remyelinated nerve axon(s) can be 
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understood as operating as normal as symptoms clear, but studies have shown conduction to 
be slower than normal (Murray, 2005). Consequently, the demyelination and remyelination 
patterns result in sclerotic plaque(s) that develop in various regions of the CNS. Therefore, 
according to Compston and Coles (2008), over time MS develops as a disease of chronic 
neurodegeneration rather than acute pathological inflammation. However, the debate remains 
as to whether a single mechanism is exclusively accountable for instigating disease 
pathophysiology or whether various mechanisms occur simultaneously. 
 
Figure 1. Illustration of the pathophysiology in MS. 
 
Symptoms  
Presenting a comprehensive account of the signs and symptoms of MS would neglect the 
difficulties associated with the intricacies of individual symptom recognition. In the absence 
of such information, symptoms in virtually every advanced case of MS can be the direct result 
of “nerve axon conduction issues secondary to demyelination, responses to acute relapse, or as 
a long-term consequence of previous demyelination and axonal injury” (Burke, 2019, p.25-
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26). According to McAlpine et al. (1955), commonly affected sites to produce symptoms are 
the optic nerves, the cervical portion of the spinal cord and the brainstem. This symptomatology 
can vary greatly, occur in isolation or in combination, be the result of a sudden relapse or as 
part of a steady progression (Crayton & Rossman, 2006; Newland et al., 2016).  
 
Clinical manifestations of MS are dependent on the anatomical site affected by demyelination 
but will typically include disturbances of the visual pathway (e.g., acute optic neuritis), sensory 
disturbances (e.g., cortical sensory loss), paroxysmal symptoms (e.g., trigeminal neuralgia), 
autonomic nervous system symptoms (e.g., bowel and/or bladder dysfunction), motor 
disability (e.g., fatigue), and disturbances of cognition. Clinical manifestations researched 
frequently are neuropsychiatric’ symptoms (Compston, 2005; Mitolo et al., 2015; Motl et al., 
2008). For instance, Garfield and Lincoln (2012) implicated a role of depression, low levels of 
self-efficacy, and stress to increase the possibility of anxiety amongst people with MS (PwMS). 
Equally, studies have shown fatigue to be a common experience for PwMS (Bakshi et al., 2000; 
Capone et al., 2019; Krupp, 2003). Specifically, research has shown fatigue to affect up to 80% 
of PwMS (Leocani et al., 2008; Tur, 2016) and can be regarded as the most disabling symptom 
(Capone et al., 2019). Other studies have highlighted MS-related fatigue to be complex, 
multidimensional, poorly understood (Smith et al., 2013) and a constantly paralyzing force 
(Newton et al., 2016). 
 
At this point, whilst a detailed exposition of MS symptomology is beyond the scope of this 
thesis, readers are advised that many symptoms are often not noticeable. Therefore, symptoms, 
at times, are expressed as “hidden” or “invisible”, which often leads to conceivable 




Although the course of MS is variable, two distinct phenotypes can be discerned; the 
progressive phenotype (including primary-progressive MS and secondary-progressive MS) 
and the relapsing phenotype (including progressive-relapsing MS and relapsing-remitting MS) 
(see Figure 2). 
 
Primary-Progressive MS (PPMS)  
PPMS affects 10%-20% of the overall MS population (Miller & Leary, 2007; Milo & Miller, 
2014; Tsang & Macdonell, 2011) with an average onset age of forty years (Kamm et al., 2014). 
In short, PPMS is characterized by a gradual uninterrupted decline of neurological functioning 
from symptom onset without distinct exacerbation and/or relapse occurrence (Lublin et al., 
2014; Talbot, 2010). 
 
Secondary-Progressive MS (SPMS)  
In the relapsing-remitting phenotype, neurological sequelae from relapses results in incomplete 
recovery and accrual of disability over time (Compston & Coles, 2008; Rovaris et al., 2006). 
In contrast, the hallmark of SPMS is an “initial relapsing remitting disease course followed by 
progression with or without occasional relapses, minor remissions, and plateaus” (Lublin & 
Reingold, 1996, p.907–11). With this in mind, Tremlett et al. (2008) have suggested that SPMS 
occurs approximately twenty years after the onset of relapsing remitting MS. 
 
Progressive-Relapsing MS (PRMS) 
As the least prevalent phenotype of MS, PRMS is characterized by a progressive deterioration 
of neurological functioning from symptom onset, a subsequent superimposed distinct acute 
relapse with or without full recovery, and a continuous disease progression in-between phases 
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of relapses (Tullman et al., 2004). It is believed further disability is accrued due to incomplete 
recovery from acute relapse and/or exacerbation (Lublin & Reingold, 1996). 
 
Relapsing-Remitting MS (RRMS) 
Based on research, RRMS affects 85% of PwMS (Castro et al., 2020) and is commonly 
diagnosed between the age of eighteen and forty years (Compston & Coles, 2008). This 
phenotype of MS is characterized by unpredictable relapses often evolving over days to several 
weeks before a resumption to baseline (before the relapse) functioning and followed by periods 
of stable neurological functioning (i.e., symptomatic remission) (Lublin et al., 2014). 
Typically, recovery from a relapse and a resumption to baseline functioning occurs over a 
period of four to eight weeks (Sorensen et al, 2014). However, uncertainty, variability and 
incompleteness remain common. Compston and Coles (2008) have reported that a new relapse 
can arise unpredictably but seldom arise more than once to twice per year. It is worth 
recognizing that relapses are defined as a “patient reported or objectively observed event 
typical of an acute inflammatory event in the CNS, current or historical, with duration of at 
least twenty-four hours, in the absence of fever or infection” (Polman et al., 2011, p.293). 
 
Alternative phenotypes of MS are known based on clinical features, pathological and imaging 
appearances, and aetiological considerations. For instance, benign MS (BMS), clinically 
isolated syndrome (CIS), radiologically isolated syndrome (RIS), single attack progressive MS 
(SAPMS), and transitional MS (TMS). With these phenotypes in mind, a study by Lublin et 
al. (2014) proposed a reclassification based on a relapsing or progressive path, either active or 
inactive disease, and either progression or non-progression. However, this is yet to be 
universally adopted.  
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Figure 2. Classification and clinical course of multiple sclerosis based on two distinct phenotypes: the 
progressive course and the relapsing course (adapted from Lublin & Reingold, 1996). 
 
 
1.1.3 Prevalence and Epidemiology  
The worldwide prevalence of MS is estimated to be 2.3 million (Brownlee et al., 2016). This 
prevalence entails the traditional ‘latitudinal gradient view’ (i.e., increased prevalence farther 
from the equator) which varies from less than 5/100,000 in low-risk areas (i.e., most of Africa 
and Eastern Asia) to more than 100/100,000 in high-risk areas (the ‘continental gradient view’) 
(i.e., Northern and Central Europe, North America and South-Eastern Australia) (Pugliatti et 
al., 2002; Sahraian et al., 2012). Similarly, Benito-León and Bermejo-Pareja (2010) support 
the prevalence of MS being increased in the Mediterranean Basin.  
 
In the United Kingdom, accurate data relating to the number of PwMS remains limited. The 
MS Society estimate there to be 110,000 PwMS in the UK and approximately 5,200 newly 
diagnosed individuals per year. These figures indicate a prevalence of 190 cases per 100,000 
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of the population. Interestingly, McKenzie et al. (2014) attempted to decipher these prevalence 
trends. Based on data from 2010 and earlier and by coupling primary care and hospital activity 
records, the researchers’ estimated there to be 126,669 PwMS in England in 2010. What this 
meant was that there was a prevalence of 203 per 100,000 and 6,003 new diagnosed cases at a 
rate of 9 per 100,000 of the population. However, these focal trends were based on records in 
which an element of doubt concerning diagnosis existed and hence vulnerable to factors such 
as the marked variability in symptoms and the subsequent influence on diagnosis. This critique 
levelled against the findings of McKenzie et al., (2014) can be associated to the work of 
Minderhoud et al. (1988). In short, Minderhoud et al. (1988) highlight the variable nature of 
MS progression which means that there exists no common disease course. Thus, in the event 
that cases of doubt concerning diagnosis were omitted, the resulting number of PwMS in 
England would be 110,000. 
 
In terms of epidemiology, MS prevalence has a female preponderance in that the disease was 
more than twice as common in females than males (289 and 115 per 100,000 of the population), 
females aged between thirty and thirty-nine years were three times more likely than males of a 
similar age to be diagnosed, the sixty to sixty-nine years of age group for both sexes was 
identified as having the highest prevalence, and the lowest prevalence was identified as being 
in childhood which increased after the age of twenty (McKenzie et al., 2014). Equally, 
according to researchers, MS occurred in approximately 5% of individuals before the age of 
eighteen (Lulu et al., 2016) and there was an increased prevalence in adolescents compared to 
younger children (Waldman et al., 2016). It is worth highlighting that research has implicated 
prognostic features to forecast either a poorer prognosis or an excelled disease progression. For 
instance, MS was identified as being more frequent among Caucasians (Sahraian et al., 2012) 
and although Northern and Central Europe, North America, South-Eastern Australia and New 
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Zealand contained the highest prevalence of MS (Sahraian et al., 2012), ethnicities in these 
regions appeared resistant (Flachenecker, 2006). This relates closely to studies (see Svenson et 
al., 2007; Williamson et al., 2007) which found MS frequency to differ amongst ethnicities 
living in equivalent environmental conditions. 
 
1.1.4 Causes 
Although no consensus on the cause of MS is available, an amalgamation of features ubiquitous 
to the developed world may well provide clues to understanding the initiation and development 
of MS. Polman et al. (2011) categorised these factors into microbial, viral and other infection. 
At this point, to re-iterate, the complex nature of the disease indicates toward the unlikelihood 
of MS resulting from a single causative event (Ramagopalan & Sadovnick, 2011). 
 
Microbial Infection 
It is perhaps the hallmark of MS research that microbial infection can be associated to initiating 
and developing the severity of demyelination in MS (Savarin et al., 2015). The mechanisms of 
such action can be categorised into two distinct hypotheses. The poliomyelitis hypothesis which 
proposes bacteria assimilated in either late childhood or early adulthood proliferates the 
probability of MS (Poskanzer et al., 1976), and the prevalence hypothesis which demonstrates 
the cause of MS to be a pathogen commonly associated in populations with increased MS 
(Kurtzke et al., 1993). It is this pathogen that initiates an asymptomatic persistent infection and 
later develops into a clinical neurologic MS (Kurtzke et al., 1993). In commenting on the 
uptake of the microbial infectious agent line of inquiry, the literature has taken favourably to 
the former hypothesis in comparison to the latter (Bach, 2002; Compston & Coles, 2008; 




More recently, researchers have substantiated the departure from microbial infection to viral 
infection in determining the likely cause of MS. For instance, Gilden (2005) found above 90% 
of PwMS to have increased concentrations of immunoglobulin-G (i.e., a type of antibody) 
exhibited in the brain and the cerebrospinal fluid. Recently, Hogeboom (2015) concluded the 
lymphocytic choriomeningitis virus to be harmonious with the mechanisms of MS. Taken 




Charles Davenport (1922), in a much-cited paper, concluded with the following:  
 
“In conclusion, may I be permitted the suggestion that whatever may eventually prove 
to be the endogenous cause of multiple sclerosis, the factor of heredity cannot be left 
out of account... there are probably internal conditions that inhibit and others that 
facilitate the development of this disease or the endogenous factors upon which it 
depends and so it comes about that the manifestations or symptoms of the disease 
differ in different persons; and that they are sometimes very similar in closely related 
individuals because the hereditary factors of the constitution in which they operate 
are similar. It seems most probable that such geographical, ethnological and familial 
distribution as multiple sclerosis shows depends in part upon one or more hereditary 
factors” (p.57–58).  
 
Against this backdrop of a hereditary influence, Robertson et al. (1996) found a 2.77% relative-
risk in first-degree relatives, a 1.02% relative-risk in second-degree relatives, and a 0.88% 
relative-risk in third-degree relatives in comparison to a 0.3% relative-risk to the wider 
population. By carrying this line of inquiry to its logical next step, the study by Ebers et al. 
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(2004) corroborated with these findings by highlighting the cause of MS to be influenced by 
the gender of the affected family member. 
 
An association that has diminished over the past decade yet remains relevant is that of the 
gestational environmental influence on MS. A study showed a greater MS prevalence for 
individuals born in May and a lessened prevalence for those born in November, within the 
northern hemisphere (Willer et al., 2005). Studies (see Marrie, 2004; Steelman, 2015) have 
equally shown environmental toxins (i.e., exposure to solvents) to induce MS. For instance, 
investigations exploring the effects of toxins on MS susceptibility and disease progression have 
evidenced a correlation between smoking and a probability of conversion to SPMS (Ascherio 
& Munger, 2007; Marrie, 2004; Pugliatti et al., 2008; Wingerchuk, 2012).  
 
Psychoanalytical Theory 
The psychoanalytical and psychodynamic approach has offered an alternative contribution to 
the study of chronic illnesses. That is, chronic illness is approached from the view that 
unconscious processes influence personality functioning and it is these processes that are also 
associated to psychological distress. Alternatively stated, and in contrast to the nosological 
view, focused is placed on tracing illness to its origins and understanding what is ‘behind’ the 
overt signs and symptoms (Kernberg, 1988). It is theorized that from “the early stage of 
development, an individual experiences life in peculiar ways that will progressively determine 
their identity, including attitudes, coping strategies, cognitive processes, and relational 
dynamics” (Conversano et al., 2020, p.1). Conceptualising illnesses in this way has facilitated 
an understanding of the link between the body and the mind and a detection of cyclical 
relational patterns. For instance, studies have indicated toward a role of personality in the 
development and progression of psychopathological and organic diseases (see Boldrini et al., 
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2019; Catalano et al., 2019; Martino et al., 2020). Studies have equally explored how 
personality characteristics can increase the risk of somatic diseases or an individual's general 
susceptibility to diseases (see Denollet et al., 1995; Horwood et al., 2015). Research on 
individuals who use mature defense mechanisms, “defined as the use of high-adaptive 
defensive strategies that lead the individual to the best adjustment and possible resolution of 
internal and external stressors” (Conversano et al., 2020, p.1), have reported higher physical 
and psychological functioning (see Paika et al., 2010; Petric et al., 2011; Perry et al., 2015; Di 
Giuseppe et al., 2019). Conversely, maladaptive defense mechanisms, “defined as a 
combination of immature defensive strategies activated to keep the individual unaware of 
experiencing unmanageable feelings, desires, and thoughts” (Conversano et al., 2020, p.1), 
have been shown to predict ill-health and acute clinical conditions (see Beresford et al., 2006; 
Bortolato et al., 2017; Hyphantis et al., 2011, 2013a, b; Hyphantis et al., 2016; Conversano et 
al., 2020). 
 
Speculation influenced by psychoanalytical and psychodynamic theory has also emphasised 
the necessity of recognizing the coexistence of organic and psychological distress. For instance, 
the biography of Augustus d'Este raises the question of whether emotional arousal over the 
death of a close relative might be related to the abrupt beginning of ophthalmological 
symptoms. Equally, Charcot (1872) considered the possibility of psychological trigger 
mechanisms in MS. Specifically, his work indicated toward a possible association between 
grief, worry, and adverse changes in social circumstances possibly being causally linked to 
disease onset. A limited number of reports continued with this line of inquiry. The article titled 
Observations on the Psychoanalytical Treatment of a Patient with Multiple Sclerosis by Leon 
Wallace (1975) investigated a patient with MS which followed the formal investigations by 
Jelliffe (1921) who reported the psychoanalytical treatment of his MS patients. Jelliffe (1921) 
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suggested that stress could produce cerebrovascular alterations which might be etiologically 
related to plaque formation (Al-Afasy, Al-Obaidan, Al-Ansari, Al-Yatama, Al-Rukaibi, 
Makki, Suresh, & Akhtar, 2013). In addition to the exact mechanistic pathway of this 
relationship not yet being clearly understood, VanderPlate (1984) argued that “with few 
exceptions, early psychoanalytically-orientated studies adopted small samples subject to 
selection bias, employed no standardised objective measures, and drew conclusions about 
“premorbid personality” and emotional disturbance in MS patients not fully warranted by the 
data. Few if any conclusions can be drawn for these studies concerning psychological issues in 
MS” (p.256). 
 
Attempts to consider organic disability as representative of a psychological trauma that may 
lead to responses that are ordinarily considered neurotic are also available. For instance, 
neurotic conflicts between dominance and submission which expressed themselves as 
neurological symptoms have been studied (see Langworthy, Kolb, & Androp, 1941; 
Langworthy, 1948; Langworthy, 1950). As have individuals who could develop organic 
disability in the context of protracted emotional arousal (see Braceland & Giffin, 1950) or 
anger (see Grinker, Ham, & Robbins, 1950). Given that the primary objective of these studies 
was to describe personality patterns and psychopathology, the general conclusions were that 
individuals with MS evidenced a high degree of psychopathology and a hysterical personality 
structure. Other investigators focused on delineation of a uniform MS personality, ‘premorbid’ 
psychological characteristics, or emotional response to the disease (VanderPlate, 1984). 
Nevertheless, given that the evidence to support the association between affective response and 
MS-related variables is not well understood, few conclusions can be drawn from these 
investigations. Rather, the consensus believed by most investigators is that psychological 
response is a complex interaction with wide individual differences. 
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1.1.5 Diagnosis 
The challenges associated with diagnosing MS have been well documented (Poser et al., 1983). 
In the context of this thesis, specific reference is given to the McDonald Criteria of 2017 (see 
Table 1) which reflected the developments in MS evidence, knowledge and practice. According 
to Mantero et al. (2018), the McDonald Criteria enabled clinicians to; diagnose MS earlier, 
increase treatment initiation, reduce the risk of disease progression, and identify MS more 
effectively than previous clinical classification systems allowed. For those interested, Rudick 
(2011) has outlined both the benefits and drawbacks of this contemporary classification system. 
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No curative treatment for MS is available owing to the heterogeneity, chronicity, and limited 
understanding of the underlying processes causing disease onset and progression. Therefore, 
treatment strategy is an area of significant debate. In principle, treatment can either influence 
symptoms, lessen the occurrence and severity of relapse(s), or reduce brain lesion accumulation 
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(Stüve & Racke, 2016). Accordingly, treatment strategy can be categorised into either; disease-
modifying treatment (DMT) or symptomatic treatment (SMT). The purpose of DMT is to 
refashion the pathological process underlying MS in a bid to reduce relapse frequency and 
disease progression (Cree, 2007; DeLuca & Nocentini, 2011). Conversely, by attending to the 
symptoms caused by MS activity, SMT attempts to; address the symptoms associated with MS 
lesion location and/or activity, reduce the occurrence of relapse(s), preserve neurological and 
individual function, and to promote quality of life (Brunton, 2005). 
 
Other 
Stem Cell Treatment 
Another trend of MS treatment developed over the last twenty years but remains in its infancy 
is stem-cell treatment (SCT). For those interested, a thorough exploration of the intricacies of 
SCT is provided by both Pluchino et al. (2009) and Scolding (2011). Stem-cell trials (see 
Atkins et al., 2016; Burt et al., 2015; Liao et al., 2016; Nash et al., 2015) have identified rates 
of MS free survival to be between 60% and 80%, which is far greater than established 
treatment. However, of note is the low number of participants in these trials. 
 
Alternative Treatment 
Based on the inefficiencies of both DMT and SMT, alternative forms of treatment are 
frequently utilised (DeLuca & Nocentini, 2011). For those interested, a substantial review of 
these can be found in the work of Bowling (2011). Often referred to as complementary and 
alternative medicine (CAM) (Claflin et al., 2018), CAM extends to several types; cannabis 
(Novotna et al., 2011; Rezapour-Firouzi et al., 2015), physical exercise (Doring et al., 2011; 
Khan et al., 2008a; Khan et al., 2008b; Taylor et al., 2007), psychological-intervention (Mohr 
et al., 2000; Lincoln et al., 2000; Thomas, et al., 2006) and diet (below). Interestingly, the 
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findings of Claflin et al. (2018) corroborated with previous studies (see Farinotti et al., 2007; 
James et al., 2013; Olsen 2009) in questioning the overall efficacy of CAM. These forms 
deserve further consideration. 
 
Diet  
Epidemiological data has pointed toward a potential effect of vitamin-D (as an 
immunomodulatory agent) on the clinical course of MS. In a study by Mosayebi et al. (2011) 
on Iranian PwMS, a six-month vitamin-D intervention was devoid of effect on both symptoms 
and gadolinium-enhancing lesions in comparison to the control group. However, six-months 
afterwards, not only was the concentration of cell proliferation significantly reduced 
subsequent to the vitamin-D intervention in comparison to the control group but the levels of 
transforming growth factor-beta and interleukin-10 in the treatment group were found to be 
significantly higher than the control group. These findings warranted further investigation as 
they provided a preliminary indication toward vitamin-D being a useful addition to treatment 
as an add-on. Soilu-Hänninen et al. (2008) examined the effectiveness of vitamin-D (as an add-
on) in combination to interferon beta-1b (IFN-β1b) and found a reduction in the number of 
lesions following intervention. However, no effect was found on MS burden and MS disease 
accumulation.  
 
Two alternative dietary interventions; biotin and ginkgo biloba have also been studied. For 
thirteen treated PwPMS, disability progression (as measured by the Expanded Disability Status 
Scale) was reduced following the administration of a high-dose biotin intervention in 
comparison with placebo. In a follow-up, the biotin intervention-maintained efficacy and the 
safety profile was parallel to that of placebo. In contrast, study results for the ginkgo extract 
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found no significant effect on neurological functioning compared to placebo (Lovera et al., 
2012). 
 
Other CAM include a polyunsaturated fatty acids (PUFA) supplementation in combination 
with a ‘hot-natured diet’ (originating from customary Iranian medicine in which a ‘heating’ or 
‘cooling’ effect is applied to food) (Rezapour-Firouzi et al., 2015). The study identified the 
PUFA intervention, both with and without a ‘hot-natured diet’, to reduce the relapse rate and 
reduce disability in PwRRMS over a six-month period (Rezapour-Firouzi et. al., 2015). 
However, drawing conclusions from these findings can be troublesome as Rezapour-Firouzi et 
al. (2015) did not provide a statistical comparison between the intervention and control group. 
 
1.2 Disease Modifying Treatment  
1.2.1 Disease Modifying Treatment  
The history of DMT for MS can be separated into three phases. In the first era (1993–2003), 
investigations concluded “that intensive immunotherapy could alter the course of MS, and that 
MS exacerbations could be treated with intravenous methylprednisolone” (Ransohoff et al., 
2015, p.2). Distinctively, the second era (2003–2009) was marked by the approval of 
Natalizumab and Fingolimod (Cohen et al., 2010; Kappos et al., 2006; 2010). Natalizumab 
(brand name Tysabri®) “is a humanized monoclonal antibody which binds to α4β1-integrin” 
(Hutchinson, 2007, p.1) and inhibits leukocytes from entering the brain via the blood-brain 
barrier. Conversely, Fingolimod (brand name Gilenya®) is an immunomodulatory and 
immunosuppressive which bind to the receptors of sphingosine-1-phosphate in order to reduce 
MS activity. By the third era (2009–present), various DMT agents were available for the 
relapsing phenotypes of MS; interferon beta-1a (IFN-β1a), IFN-β1b, mitoxantrone, 
natalizumab, glatiramer acetate, fingolimod, dimethyl fumarate, teriflunomide, alemtuzumab, 
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pegylated interferon beta-1a and daclizumab. For the purposes of consideration, the mechanism 
of action and form of administration of some of these agents have been highlighted (see Table 
2.). Ultimately, the emergence and availability of agents of DMT provide insights into the 
complexities involved in deciphering disease progression and treatment.  
 
In summary, an overview of MS has been provided whilst giving consideration to agents of 




Table. 2. The mechanisms of action and administration of alemtuzumab, dimethyl fumarate, 

















This chapter presents a background and rationale for this thesis. To begin with, an introduction 
to the search strategies implemented in identifying the literature relating to relapsing-remitting 
multiple sclerosis (RRMS) and disease-modifying treatment (DMT) is provided. Next, whilst 
drawing attention to the vast strides that have been undertaken in understanding the lived 
experience of people with multiple sclerosis (PwMS), emphasis is placed on explicitly 
identifying the literature that is pertinent to this thesis. By acquiring a detailed understanding 
of the literature, the argument is then made that it is possible to discern a gap in the body of 
knowledge which requires filling. Therefore, making this thesis a timely and relevant piece of 
work. At this point, the chapter provides a rationale for this thesis. To support this rationale, it 
is necessary to explicate and contextualize this thesis’ contribution and relevance to the practice 
of counselling psychology. With this all-in mind, the chapter concludes with a statement on 
the aims of this thesis and the associated research questions. 
 
2.1 Literature Search 
This literature review attempted to synthesise the body of knowledge into two fields: (i) the 
lived experience of RRMS and (ii) the lived experience of taking DMT. The task of collating 
both quantitative and qualitative research studies began with accessing the following databases: 
 
• EBSCO (2001 - present) 
• Elsevier (2001 - present) 
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• Google Scholar 
• PubMed (2001 - present)  
• Science Direct (2001 - present) 
• Scopus (2001 - present) 
• The Cochrane Database (2001 - present) 
The search strategy involved the following terms (either singularly or in pairs):  
• Multiple Sclerosis OR Primary-Progressive Multiple Sclerosis OR Secondary-
Progressive Multiple Sclerosis OR Progressive-Relapsing Multiple Sclerosis OR 
Relapsing-Remitting Multiple Sclerosis 
• Disease-Modifying Treatment OR Disease-Modifying Therapy OR Disease-Modifying 
Therapies 
• Experience OR Lived Experience        
The retrieved studies were confined to those available in English and those which stemmed 
back twenty years. The reasons for which are as follows. As mentioned (see 1.1.5 Diagnosis), 
this thesis incorporated the McDonald Criteria (2017) due to this classification system 
reflecting the developments in MS evidence, knowledge and practice. Therefore, given that the 
McDonald Criteria was originally published in 2001, this thesis aspired to capture relevant 
research papers which may have classified PwMS using either the 2017 or 2001 classification 
system or even the revisions of 2005 and 2010. On the same line, the search for DMT literature 
corroborated with the third era of DMT availability (see 1.2.1 Disease-Modifying Treatment). 
 
2.2 The Lived Experience of Multiple Sclerosis 
Since 2001, a body of knowledge emerged which took a committed stance toward exploring 
the experience of individuals afflicted by MS. For example, Toombs (2001) provided 
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invaluable phenomenological insights through documenting her own experience of living with 
MS. Through an exploration which began in 1988 and later in 1990, 1992, and 1995, Toombs 
eloquently portrayed the spatial distortions shaped by living in a wheelchair. Such portrayals 
suggested that her experience of MS was primarily a disturbance of the lived body rather than 
a dysfunction of the biological body. That is, how “features of embodiment as bodily 
intentionality, primary meaning, contextural organization, body image, gestural display, lived 
spatiality and temporality, are disrupted” (Toombs, 1988, p.201). Indeed, it was this heightened 
sense of deeper meaning that made the lived experience of MS accessible to a wider audience. 
Yet, efforts to produce more contemporary work were required (Burke, 2019). 
 
Several studies have provided meaning and discernment into the lived experience of MS. As 
per the literature, these sources point to a dynamic personal quest for mastery over the 
unpredictable disease course. Often, by beginning with the question of ‘what was it like to have 
symptoms of an illness and then to be told you have MS?’, studies have shown that this quest 
begins prior to receiving a diagnosis. For example, Isakkson and Ahlström (2006) reported this 
initial experience varied from ‘disablement and death’ and to a ‘nuanced picture of MS’. That 
is: 
“the conception of MS before diagnosis in this patient group was mostly traumatic in 
nature, independent of earlier experience or knowledge. Statements about being 
bound to a wheelchair, being handicapped, or dying from MS emerged when the 
patients described their image of MS before diagnosis” (Isakkson & Ahlström, 2006, 
p.230). 
As the initial symptoms were experienced, these were related to the theme ‘becoming 
vulnerable’ which caused emotional distress. Isakkson and Ahlström (2006) reported that as 
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participants attempted to decipher what was happening to them, several experienced ‘anxiety, 
fear, shame, mistrust, and anger’. Others coped by maintaining a ‘distance and hoping for the 
best’. Being informed of the diagnosis was discerned to be a prominent part of the participant 
narratives. This was characterised by the theme ‘from vulnerability to acquired strength’. 
Furthermore, this experience gave way to more deepened emotions of ‘uncertainty, loss of 
identity, abandonment, and confirmation’. Although these findings resemble those identified 
by other studies (see Johnson, 2003; McCabe, 2005) and are salient, they are not inevitable.  
 
The interlocking nature of the vicissitudes of ordinary life and the complex lived experience of 
MS was reported in another study based in New Zealand. Clair (2003) made a telling 
contribution to the emerging conceptualisation of the lived experience of MS which had so far 
been characterised by pre-conceptions of MS, a transitory relationship with initial symptoms, 
an intrusion to the harmony between the body and the self, and diagnosis causing an identity 
renegotiation. Claire (2003) reported the theme ‘MS as a guest’ which referred to the disease 
resembling: 
“having an unwelcome houseguest… although the woman did not invite the illness 
in, once it was there, she needn’t make a fuss but just gets quietly on with her usual 
day in the hope that the illness will fit into her usual occupational routine” (p.49-50). 
At the same time, MS was discerned to be an ‘adversary’. That is: 
“rather than feeling like it should be a fight, illness can inspire the person to overcome 
the obstacles to doing the things they want and need to do. In these stories the women 
described needing to be mentally strong in order to stay on guard to the challenge 
especially when it could present itself at any time” (p.50).  
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Given the significance of these contributions, it merits noting that these narratives were 
elaborated and embedded in rich imagery and metaphor and engaged in intuitive story making 
and storytelling. For instance, a lived experience was described as “it was like living in the 
twilight zone. You sort of keep it at bay… but it is like having the crew of the Marie Celeste 
in your hot water cupboard. That is what it is like, that is exactly what it is like. Who knows 
when they will pop out and see you?” (Clair, 2003, p.50).  
 
More recently, Al-Sharman et al. (2018), in their phenomenological paper titled Living with 
Multiple Sclerosis: A Jordanian Perspective, summarized their reported themes into two main 
categories; disease-related experiences and experiences related to the healthcare system. 
Experiences of the former related to ‘physical decline’, ‘psychosocial withdrawal’, and a ‘fear 
of the future’. On this latter theme, a ‘difficulty of diagnosis’, ‘lack of awareness’, and ‘poor 
communication and rapport with healthcare providers’ was reported. In the authors’ view, this 
was “the first study that investigated the daily living experiences and challenges of Jordanian 
individuals with MS … [The study has] discussed a wide range of issues that represent the 
lived experiences for living with the disease… such knowledge would provide a background 
to hidden aspects of human concepts, such as culture, perception, perspectives, attitudes, and 
opinions about chronic diseases” (Al-Sharman et al., 2018, p.6). Such a claim can equally 
provide insight into the prevalence and epidemiology of MS worldwide (see 1.1.3 Prevalence 
and Epidemiology). 
 
So far, this chapter has discerned some ideas about the lived experience of MS. These ideas 
consist of transitory relationships with initial symptoms, an intrusion to the harmony between 
the body and the self, diagnosis causing identity, relations, and future plans to be renegotiated, 
and individual attempts to create or maintain a progressive narrative in the face of MS. Such 
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ideas provide a complementary source of themes to that generated by other studies (see 
Evanson et al. 2001, Koopman, 2003; Kroll & Neri, 2003; Maclurg et al. 2004). Before carrying 
this elucidation to its logical next step, it is important to highlight some of the limitations of 
the presented studies. In commenting on the study by Al-Sharman et al. (2018) and by 
considering the geographical region and the associated cultural implications, questions can be 
raised relating to the applicability of the findings to the western world. Equally, according to 
Metcalfe (2008), the implication of splitting the participants into groups to facilitate 
unrestricted dialogue might have been impeded by cultural underpinnings which prevent 
females from discussing certain elements of their experience in the presence of males. By 
taking into consideration the recruitment of sixty-one participants in the study by Isakkson and 
Ahlström (2006), it is important to remember the “bewildering array” (Toombs, 1995, p.7) of 
symptoms and that each PwMS follows a unique disease course (Minderhoud et al., 1988) (see 
1.1.2 Pathophysiology, Symptoms and Classifications). Therefore, it seems in practice and in 
terms of applicability that the study design created by Isakkson and Ahlström (2006) can be 
brought into question. As can the researchers’ decision to not disclose the phenotypes of MS 
of the recruited participants.   
 
The body of knowledge has benefitted from studies exploring the individual, the individual 
experience, and the individual relationship with MS (see Finlay, 2003; Fawcett & Lucas, 2005). 
For example, Finlay’s (2003) combination of a case study approach and an existential-
phenomenological method (Ashworth, 2003; Giorgi, 1985; Valle & Halling, 1989) marked a 
departure from the previous literature. Yet, it was similar in the sense that the study commenced 
with the question: ‘what is living with MS like for you?’. The study’s agency is evident in that 
Finlay (2003) contributed to the literature by reporting the subsequent themes: sense of self, 
intersubjectivity and life projects being experienced as threatening and individual identity 
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being reclaimed through living a ‘normal’ present life. In short, such themes provide a 
complementary source of understanding as the findings are generated through alternative 
research methods.  
 
Fawcett and Lucas (2005) similarly employed a case study approach to explore a female 
participant’s journey with MS. That is, from symptom onset to the potential challenges that lay 
ahead. The following was discerned through the analysis of the data. Firstly, healthcare 
professionals (HCP), in specific reference to nurses, perform an integral role in the care and 
experience(s) of PwMS. For example, the recruited participant shared how her initial positive 
experience was overcome with a felt sense of being a “major inconvenience” as HCP strove to 
“get through the clinic” (Fawcett & Lucas, 2005, p.48). Secondly, on the same line, 
understanding the meaning PwMS attribute to their experience “can facilitate the role the nurse 
and other healthcare professionals can play” (Fawcett & Lucas, 2005, p.51). Thirdly, a crucial 
element to the experience of the participant was accessibility to information and support. This 
latter finding corroborated with that of the study published by Embrey (2005).  
 
In critique, there is reason to tread with caution which both studies do not neglect to add. On 
the one hand, the respective researchers and the research participant were united in friendship 
prior to undertaking the study. And so, it can be said that this was beneficial to the research 
process in that it may have aided to the transparency between the two parties. On the other 
hand, the relationship may have introduced bias and assumed knowledge into the interviewing 
process. Perhaps, it is for this reason that drawing definite conclusions from both studies can 
prove to be a challenge. Nevertheless, the case study approach has elucidated the experience 
of MS to be grounded in lived relations. That is, “through the intertwining, body, self and 
world” (Finlay, 2003, p.176). 
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2.3 The Lived Experience of Relapsing-Remitting Multiple Sclerosis  
A common thread uniting the qualitative research explored so far is the non-disclosure of the 
phenotype of MS. By attesting to the view that knowing the phenotype of MS is invaluable to 
understanding the lived experience, this chapter continues by synthesising the retrieved studies 
relating to the experience of RRMS specifically. 
 
In her paper titled the Experience of Young Adults Living with RRMS, Beshears (2010) adopted 
a Heideggerian phenomenological method (Heidegger, 1959) which was supported by three 
subsidiary questions, namely, “for young adults, what is the meaning of changes that might 
have occurred since the RRMS diagnosis”, “how do young adults make meaning of the 
expectations that others have of them while living with RRMS”, and “how do young adults 
learn new ways of being during periods of exacerbations” (p.20). The following themes were 
reported: “wishing for an opportunity to talk to others like me, finding that nobody really 
understands what it is like, wanted to know more about RRMS while not wanting to know too 
much, seeing life through a new lens, realizing that living with RRMS involved uncertainty, 
coming to know that RRMS can be scary, discovering that RRMS is frustrating, realizing that 
planning is important to help maintain a sense of control” (Beshears, 2010, p.80).  
 
In the view that each PwRRMS has their own tapestry of symptoms to master, Beshears (2010) 
similarly to other studies (see Courtney et al. 2009; Fawcett & Dean, 2004; Forwell, et al., 
2008; Holland et al., 2009; Howarth, 2000; Ward & Winters, 2003) recognised the variable 
nature of this common phenomenon. With this in mind, Beshears’ (2010) provided a rich 
contribution to the lived experience of RRMS. That is, the vantage point offered by her study 
was that previous literature had not reported the theme of ‘seeing life through a new lens’ which 
captured how young adults with RRMS found “joy in being able to walk, and …recognizing 
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what is important in life” (Beshears, 2010, p.118). Equally, although the ‘inverse association 
between knowledge and duration of the disease’ reported by Beshears (2010) was consistent 
with previous studies, she went one step further by reporting that PwRRMS sought to learn at 
their own pace. That is, PwRRMS sought to maintain a sense of control over particular facets 
of their experience. However, the following limitation points to an intrusion upon the overall 
inferences that can be elicited from the work of Beshears (2010). With specific reference to 
demographics, the recruited participants from a rural region of northeast Missouri and central 
Illinois, were married. Therefore, the themes reported may only be applicable to those females 
in a similar geographical and relational set-up. But, of course, delimiting the sample in this 
way was beneficial to understanding experiences that were yet to be explored. 
  
A later study (see Pretorius & Joubert, 2014) incorporated a thematic analysis (Braun & Clarke, 
2006) to extend the body of knowledge. The authors reported the following main themes and 
subthemes: ‘challenges (main theme); diagnosis, daily life, invisible illness, and medical aid 
schemes (subthemes)’ and ‘resources (main theme); social support, mobility aids, religion, and 
knowledge about multiple sclerosis (subthemes)’ (Pretorius & Joubert, 2014, p.5). 
Interestingly, these themes corresponded with findings from other studies. For instance, the 
subtheme ‘diagnosis’, captured not only the majority of participants response to being 
diagnosed which ‘varied between shock and devastation’ but how one female participant 
experienced a positive reaction as it enabled her to understand ‘what was wrong with her’. 
Other emotions which remain embedded in the experience is that of ‘shock and devastation’ 
which was supported by findings reported by Barker-Collo et al. (2006) and Malcomson et al. 
(2008). In addition, the findings reported by Pretorius and Joubert (2014) evidenced that an 
insufficiency in the communication between the participants and HCP resulted in damaging 
encounters in terms of the former experiencing a lack of support. Such findings have been 
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reported by Barker-Collo et al. (2006), Edwards et al. (2008), Johnson (2003), and Thorne et 
al. (2004). Notably, Dalton and Gottlieb (2003) delineated rather succinctly vulnerability 
initiating strength in instances in which the PwMS felt supported by HCP.  
 
Although the study by Pretorius and Joubert (2014) substantiated important elements 
pertaining to the lived experience of MS, limitations with their study can be discerned. Similar 
to a previous study (see Beshears, 2010), the study findings cannot be generalised to the wider 
population. That is, those residing outside of Western Cape, South Africa. On the same line, 
for some participants, sharing their experience of the diagnosis process may have been 
inaccurate due to the time frame between the diagnosis and the research interview. Equally, the 
argument can be made that adopting a thematic analysis can mean interpretations lacking a 
deeper sense of meaning and a lack of consistency between discerning themes in relation to the 
lived experience (Smith, 2010). Finally, again, it is unclear which themes apply to which 
phenotype of MS. 
 
Most recently, Burke (2019) explored the lived experience of PwRRMS. Specifically, the aim 
of her research was to answer the following research question: ‘what is the experience of living 
with RRMS?’. For Burke (2019), the objective was to explore these experiences along the life 
trajectory which once taken into consideration would lead to MS nurses having a ‘deeper 
understanding’ of PwRRMS. By adopting a thematic data analysis method (Braun & Clarke, 
2006), eight primary themes and over seventy subthemes were reported. It is worth recognizing 
that this unusually high number of themes in a single study makes it difficult to contextualise 
features of the lived experience of RRMS. The primary themes included: ‘piecing together the 
puzzle (i.e., understanding what is happening); (re) defining me now that I have RRMS; 
battling the demons (i.e., facing fears and emotions); surplus suffering (i.e., suffering inflicted 
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by HCP); high (in)visibility; taming the beast; the DMT dance (i.e., DMT decision-making); 
and holding hands with hope’ (Burke, 2019). Notably, the theme ‘taming the beast’ represented 
a commitment to shape life so that it is expressive and personally significant. That is: 
 
“a time where they start to conquer the demons they have battled since suffering their 
first RRMS symptoms, a time where they have gained some experience living with 
the disease and now have some knowledge about what RRMS actually is and is not. 
It is a time for positive change, for the beginnings of acceptance, sourcing the best 
support, sharing tips, gaining confidence and for recognising the incredible things 
they have achieved… Taming the Beast brings life firmly into the foreground, 
working to be a person living with RRMS, not an RRMS person. Evolution is key to 
this theme, as the nature of RRMS means that change is always potentially around 
the corner and nothing is static” (Burke, 2019, p.264). 
 
With respect to the insightfulness of the themes reported, the study presented with two 
overarching limitations. As with the case in previous studies, the findings by Burke (2019) are 
confined to those living in New South Wales, Australia. Therefore, the themes may not be 
generalizable to women outside of the context of this study. Equally, questions can be raised 
over the method of inquiry employed. According to Braun and Clarke (2006), as a method, 
thematic analysis identifies and analyses’ themes from a dataset. With this in mind, whether 
this analysis can discern deeper interpretations can be debated. For Willig (2012), thematic 
analysis often lacks “an interpretative lens that situates the data within a wider social, cultural 




2.4 The Lived Experience of Disease-Modifying Treatment 
While much of the literature on DMT is dominated by quantitative investigation (see Boake, 
2003; Cree, 2007; DeLuca & Nocentini, 2011; Mitchell et al., 2005; Mitolo et al., 2015; Rosti-
Otajärvi & Hämäläinen, 2011; Thomas et al., 2006; Wilson, 2008), a paucity of studies 
exploring the experience of using DMT remains. In this respect and given the degree of 
attention placed on scientific investigation (see Michel et al., 2015), quantitative researchers 
can be long regarded as the vanguard of DMT literature. However, taking into consideration 
the trajectory of irreversible disability associated with MS, exploring individual experiences 
provides a way of considering matters relating to changes in health status and DMT efficacy. 
 
Qualitative studies have explored the experiences of PwMS who have been treated with 
different agents of DMT (see Lowden et al., 2014; Miller & Jezewski, 2001, 2006; Miller et 
al., 2012; van Capelle et al. 2017; van Reenen et al., 2019). In an interpretative 
phenomenological analysis (Smith et al., 2009) study of taking oral DMT, namely, 
Teriflunomide (Aubagio®) and Dimethyl Fumarate (Tecfidera®), van Reenen et al. (2019) 
identified three phases of experience. In the authors’ view, participants with RRMS oscillated 
between ‘trying to hold on to one’s familiar life’, ‘becoming familiar with one’s new life’, and 
‘being familiar with one’s new life’. In the first phase, van Reenen et al. (2019) point out that 
this experience is characterised by ‘feeling overwhelmed by insecurities, feeling obliged to do 
something, postponing the constant confrontation with being sick, experiencing support and 
reinforcement, and doing what fits best personally’ (p.4-5). They suggest that the decision to 
select DMT in an oral form is dependent on various variables: 
 
“Some people with RRMS decide right away which pill to take, while others 
thoroughly study the medication leaflets at home, carefully outweighing proposed 
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efficacy and potential side effects. Some might make an even more thorough study 
out of it, by consulting the Internet. The final choice is often based on what “fits” best 
personally and what is perceived as justifiable to oneself” (p.5). 
 
Other researchers echo these findings. Notably, Miller and Jezewski (2006) explored the 
experiences of individuals with relapsing forms of MS who self-injected glatiramer acetate 
(Copaxone®). By applying a Heideggerian phenomenological method (Kockelmans, 1989), a 
decision to choose glatiramer acetate was based on “the pros and cons of different medications, 
especially their side effects, was an important consideration in choosing a treatment regimen” 
(Miller & Jezewski, 2006, p.38). A number of other themes were reported which in many ways 
remain pertinent to the body of knowledge. These were: “self-managing care, injecting, healthy 
lifestyle, side effects, support, and advice to others” (Miller & Jezewski, 2006, p.38). 
 
Van Reenen et al. (2019) note that the phase ‘becoming familiar with one’s new life’ consisted 
of ‘awaiting bodily response, familiarizing side effects, adjusting to unpredictability, 
persevering side effects, establishing a new sense of normalcy, being committed not to forget, 
and longing for evidence’ (p.5-7). During the use of DMT agent, ‘adjusting to unpredictability’ 
was referred to as “a major obstacle interfering with daily activities” (van Reenen et al., 2019, 
p.6) which required “perseverance to give the body time to get used to the drug” (p.6). While 
a framework through which to view the experience of taking a specific agent of DMT is 
provided, a previous study has equally portrayed noteworthy conceptualisations. Miller et al. 
(2012) in a study of PwRRMS receiving natalizumab (Tysabri®) reported five theme 
categories: “quality of life, switching to natalizumab, uncertainty and fear, avoidance, and 
social support” (p.40). Notably, the researchers’ observed that: 
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“Uncertainty and fear are inseparable concepts and are emotions experienced by all 
of the study participants in some form. Uncertainty is unavoidable in the MS 
experience and begins with the first symptoms and diagnosis. Then there is the daily 
uncertainty as to whether the MS will bring a deterioration in function or is actively 
destroying the patient’s nervous system. Patients are never quite certain that they have 
made the right treatment decisions after weighing the benefits and risks. Fear of the 
future rings through each of the participants’ stories and appears to motivate them to 
consider stronger therapies with higher risks” (Miller et al., 2012, p.41). 
What can be discerned through findings of this nature is at times a high level of agreement with 
other literature. For instance, the complexity associated to the DMT decision making process 
was substantiated by previous literature (see Johnson et al., 2006; Lowden et al., 2014; Miller 
& Jezewski, 2001; 2006; van Capelle et al., 2017). In this respect, whilst acknowledging that 
the findings of each study provided a complementary source of impact and importance 
(Yardley, 2007), it remains important to note the uniqueness of each study. For instance, the 
study by van Reenen et al. (2019) was the primary contributor to the body of knowledge 
pertaining to the experiences of PwRRMS and oral DMT. 
 
According to van Reenen et al. (2019), the last phase ‘being familiar with one’s new life’ was 
typified by ‘finding new meaning, the self-evident use of medication, beyond evidence-based 
treatment and relinquishing control’ (p.7). This living in the ‘now’ as the new status quo had 
been reported in previous studies. For instance, Van Capelle et al. (2017) in a study of Dutch 
PwRRMS and the decision-making process associated to injectable interferon beta 1a 
(Avonex®), injectable glatiramer acetate (Copaxone®), and tablet form fingolimod (Gilenya®) 
reported four interrelated themes. These were “constant confrontation with the disease, 
managing inevitable decline, hope of delaying the progression of the disease, and the 
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importance of social support” (van Capelle et al., 2017, p.4). These themes represented 
particular interpretations of the lived experience of taking DMT and from the participants 
perspective showed that starting treatment with DMT was a highly complex phenomenon.  
 
Several limitations can be associated to these studies. For instance, studies (see Miller & 
Jezewski, 2006; Miller et al., 2012) specifically reported findings relating to those individuals 
who were administered either Glatiramer Acetate or Natalizumab. Thus, it is unclear as to 
whether the experiences of PwRRMS who are administered alternative DMT agents are similar 
to those who use either Glatiramer Acetate or Natalizumab. Likewise, it is unclear whether the 
experience is similar for those who do not experience improvements in MS related ill-health 
following DMT. A generalisability limitation can be attributed to the study of Miller and 
Jezewski (2006) as PwRRMS recruited from a different geographic area (i.e., not from Western 
New York) and a different healthcare setup (i.e., not from an MS centre) may have alternative 
experiences. In reference to the recruitment process, the recruitment material employed by van 
Reenen et al. (2019) included the term ‘adherence’ which due to the normative implication the 
term bears may have deterred PwRRMS who do not follow the treatment regimen. On this 
topic of individuality, van Capelle et al. (2017) also attributed an important limitation to their 
work. That is, the recruited participants stories reflected a “situation of stability in disease 
course and medication use” (p.8). What this comes to mean is that the study findings may not 
extend to PwRRMS who encounter alterations to their DMT regimen, experience unanticipated 
progression in disease course, or treatment failure. 
 
2.5 Rationale for the study 
In light of the reviewed literature, it can be said that the experience of PwMS and PwRRMS 
has long fascinated both researchers and clinicians. Yet, in counselling psychology where 
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human beings and their experiences are viewed “as inherently dynamic, embodied, and 
relational in nature” (BPS, 2019, p.6), a relatively small volume of literature exists. It is in this 
context that this thesis attempts to arrive at a deepened appreciation of the experience of being 
diagnosed with RRMS and the experience of taking DMT. Arriving at this understanding 
would mean overcoming the limitations of previous research and acknowledging that there 
remains a diverse array of frameworks and methodologies – both neurological and subjective 
- that when integrated, can facilitate a multifaceted understanding of both RRMS and DMT.  
 
If only to aid and remind, the limitations of the previous studies were as follows. Studies (see 
Al-Sharman et al. 2018; Clair, 2003; Isakkson & Ahlström, 2006) did not report the specific 
phenotypes of MS which meant evaluating the transferability of the findings to the wider MS 
population was problematic. Although Finlay (2003) and Fawcett and Lucas (2005) captured 
the severity and unique experience of PwMS by adopting an individual case study research 
design, the limitation of transferability remained due to the respective sample size. Recent 
studies (see Beshears, 2010; Pretorius & Joubert, 2014; Burke, 2019) have offered highly 
informative insights and understandings into the lived experience of PwRRMS. However, a 
number of common limitations can be attributed to these studies. For instance, within the realm 
of demographics; in the study by Beshears (2010) all six participants were ‘white’. Whilst 
Pretorius and Joubert (2014) did not report ethnicity, generalising their findings to “individuals 
with relatively-low levels of formal education or from particularly deprived socio-economic 
backgrounds would be inappropriate” (p.11). In terms of methodological limitations, an 
interpretative lens was lacking as these studies employed a thematic analysis (Burke, 2019). 
 
The most explicated qualitative inquiries into the use of DMT over the last twenty years have 
concentrated on two themes. That of the experience of taking a single DMT agent (see Miller 
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& Jezewski, 2006; Miller et al., 2012) and the use of various DMT agents (see van Capelle et 
al., 2017; van Reenen et al., 2019). While in no way minimizing the value of single DMT agent 
studies, questions can be raised as to whether such findings are applicable to PwRRMS who 
use alternative agents of DMT. Yet another crucial question, one that has received even less 
attention in the literature, concerns the experience of using different forms of DMT (i.e., 
capsule, infusion, and/or subcutaneous injection). The prominence of the work by van Capelle 
et al. (2017) and van Reenen et al. (2019) has cast a light on this phenomenon in terms of 
understanding the experience as not purely rational and individual. However, a closer look at 
the ways in which these contributions enhance the body of knowledge reveals inherent 
tensions. Some of this tension arises from the recruitment material employed by van Reenen et 
al. (2019). Further complicating matters, was individuality. Furthermore, alterations in DMT 
regimen and the unpredictable nature of RRMS meant drawing conclusions from these studies 
could be troublesome. Nonetheless, there is little doubt that contemporary research is required 
to reflect developments in theoretical knowledge. 
 
To summarise, it is apparent that there is a need for a study into the experience of being 
diagnosed with RRMS and the experience of taking DMT. The study would aim to embrace 
the complexity of both illness and treatment, whilst seeking to analyse RRMS as a phenomenon 
of experience. By opening up the experience in this way, and introducing an alternative 
framework of researching, the study would aim to overcome the limitations of previous 
research and fill gaps in the body of knowledge.  
 
2.6 Relevance to the practice of Counselling Psychology 
According to the BPS (2017), a cornerstone of the counselling psychology profession is the 
emphasis placed on the subjective experience of the individual. This thesis attempts to align 
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itself to this principle, and to the others underpinned by the profession, by moving away from 
ill-fitting paradigms of much of the research of the last 20 years, and toward a concern for 
individual experiences and the meanings of those experiences. It is envisaged that the 
conclusions drawn from this thesis will prompt discussions surrounding the subjectivity of the 
individual, which once taken into consideration could lead to revisions and developments in 
clinical practice. At the same time, this thesis aims to contribute to the professional division by 
broadening the body of knowledge pertaining to autoimmune diseases, which up to now is 
largely dominated by quantitative inquiry.  
 
For some time now, there has been a call for an integration of counselling psychology and 
neuropsychology (Goss, 2015a; 2015b; Rizq, 2007). This thesis aspires to respond to this call 
by respecting scientific exploration of RRMS but firmly positing that this phenomenon should 
not be seen as a singular concept which exists independently. By developing this stance, this 
thesis seeks to encourage counselling psychologists interested in the uniqueness of subjective 
experiences to embark on clinical experience and research in what is currently a largely 
scientific arena, whilst remaining congruent to the profession’s commitment to the ‘scientist-
practitioner’ model (BPS, 2017).  
 
2.7 Aim of Research 
The focus of this thesis is the lived experience of being diagnosed with RRMS and the lived 
experience of taking DMT. The aim is to offer a contribution to the body of knowledge by 
answering the question of whether the current theories and studies are representative of 
PwRRMS. The attempt at answering this question is not necessarily a new phenomenon. 
Throughout its history, an abundance of literature has been characterized by innovation and 
limitation, progression and regression. Whilst researchers have continually reworked their 
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methods in light of new developments, the contemporary change in research angle in this thesis 
is purposeful. It is believed that this line of inquiry will contribute findings surrounding the 
subjectivity of the individual which once taken into consideration could lead to revisions in 
clinical practice and in the packages of care for PwRRMS. 
 
2.8 Research Questions 
The research questions for this thesis were as follow:  
  

















This chapter introduces and substantiates the adopted methodology and method. Methodology 
differs from method in that the former relates to an approach to investigating whilst the latter 
relates to technique (Silverman, 2011). Willig (2008) suggests the eventual choice of 
methodology will be directly primed by the ontological and epistemological framework 
adopted by the researcher. For that reason, this chapter emphasizes and reinforces the embodied 
ontology and epistemology. More specifically, a rationale for selecting a hermeneutic 
interpretative phenomenological method against a backdrop of alternatives is presented. Next, 
the specifics of the data collection process are attended to, namely, sampling, the inclusion 
criteria, recruitment, participants, and the interview procedure. The chapter is also driven by 
the need to make clear the process of conducting a data analysis. That is, transcription, the 
analysis process, and the relevance of trustworthiness, validity, and rigour. Following a 
declaration of the ethical considerations taken into account, the chapter concludes with a 
discussion on reflexivity. 
 
3.1 Ontology and Epistemology 
 
Ontology and epistemology are often contested. “Ontology ‘relates to the nature of the social 
and political world’ and epistemology ‘to what we can know about it’, [so] ontology is logically 
prior in the sense that the ‘it’ in the second term [the definition of epistemology] is, and can 
only be, specified by the first [the definition of ontology]” (Hay, 2007a, p.117). Dixon and 
 42 
Jones (1998) disagree. They argue ontology is grounded in epistemology. Alternatively stated, 
ontology invariably rests upon epistemological priors which permit assertions relating to the 
structure of the real world. Spencer (2000) critiques this line of reasoning on the grounds that 
escaping a theory of ontology is unattainable. Thus, the question is whether or not ontology is 
consciously acknowledged and deliberated or whether ontology is left as an implicit 
presupposition of epistemology. 
 
It would be wrong to suppose that the search for an uncontentious manner in which to resolve 
this contestation is a straightforward endeavour. However, as an alternative and whilst 
recognizing the complexity of this endeavour, a framework that is understood and used 
consistently should be made available by researchers (Willig, 2008). The framework would set 
out clearly the relationship between what can be studied (ontology) and how can we know 
(epistemology). To say that there is no way of promoting one collection of beliefs over another 
means that the framework made available highlights the held position rather than the position 
being of more significance than another (Morrow et al. 2012; Ponterotto, 2005). 
 
3.2 Ontological Framework  
Ontology, originating from the Greek ónto meaning being and lógos meaning word or study, 
places inquiry onto the “nature of existence, or being” (Mills, et al., 2009, p.630). In 
Heidegger’s (1962) writing, human beings are permanently participating in the context of life. 
Therefore, ontology is the study of the mode of being in the world which is understood as the 
tactile things of the world that human beings inhabit (Heidegger, 1962). With this 
conceptualisation in mind, positions on the ontological spectrum, namely, naïve realism, 
critical realism, and relativism (Ponterotto, 2005) are now explored. 
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3.2.1 Naïve Realism 
 
“We all start from “naive realism,” i.e., the doctrine that things are what they seem. 
We think that grass is green, that stones are hard, and that snow is cold. But physics 
assures us that the greenness of grass, the hardness of stones, and the coldness of 
snow are not the greenness of grass, the hardness of stones, and the coldness of snow 
that we know in our own experience, but something very different.” (Russell, 1962, 
p.13) 
 
Naïve realism (also known as positivism), according to Ponterotto (2005), theorises an 
observable and measurable reality to exist independent of human existence. Interestingly, the 
label ‘naïve’ appears to disparage and devalue the position even if one was to subscribe to the 
associated assumptions about knowledge production (Willig, 2012). Pring (2004) suggests a 
reason for adopting this position “might be to predict what will happen in the future or what 
would happen if there were to be certain interventions” (p.62). Naturally, criticism can be 
attributed to this position. For instance, the application of universal causal links established in 
the study of natural sciences can be difficult to replicate in the social sciences as individuals 
can have multiple perspectives and interpretations of events. Consequently, an absolute truth 
can be difficult if not impossible to determine. In response, Karl Popper suggests the valuable 
qualities of the scientific method should not be disregarded. Popper in the Logic of Scientific 
Discovery (1959) proclaims no absolute truth exists and that scientific theory cannot be 
confirmed, only falsified. But, of course, in the event that theory does not obtain the absolute 
truth and rather becomes closer to the truth, an assumption remains that theory is objective and 
reflective of reality. Despite Popper’s (1959) rebuttal in relation to this discussion, naïve 
realism was deemed incompatible with the aim of this thesis. Applying a methodology 
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conventionally adopted within the natural sciences into the social sciences being the point of 
divergence.  
 
3.2.2 Critical Realism 
 
“All theories about the world are seen as grounded in a particular perspective and 
worldview, and all knowledge is partial, incomplete, and fallible.” (Maxwell, 2012, 
p.5) 
 
Critical realism (also known as post-positivism), located between naïve realism and relativism 
(Sayer, 2000), takes a step beyond naïve realism by accepting a reality to exist but “recognises 
that there are enduring structures and generative mechanisms underlying and producing 
observable phenomena and events” (Bhaskar, 1989, p.2). Subsequently, reality can only be 
known imperfectly through subjectivity, construction and interpretation. Two key criticisms 
have been attributed to critical realism. Firstly, the case can be made that what is presented 
and, therefore, talked about as extra-discursive can in fact be analysed from a relativism 
perspective. In other words, critical realism can be understood as a discursive endeavour 
meaning that material practices can be reduced to discursive practices (Edwards et al., 1995). 
Secondly, Sims-Schouten et al. (2007) make the argument that critical realism has no 
systematic method of distinguishing between discursive and non-discursive. Therefore, the 
construction of factors as one and not the other comes down to individual preference. That is, 
a preference guided by a researcher’s framework (Sims-Schouten et al., 2007). With these two 
criticisms in mind and as was with the case of naïve realism, critical realism was deemed 





“It is not that texts are more real, more singularly described than the rest of the world; 
bur rather, that the rest of the world is like text. It is all represented and interpreted.” 
(Edwards et al., 1995, p.32) 
 
Relativism (also known as constructivist–interpretivism) supposes there to be multiple, 
constructed versions of reality as opposed to a single reality (Ponterotto, 2005). If reality is 
influenced by the context of the situation, it should be known that this extends to individual 
experience and perception, the social environment and the interaction. Guba (1990) takes this 
one step further and indicates towards multiple interpretations of reality, locally and 
historically exclusive and incapable of being classified as correct or false. Ultimately, 
relativism presents conclusions which cannot be known for definite as none of the multiple 
realities have precedence over the other in terms of claims to represent the truth. This extension 
of relativism has invited criticism. For instance, Bernstein (1983) argues relativism is anti-
foundational as we float in an unbound world in which all are limited to a clash of opinion. 
Furthermore, Parker (1999) suggests “different realities can never be rationally assessed, and 
freedom of opinion is rendered equivalent to toleration of anything being said” (p.66-67). 
However, Edwards et al. (1995) suggest these criticisms are incorrect. In reference to “anything 
being said”, Edwards et al. (1995) state that this statement “is a variant of realism, suggesting 
merely a different arrangement of cogs in the underlying generative mechanism; relativists 
make assumptions about the world, but they also hold those assumptions to be permanently 
open to examination and critique” (p.81). With this argument in mind and the overall 
underpinning of the position, the corresponding ontology of this thesis was relativism. 
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3.3 Epistemological Framework 
Responding to the epistemological question, namely, how we can know requires consideration 
of the nature of the relationship between the knower and what can be known (Lincoln & Guba, 
1985). A method in which to access these assumptions is to ask a “series of questions such as: 
what kind of knowledge do I aim to create? What are the assumptions that I make about the 
world that I study? How do I conceptualize the role of the researcher in the research process?” 
(Willig, 2012, p.10). To arrive at an epistemological position, Willig’s (2012) 
conceptualisation is employed. 
 
3.3.1 Realism  
 
“To what degree can I trust the reporter that the research is true? To what degree can 
I believe that all possible occurrences of error were minimised rather than ‘built into’ 
the design?” (Brink, 1991, p.165) 
 
The realist position aims to capture and present an accurate and truthful account of what is 
occurring in the ‘known world’. The ‘known world’ is thought to exist independently of the 
researcher and the research participant and is underpinned by the premise that there exists 
“processes and/or patterns of a social and/or psychological nature which characterise and/or 
shape the behaviour and/or the thinking of research participants, and that these can be identified 
and conveyed by the researcher” (Willig, 2012, p.15). Furthermore, the researcher is thought 
to be capable of investigating the ‘known world’ without bias and influence and vice versa 
(Ponterotto, 2005). According to Willig (2012), the realist position can be divided into a naïve 
or a more critical distinction. The naïve realist position proclaims an associated theory of truth 
in which there is a knowable and direct relationship between what presents itself and what it 
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represents. The critical realist position varies from the naïve position in that the former is based 
on the assumption that although data can be informative of the ‘known world’, this data is 
unable to do so in a self-evident, unmediated manner. Alternatively put, the critical realist 
position requires data to be interpretated in order for the underlying structures to be accessed. 
The question then needs to be asked if either of these two distinctions are compatible for the 
purposes of this thesis. The answer was no, with the reasons as follow. Firstly, the position can 
neglect and/or diminish the interpretive potential of the data by taking research participant 
accounts at a certain value as opposed to considering the contextual and symbolic meaning and 
function. Secondly, although not always the case, conclusions can be derived that are unable 
to be justified using qualitative methods. 
 
3.3.2 Social Constructionism  
 
“In order to account for the thing(s) you find yourself and other people doing … you 
have to come up with the idea that people have a thing called personality that is 
responsible for this behaviour.” (Burr, 2003, p.21) 
 
Peter Berger and Thomas Luckmann’s influential book The Social Construction of Reality: A 
Treatise in the Sociology of Knowledge (1966) suggests the ‘known world’ is socially defined. 
Similarly, Kelly (2008) suggests the ‘known world’ is “an invention or artefact of a particular 
culture or society” (p.21). A question required to be asked is what does this mean for research 
and researchers. According to Berger and Luckmann (1966), researchers should abandon 
aspirations to gain insight into the inner experience of the research participant and/or how sense 
is made of experience in favour of understanding how research participants construct versions 
of the ‘known world’ depending upon their social context.  
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The social constructionist position can be labelled relativist (Willig, 2012). The label can be 
assigned on the grounds that brought into question is the ‘out-there-ness’ of the ‘known world’ 
and discarded is the notion that “objects, events and even experiences precede and inform our 
descriptions of them” (Willig, 2012, p.26). Thus, the social constructionist position as relativist 
conceptualises experience as “socially manufactured through human interaction and language” 
(Houston, 2001, p.846). In other words, contextual, linguistic, and relational factors combine 
to construct the ‘known world’ rather than the ‘known world’ determining how it is described 
or talked about. It remains important to remember that not all social constructionist researchers 
would label themselves as relativists (Schwandt, 2003). Radical constructionists break with 
convention and develop a theory in which knowledge does not reflect an ‘objective’ ontological 
reality, but exclusively an ordering and organization of a world constituted by a socially 
negotiated meaning. Although, advocates have different conceptualisations of this argument 
depending upon the ontological framework adopted, the assumption remains that the ‘known 
world’, no matter how it is defined, is subjective, and the thinking subject has no alternative 
but to construct what he or she knows on the basis of his or her own experience. In contrast, 
the moderate constructionists go beyond “the study of localised deployments of discursive 
resources and make connections between the discourses which are used within a particular 
local context and the wider socio-cultural context” (Willig, 2012, p.28). A difference between 
the radical and moderate constructionist position is that the former position is relativist in 
which there is ‘nothing outside the text’; whereas the later, believes that social constructions 
take place in a material world of bodies, objects, politics and economics (Hammersley, 1992). 
Having mapped out three social constructionist positions, a decision was made to opt against 




3.3.3 Phenomenology  
 
“Human beings, who are almost unique in having the ability to learn from the 
experience of others, are also remarkable for their apparent disinclination to do so.” 
Douglas Adams (1991, p.188). 
 
Etymologically, Friedrichsen and Burchfirld (1996) state phenomenology originates from two 
Greek terms phainómenon and lógos. Phainómenon, meaning that which appears, and which 
can be traced back to the Indo-European root pha connected with the idea of light or clarity, 
and lógos, meaning word or to study. In his text Being and Time (1962), Heidegger clarifies 
his conceptualisation of the term phenomenology. He suggests phenomenon means “that which 
shows itself in itself” (1962, p.51) and logos meaning “lets something be seen” (1962, p.56). 
 
“Phenomenology means: to let what shows itself be seen from itself, just as it shows 
itself from itself. That is the formal meaning of the type of research that calls itself 
“phenomenology.” But this expresses nothing other than the maxim formulated 
above: “To the things themselves!” (Heidegger, 1962, p.32)  
 
The epistemological underpinnings of phenomenology can be separated into analytical and 
continental. The former places emphasis on objectivity in terms of logic and reason and strives 
to verify truth and untruth. Meanwhile, the latter typically considers relationships “to be ‘parts 
of the larger unities’ and as properly understood and dealt with only when fitted into those 
unities” (Prado, 2003, p.10). The continental underpinning can be further separated into two 
branches: transcendental and existential. The point of divergence pertaining to the notion of 
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the epoché. That is, epoché supposes the possibility of performing a suspension of the natural 
attitude toward the world. 
 
Edmund Husserl, widely considered to be the intellectual founder of transcendental 
phenomenology, presented the epoché as an essential method for the practice of 
phenomenology. He said: 
 
“How does it become possible, thanks to the epoché, this subjectivity in its 
accomplishment, in its transcendental “conscious life,” extending into hidden 
subsoils, in the distinct manners in which it “brings about,” within itself, the world as 
ontic meaning.” (1983, p.153) 
 
This conceptualisation of the epoché was revisited and reworked until Husserl published The 
Crisis of the European Sciences and Transcendental Phenomenology (1936). There he 
describes the epoché as a method of phenomenological suspension of all naïve prejudices that 
have the givenness of the natural attitude. It extended to the suspension of all the elements of 
experience, so that phenomena can be seen as they really are. Phenomenological epoché 
represented a gravitation toward the essential structures of experiences or a construction of the 
world as it is when all judgements are suspended. 
 
“We place in brackets whatever it includes respecting the nature of being: this entire 
natural world therefore which is continually “therefore us”, “present to our hand”, 
and will ever remain there, is a “fact-world” of which we continue to be conscious, 
even though it pleases us to put it in bracket” (Husserl, 1970, p.110). 
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Whilst Husserl argued that by the use of the phenomenological epoché individuals could 
distance themselves objectively from that which was to be phenomenologically investigated, 
future philosophers disagreed. For instance, the existential branch of Martin Heidegger (1889-
1976) broke away from transcendental phenomenology due to this point of divergence. 
Although Heidegger’s description of the epoché appeared to remain tied to Husserl’s original 
conceptualisation, Heidegger (1962) changed the focus of attention from the invariant meaning 
of something to the mode of being of something. This point of divergence fashioned descriptive 
phenomenology and interpretive phenomenology. Descriptive phenomenology suggests “the 
impact of the researcher on the inquiry is constantly assessed and biases and preconceptions 
neutralized, so that they do not influence the object of study” (Lopez & Willis, 2004, p.14). By 
contrast, interpretive phenomenology viewed description and interpretation as inextricably 
linked. Analysing parts of phenomena required the phenomena to be appreciated in conjunction 
to the whole and vice versa. This circulatory process referred to as the hermeneutic circle 
suggests each and every element (may it be a word, an action, an experience) has its meaning 
only in a certain context, in a certain connection to which it belongs as a part of this whole. 
The meaning of the whole depended on the meaning of the single things as its parts. Thus, 
hermeneutics is founded on change. That is, as the world is in constant change, so are 
individuals, and subsequently, their interpretations. 
 
To further understand interpretive phenomenology, Heidegger (1962) proposed individuals are 
born and embedded into the context of the world and it is how they interpret the world which 
determines the way they are affected by it. If the world is in this constant interpretative state, 
then individuals create themselves through this interpretation. Therefore, for Heidegger (1962), 
the focus is not on studying the essence but rather studying the experience of being in the world, 
whereby contextual underlying meanings are obtained and valued through interpretation 
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(Gearing, 2004). Heidegger (1962) emphasised this point by adopting the German term 
‘dasein’. Da meaning there and sein meaning being. Dasein is a unified concept meaning that 
it cannot be viewed separately and independently of the world. According to Heidegger (1962), 
the central question of what it meant to be was a question in which being preceded an 
explanation of why, primordial in this sense. Heidegger (1962) opposed the traditional ontology 
as this central question of being was sidestepped. He referred to this ontology as a ‘substance 
ontology’. Although Heidegger (1962) argued that this ‘substance ontology’ was the most 
prevalent mode of perceiving and experiencing the world, he maintained that substances are 
not reducible to self-sufficient, independent entities.  
 
To summarise, various points of divergence have been posited, each growing from a particular 
view and assumption about the epoché. Specifically, this thesis aligns with interpretative 
phenomenology in that it moves away from acquiring an understanding of the world by simply 
determining elements. Instead, if truth was found to exist, experiencing it would be felt in a 
kind of being-ness and would be a result of a thing being understood as it was meant to be as 
opposed to an object corresponding accurately with a mental representation. With that said, 
given the importance of remaining consistent when selecting a method of inquiry, the question 
of “how can the inquirer go about finding out what he or she believes can be known” (Guba & 
Lincoln, 1994, p.108) will be explored next. 
 
3.4  Methods  
3.4.1 Qualitative Research Methods 
Various methods of performing qualitative research are available. According to Willig (2008), 
the decision to give preference to one method over another stems from a researcher’s line of 
inquiry. This line of inquiry should inform the method selected as each method will seek to 
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understand a different layer of experience (Willig, 2008). The following research methods were 
considered during the design process but were dismissed with the rationale for doing so now 
explained.  
 
3.4.1.1 Grounded Theory  
Strauss and Corbin (1998) suggest Grounded Theory (GT) aims to achieve ‘saturation’ - a 
position in which no additional themes emerge but existing themes are developed in order to 
account for known instances of a phenomena. Often the argument is held that GT is better 
suited to instances in which there is a concentration on social processes that account for 
phenomena, rather than being a method striving to obtain an understanding of individual 
experiences (Willig, 2008). With this in mind, adopting a GT approach was deemed to be 
counterintuitive to the objectives of this thesis.  
 
3.4.1.2 Discourse Analysis  
Broadly speaking, Discourse Analysis (DA) places focus on how individuals adopt language 
to construct and impose on a societal level (Burman & Parker, 1993). DA begins with the 
premise that not only is language an active agent applied to mediate but language provides a 
position and structure through which individuals are mediated (Willig, 2008). In other words, 
DA moves beyond content and examines orientation (i.e., how language can aid in negotiating 
phenomena). Due to this emphasis placed on the function of language and social processes, 
DA was ruled out as an appropriate method for this inquiry. 
 
3.4.1.3 Thematic Analysis 
According to Howitt and Cramer (2008), Thematic Analysis (TA) places an emphasis on the 
identification of themes and patterns of behavior. This process of identifying themes involves 
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the coding of data. Coding and theme development in this way places a focus on outlining 
meaning across a whole data set. With this in mind, TA was ruled out as a method as it is often 
better suited to greater samples, or in the event that the research aim, and objectives do not 
require a deeper sense of meaning to be made of individuals’ and their experiences (Smith, 
2010). 
 
3.4.2 Hermeneutic Interpretive Phenomenology 
Max van Manen followed the phenomenological tradition by reflecting the existential legacy. 
He said: 
 
“as we research the possible meaning structures of our lived experiences, we come to 
a fuller grasp of what it means to be in the world as a man, a woman, a child, taking 
into account the sociocultural and the historical traditions which have given meaning 
to our ways of being in the world” (1984, p.38).  
 
He writes further: 
 
"phenomenology does not offer us the possibility of effective theory with which we 
can now explain and/or control the world but rather it offers us the possibility of 
plausible insight which brings us in more direct contact with the world" (1984, p.38).  
 
Phenomenology in this sense attempts to trace and uncover variations of experience through 
visiting and revisiting the phenomenon to expose that which lays just behind it in a process of 
revelation (van Manen, 1990). Specifically, the heuristic approach formulated by van Manen 
(1990) advocates engaging with the data to allow the phenomenon to come to light in a specific 
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way which opposes the adherence of a set of rules or techniques (Earle, 2010; Ihde, 1986; van 
Manen, 1990). Furthermore, this heuristic approach includes interpretation which Willig and 
Bellin (2012) conceptualise as: 
 
“a movement from presupposition to interpretation and back again, whereby the 
researchers’ presuppositions (e.g., about the meaning of a word or the significance of 
an expression) are tested in the light of an evolving meaning of the account he or she 
is trying to understand and make sense of. This process has been referred to as the 
hermeneutic circle.” (p.117-118). 
 
This process described as interpretive and engaging with the phenomenon through a reciprocal 
process of dialogue with the individual is integral to the hermeneutic interpretive 
phenomenological method. With this in mind, not only does this process align with the 
corresponding ontology of this thesis but also the aim and objectives. The question is then how 
hermeneutic interpretive phenomenology should be implemented. The answer is a simple one. 
There is no method (van Manen, 1990). But, of course, van Manen, (1990) did pose the 
following steps which form the procedural organising structure: 
 
“(1) turning to a phenomenon which seriously interests us and commits us to the 
world.  
(2)   investigating experience as we live it rather than as we conceptualise it. 
(3)   reflecting on the essential themes which characterise the phenomenon. 
(4)   describing the phenomenon through the art of writing and rewriting. 
(5)   maintaining a strong and oriented pedagogical relation to the phenomenon. 
(6) balancing the research context by considering parts and whole” (p.30-31).  
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Following an explanation of the data collection procedure, an account of how van Manen’s 
method was interpreted and operationalized is provided. 
 
3.5 Procedure: Data Collection  
3.5.1 Sampling 
The following describes the composition of the participant sample and the recruitment 
procedures.  
 
3.5.2 Inclusion Criteria 
Eligible participants satisfied the following criteria: either gender; aged eighteen or above; a 
diagnosis of RRMS according to the McDonald Criteria of 2017; and to have taken a DMT 
agent either in capsule, infusion, and/or injection form. Applicable DMT agents included but 
not limited to: Alemtuzumab (Lemtradaâ); Natalizumab (Tysabriâ); Ocrelizumab 
(Ocrevusâ); Dimethyl Fumarate (Tecfideraâ); Fingolimod (Gilenyaâ); Glatiramer Acetate 
(Copaxoneâ); Ocrelizumab (Ocrevusâ); and/or Peginterferon Beta-1a (Plegridyâ). Those 




A Recruitment Poster (see Appendix 1) pertaining to the research, the inclusion criteria, and 
the researcher’s contact details was advertised via; noticeboards at local Community Centres 
(i.e., physical centres); Social Media platforms (i.e., Facebook, Twitter, and Instagram); and 
through user forums available via the National MS Society. Individuals’ wishing to take part 
in the study contacted the researcher directly via email or telephone. Following an agreement 
of meeting the inclusion criteria and providing an initial consent to participate, a research 
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interview was scheduled and agreed at a convenient time for both parties. All interviews were 
undertaken between October and November 2019 via an online platform, namely, Skype.  
 
3.5.4 Participants 
Six participants (see Table 3.) were recruited from across England for this study. In order to 
preserve confidentiality and anonymity (see 3.10 Ethics), pseudonyms were utilized and detail 
intentionally restricted. 
 
Table 3. Participants’ Profile 
 
3.5.5 Interview Procedure 
 
In preparation for the data collection phase, pilot interviews were conducted so that an ability 
to ask open-ended questions whilst building rapport, gaining trust, and exploring different 
aspects of the phenomena could be developed. According to Kvale and Brinkmann (2009), 
pilot interviews enable plans to be put in place for difficulties should they arise. With this in 
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mind, two pilot interviews with non-participants were undertaken. These interviews resulted 
in the development of possible probes and prompts to facilitate elaboration (discussed below) 
and participants having an opportunity to provide feedback on the interview platform, namely, 
Skype, which was deemed to be suitable. 
 
Before the interview commenced, participants were presented with a Participant Information 
Sheet (see Appendix 2). Given that an interview of this kind may be regarded as a co-
determined interaction, Kvale and Brinkmann (2009) suggest creating and employing an 
interview schedule. An interview schedule, designed to guide rather than dictate, for an 
articulated adult should last between forty-five to ninety minutes in duration and contain 
between six and ten open questions along with prompts (Kvale & Brinkmann, 2009). In 
corroboration with commonly associated symptoms of RRMS (see 1.1.2 Pathophysiology, 
Symptoms and Classifications), a flexible interview schedule with economically selected open-
ended questions was adopted (Paterson & Scott-Findlay, 2002). At the interview, participants 
were provided with an opportunity to ask questions about their involvement in the study after 
which they were presented with the Informed Consent (see Appendix 3). The Informed Consent 
explained how information derived from participation would be disseminated and stored. Each 
participant was provided with; (i) details of the researcher’s position; (ii) an explanation of the 
aim of the research and interview; and (iii) a detailed description of the confidentiality protocol. 
Participants were encouraged to abstain from disclosing information in the interview, which 
could lead to the identification of a third party. In the event they needed to make reference to 
a third party, they were asked to adopt a pseudonym. At this point, participants were again 
encouraged to ask questions and then invited to sign the Participant Information Sheet and the 
Informed Consent. Data collected from each participant pertained to information relevant to 
the inclusion criteria, as well as information relating to the participants’ profile (see 3.5.4 
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Participants). With consent, audio recording of the interview began. Interviews, all of which 
were audio-recorded, contained up-to seven openly phrased questions. Each participant was 
allowed time to provide full answers and in the event that this was not possible the use of 
probes and prompts facilitated this process. For example, all participants were posed the 
question: can you tell me about your experience using DMT? The probes and prompts were as 
follows; can you describe your experience of using DMT. What things could you do before 
and/or after DMT? Can you tell me anything about your experience that has been successful 
and/or difficult? The effect of the questioning on the participant was continuously monitored 
throughout the interview process by remaining vigilant to deviations in participant non-verbal 
behaviour. None of the participants presented with discomfort during or after the interview. 
Following the completion of the questioning, participants were provided an opportunity to 
deliberate and reflect on the process and invited to ask questions. Additionally, participants 
were debriefed with the assistance of the Debrief Information Sheet (see Appendix 4) and 
encouraged to make use of the contact details of the external agencies provided as a result of 
their participation, if required. 
 
3.6 Procedure: Data Analysis  
3.6.1 Analysis Process 
The analysis process reflected an interpretation of van Manen’s (1990) framework which meant 
incorporating four reflective methods: immersion into the lived experience, composing textual 
portrayal, phenomenological thematization, and reflective writing. Immersion into the lived 
experiences was facilitated by listening to the audio files and reading the transcripts. 
Immediately, the urge to do something was contained, as was suspending understanding. 
Receptivity was the position sought. Having read and listened to the transcripts as a whole, 
each transcript was read again. This time with a focus on each sentence, line-by-line. Van 
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Manen (1990) termed this the ‘selective reading approach’ whereby thoughts, questions, and 
comments related to RRMS and DMT are marked in the margin to capture pre-understanding. 
Here, pre-understanding is in reference to the already held understanding of the phenomena 
and includes, among others, presuppositions, traditions, expectations and hopes in relation to 
the research (outcome). Next, composing textual portrayals meant identifying experience-
based descriptions that would form the foundation of the analysis. A textual portrayal referred 
to a fragment of text that described elements of the experience in language that spoke to the 
readers imagination and provided insight into the phenomena. In commenting on this process, 
it should be noted that the textual portrayals did not necessarily follow each other 
chronologically in the transcript. And so, at times the content structure was changed in an 
attempt to construct a more evocative phenomenological narrative. The textual portrayals 
reflected the phenomenological thematization (i.e., structures of the meaning of the 
experiences). To that end, and for purposes of clarity and coherence, the phenomenological 
themes were arranged in accordance with existential life worlds (van Manen, 1990). That is, 
corporeality, relationality, spatiality, and temporality (van Manen, 1990). The themes were 
finalized by means of reflective writing. 
 
3.6.2 Trustworthiness, Validity and Rigour 
As Finlay (2008) argues, trustworthiness, validity and rigour are key components to qualitative 
research. This is very much consistent with the criteria that can be used to assess such 
components, namely, “sensitivity to context, commitment and rigor, transparency and 
coherence, and impact and importance” (Yardley, 2000, p.180-183). The first dimension (i.e., 
sensitivity to context) can be established through multiple means. For instance, sensitivity to 
the relevant theoretical literature, the sociocultural context, and/or the participants’ 
perspectives. In the context of this thesis, sensitivity was demonstrated through the selection 
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of the hermeneutic interpretative phenomenological method as a means of honouring the 
experience of each participant and through promoting a respect for the quality of data emerging. 
Maintaining such sensitivity throughout the interview process is integral as Stern (1985) argues 
“there can be no fixed criteria for establishing truth and knowledge, since to limit the criteria 
for truth would mean restricting the possibilities for knowledge” (p.217). In a related vein, the 
second dimension (i.e., commitment and rigour), is suggestive of the need for an extended 
engagement with the research study, methodological competency, immersion into the data, and 
a demonstration of delving beyond the descriptive account into a detailed analysis (see 3.6.1 
Analysis Process). According to Yardley (2000), the third dimension (i.e., transparency and 
coherence), “describes the “fit” between the research question and the philosophical 
perspective adopted, and the method of investigation and analysis undertaken” (p.222). Various 
endeavours were undertaken to underline the clarity of the proposed argument and transparency 
of methods. For example, the development of the interview schedule was responsive to the 
input from both the pilot interview participants and the research director of studies. The realm 
of the fourth dimension (i.e., impact and importance), emphasises the manner in which study 
results can be applied theoretically, socio-culturally, and practically. For Yardley (2000), 
“there are many varieties of usefulness, and the ultimate value of a piece of research can only 
be assessed in relation to the objectives of the analysis, the applications it was intended for, 
and the community for whom the findings were deemed relevant” (p.223). In the context of 
this thesis, an alternative theoretical method of understanding the experiences of being 
diagnosed with RRMS and taking DMT was proposed. Not only is it envisaged that this may 
provide an original contribution to the body of knowledge pertaining to RRMS and DMT, but 
the thesis offers a methodological perspective as to how a phenomenological approach may be 
applied to future research in the field. 
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3.7 Ethical Considerations  
Ethical approval from the University of East London’s (UEL) School of Psychology Research 
Ethics Sub-Committee was sought and gained prior to the commencement of participant 
recruitment (see Appendix 5). In addition, the policies and practices set out in the British 
Psychological Society (BPS) ‘Code of Human Research Ethics’ (BPS, 2014) and the UEL’s 
‘Code of Practice for Research Ethics’ (UEL, 2015) were maintained throughout the research 
process.  
 
3.7.1 Defining Ethics 
The BPS in the Code of Human Research Ethics refer to research ethics as “the moral principles 
guiding research from its inception through to completion and publication of results” (2014, 
p.5). Given the dynamic nature of ethical research practice which involves monitoring 
throughout the course of research and the nature of phenomenological studies aiming to enter 
the ‘lifeworld’ of participants, a duty of care was placed on ensuring the physical and emotional 
safety of participants. In corroboration with the ethical principle of ‘respect for the autonomy 
and dignity of persons’ (BPS, 2014), although the research study did not anticipate causing 
distress to any participant, in the event of distress being experienced, participants were verbally 
reminded of their voluntary participation and their right to withdraw. A subsequent decision to 
withdraw would be respected. 
 
3.7.2 Informed Consent  
In addition to the Informed Consent (see Appendix 3), the principles outlined by the BPS 
(2014), namely, responsibility relating to the avoidance of harm, and integrating and 
embodying honesty, accuracy, clarity, and fairness were adhered to. The principle of 
responsibility was adhered to in various ways. For instance, participants were informed that 
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they were under no obligation to take part in the research and research interview. Should they 
wish to take part, they were at complete liberty to withdraw at any time. Although no 
participant took up this option to do so, had they done so, any data provided would have been 
destroyed. Furthermore, participants were provided with an option to withdraw their informed 
consent up to three weeks after the interview by advising the researcher of their decision. In 
relation to integrating and embodying honesty, accuracy, clarity, and fairness, the informed 
consent, audio recordings, electronic interview transcripts and researcher notes were all stored 
separately in a secured location in accordance with the Data Protection Act 1998. The material 
was only available to the researcher, potentially the research director of studies, and the 
research examiners at their request. All the material would be destroyed one year after the 
thesis had been marked and the results ratified. Finally, participants were notified that the 
research would contribute toward a thesis, which would be assessed and may potentially be 
published. In the event of any publication, participants were informed that their name would 
not appear and the likelihood of verbatim, but anonymised extracts being included. 
 
3.7.3 Debriefing  
 
Participants were presented with a Debrief Information Sheet. The purpose of which was to 
notify participants’ of: (i) the nature of the research; (ii) the confidentiality protocol; (iii) their 
right to withdraw their consent to have their interview material included in the research (in the 
event a participant wished to do so they were required to inform the researcher of their decision 
within a three-week period starting from the time of the interview); and (iv) suggested support 
services that are available should the participant require them as a result of their participation 
in the study. In the event of adverse experiences to the researcher, these would be discussed 




The procedural steps intended to preserve anonymity and confidentiality were discussed with 
each participant in line with the Participant Information Sheet. In respecting such 
confidentiality, a pseudonym was assigned to each participant and any identifying information 
was intentionally removed. In addition, all consent forms were stored securely and separately 
from the audio recordings and transcribed materials. The sole responsibility for this data was 
held by the researcher. 
 
3.8 Reflexivity   
Malterud (2001) defined reflexivity as a “researcher’s background, worldview, and position 
will shape what they choose to investigate, the angle of investigation, the methods judged most 
adequate for this purpose, and the findings considered most appropriate” (p.483-484). 
Meanwhile, Alase (2017) suggested that “it is very important that a thick [and thoughtful] 
personal reflective description be included in the narrative of the research study, so that the 
audience can see for themselves the journey that the research study has gone through” (p.146-
149). By accepting these two statements, the question of how to facilitate this process emerges. 
Willig (2008) emphasised personal and epistemological reflexivity to guide this process.   
 
According to Fook and Gardner (2007) personal reflexivity can be regarded as an ability to 
discern that all elements of the researcher and their context influences the way they research. 
This can require an exploration of areas such as power, inequality, gender in addition to 
discerning how assumptions, values, emotions and so forth can influence the research process 
(Finlay & Evans, 2009). By pursuing this line of inquiry, questions naturally arise. Can a 
researcher suspend their judgement(s) in the research process? Who is a researcher in front of 
the research participant? Would becoming all accepting and understanding render a researcher 
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artificial? In doing so, would this reflect reality? Or rather, reinforce a power differential, 
perceived or otherwise. By adopting a reflexive attitude in acknowledging the possible impact 
of personal factors on the research process, an attempt (as far as reasonably possible) was 
sought to minimise the challenges and difficulties in conducting research. Firstly, identifying 
as a British-Asian researcher meant commonality with one of the six research participants. 
What was striking was the way ‘Sonal’ at times alluded to this unity. For example, in her 
account, as she talked about the importance of marriage in the culture in a condensed and 
skipping style, this concept was well understood. As was how the prospect of marriage would 
be difficult for her due to the moral fortitude, and the commitment to the principles of the 
culture. Equally, the buoyancy of spirit in which she made inferences to her conceptualisation 
of the cycle of life (i.e., birth, death, and rebirth through which the soul crosses from one life 
to another) yielded further familiarity. Secondly, undertaking clinical placements at two 
different neurological services may have made it easier for the recruited participants to be 
interviewed about their experiences since both parties were familiar and versed in the 
phenomena. Here, it may be helpful to be reminded of the words of Langdridge (2007) who 
argued that being contextually sensitive, and selecting a suitable methodology embedded in 
sound reflexive orientation, demonstrates trueness to the theoretical underpinnings of 
phenomenological inquiry. 
 
Epistemological reflexivity can refer to what is anticipated to be captured by the research, the 
assumptions made throughout the research process, and the influence of this on the research 
results. To begin with, it must be acknowledged that the desire to embark on this research stems 
from the requirements of the Professional Doctorate in Counselling Psychology. In addition to 
fulfilling the assessment criteria of this programme of study, the motivation to engage in this 
particular area of research stemmed from two further factors. Firstly, an influencing motivation 
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is a piece of work undertaken with a service user at a previous employment endeavour. The 
service user in question had presented to an Improving Access to Psychological Therapies 
service with a diagnosis of MS. As an employment advisor, the purpose of my role was to 
support the service user back into sustainable employment. What was enriching and captivating 
about the work with this service user was not only how the work sparked an interest in MS but 
how the working relationship cultivated an interest in psychoanalysis and later, an 
understanding of psychoanalytical concepts. For instance, at the initial appointment, a role was 
immediately inscribed in that I was required to ‘do’ something to the service user. In other 
words, I was required to utilise specialist knowledge in order to ground the nature of the service 
user’s diagnosis, and that specific interventions would be applied in the social norms to which 
if the service user followed would ameliorate or remove the barriers ascribed to his disabling 
symptoms. On recollection, internal questions emerged which were as follow: what do 
nosological designations refer to? What will influence that choice of name? What are the 
effects? Is it possible to work with a designation without having a previous understanding of 
it? And what is the relationship between these designations and the work of an employment 
advisor? Unable to answer any of these questions at the time, I experienced myself as fragile. 
That is, I experienced a tension between helplessness and a desire to empower. To further 
complicate matters was the evolving relational pattern that had begun to emerge in the sessions. 
As the service user reported experiencing both difficulty in understanding the aetiology of MS 
and explaining to potential employers the adjustments that would be required to help facilitate 
a transition into employment, I experienced an intense felt sense of somehow finding a way to 
alleviate the service users’ distress through the limited number of available interventions. Here, 
further questions arose; what would it mean to the service user if an immediate and direct 
response to his distressing experiences, thoughts and anxieties was not provided? What would 
it mean if the helm of the ship of returning to sustainable employment was not kept steady? 
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And how will the decisions made affect the working alliance? Reflecting in this way, 
particularly during the second year of the professional doctoral training, has meant coming to 
an understanding that this experience might be, as traditional psychoanalytic theory might 
suggest, an enactment, a counter resistance, or an issue of countertransference. Perhaps, most 
importantly, combining this experience and the second-year training experience had provided 
an opportunity to learn that at times conflict can be identified within the meaning in the 
presenting conflict. That is, a direct expression of the conflict may not be visible and there may 
be a disguised expression of unconscious processes. It is through this experience that the work 
of Josef Breuer and Sigmund Freud was deemed to be of significant theoretical weight and 
clinical significance. Equally, a desire to know more emerged. 
 
Secondly, the neuropsychological training experience gained in Year 2 and 3 of the programme 
of study. This specific clinical experience facilitated a degree of wonder. That is, what did it 
mean to be diagnosed with RRMS? What was it like to be prescribed DMT whilst the aetiology 
of RRMS remained unknown? This quest for knowledge would commence with a departure 
from positivist methods whilst endeavouring to explore deeper processes. The quest for 
knowledge would also acknowledge that whilst it is not possible to have unmediated full and 
direct access to individual experiences, it is possible to understand those experiences and 
meanings through a process of co-construction. Phenomenological inquiry complemented 
these quests whilst corroborating with the aim of this research which was to transition away 
from simply reporting individual experience and toward contributing to revisions in clinical 
practice to foster improved packages of care. For Gergen (2015), this orients the research to 
future forming in that by incorporating novel approaches, reflections, and practices, a shift 
beyond the more traditional approach can be explored.  
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In summary, this chapter focused on presenting an orientation to the selected methodology and 
method. It was beyond the scope of the thesis to outline the varied association between 
phenomenology and neuropsychology. Yet, by substantiating the ontological and 
epistemological position, a rationale for adopting Max van Manen’s hermeneutic interpretative 
phenomenology as the preferred method of choice was provided. Equal consideration was 
given to the various dimensions involved in conducting this research. What follows in the next 














Based on the theoretical underpinnings of the previous chapter, this chapter presents the themes 
discerned from the experiential material derived from the research participants. These 
phrasings correspond to the variant and invariant themes of the reduction and are supported by 
excerpts taken from transcripts across each of the six participant interviews. The themes serve 
as navigators through the subjective accounts given on the experience of being diagnosed with 
RRMS and the experience of taking DMT. For purposes of clarity, each experience is organised 
around four existential aspects; corporeality (lived-body), relationality (lived-relation), 
spatiality (lived-space), and temporality (lived-time). It should be stressed that in no manner 
does this experiential material form fixed categories or traits. Rather, the experiential material 
implicates all other material, and none is more privileged than any other. Equally, there is a 
recognition that this analysis is only possible because the experiences have been expressed in 
language. 
 
4.1 Overview of Themes  
The following overview summarizes the themes discerned from the analysis process. The 
overview functions as a navigator to the discerned themes; whereby the theme is presented and 
supported by excerpts taken from the participant narratives. A phenomenological description 
is equally provided which communicates how participants made meaning from their lived 
experiences. 
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§ Bodily Interruption 
§ Fatigue  




§ Guilt  











§ Diagnosis Inconsistencies  
 
 





§ Body Object 
§ Decision Dilemma  
§ Pain 
§ Reformulated Life 




§ Future Orientated 
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4.2 Experiences of Relapsing-Remitting Multiple Sclerosis 
 
4.2.1 Corporeality  
4.2.1.1 Bodily Interruption  
 
The World Health Organization (2020) considers health to be “a state of complete physical, 
mental and social well-being and not merely the absence of disease or infirmity”. If health is a 
question of integration, how can the experience of ill-health be conceptualised? Does ill-health 
permeate everyday living so that one’s human existence, one’s experience of the world and of 
themself becomes inferior? Or does this encounter with inferiority threaten one’s perception of 
being? If so, is one summoned into distillations as to their state of being? Or does one 
incorporate the inferiority that holds the power to threaten one’s notion of being? Experiencing 
ill-health seems indeed a wondrous phenomenon. 
 
“I worked in a call centre and I was tapping away, and my left hand just kept flicking 
up on its own. I found that odd. So, I massaged it … the next thing was my left leg 
used to freeze. So, I'd be walking somewhere, and it would just stop me dead in my 
track. After a couple of minutes, it would ease out. My vision would play out and it 
was just weird things. So, I kept going. I used to be a kind of person that something 
would happen in my body and I would just ignore it because at that age when you're 
twenty-four, you think you're invincible and it's fine. It's just random so let it happen.” 
(Audrey) 
 
Much like Audrey, Naira recounts her experience: 
 
“I was working really long hours in retail, standing prolonged periods and I thought 
I'm just really tired. It progressively got so bad that I couldn't see at all. It was just, it 
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was so much easier just to lay and close my eyes… I started to notice like a heaviness 
in my mouth and I kind of noticed that like I was brushing my teeth and I couldn't 
quite keep the toothpaste in my mouth. I was like “cool, I must be really tired.” And 
you know, “what's going on?” I was looking in the mirror and I was like “okay, that's 
fine” and I just kind of carried on and then like ten minutes later, I was trying to drink 
water and the water just spilled out my mouth and I was like “what is going on?” And 
then I went and looked in the mirror and half of my face had dropped.” (Naira) 
 
In these preliminary excerpts, Audrey and Naira produce a startling account of the manner in 
which their physical capabilities are altered and how they are forced to adapt their relationship 
with their bodies. What appears especially striking is the experience of MS being marked by 
an interruption. That is, life is interrupted. It is this experience that results in an eventual living 
with perpetual interruption. Yet, Audrey and Naira respond contrarily to this interruption. As 
Audrey shares, “something would happen in my body and I would just ignore it because at that 
age when you're twenty-four, you think you're invincible and it's fine.” As the present presents 
itself, Audrey’s sense of body is redefined and taken for granted as it is afforded a different 
view when bodily interruption becomes the norm. Whereas, for Naira, the bodily interruption 
gives rise to several emotions: uncertainty, fear, and anxiety, whilst being an abrupt reminder 
of the limitations of the body. In the attention she must now pay to every act, Naira is no longer 
able to assume the taken-for-granted and absent-minded tranquil characteristic of drinking 
water. Her very ability to do so is suspended, called into question. In this incremental loss of 
ability, the instrumentality of her body reveals itself. The body is an entity whose readiness-to-
hand can break down and such a bodily breakdown illuminates the conditions of the world. 
Perhaps it is this illumination that reveals how the body forms a vital part of her transcendence 
into the world. That is, how her body presents itself as inextricably woven into the world. From 
the very first breath to the moment of death. What this comes to mean is that the body is not 
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the objective body that can be seen by others but, rather the body that is the vehicle for seeing. 
For one’s body has its own functions and its own ineluctable trajectory into finitude.  
 
“It started off as blurriness in one eye, in my right eye and the last time I had optic 
neuritis it was in both my eyes … Numbness I’ve had that a few times where I’ve had 
it like on my shoulder, my back and from my stomach and pins and needles. Memory 
problems… I ended up getting really bad in the beginning of my second year, so I 
converted to part-time in my third year. So, I ended up with my three-year degree and 
it turned into a five-year degree instead. I then got a job but that was full-time. It was 
two-hours traveling a day, plus eight-hours of work which is way too much for me.” 
(Sonal) 
 
The common thread uniting the excerpts of Audrey and Naira to Sonal is that the body is the 
locus of intentions. For instance, projects are presented as invitations to the body’s potential 
undertakings, which require calculation, consideration, and configuration. Specifically, for 
Sonal, university no longer remains a quest for autonomy, knowledge, reason, and 
philosophical openness. But rather a quest for completion. In the same way employment is no 
longer an invitation for the surrendering of time and services in return for a salary. But rather 
a constant and intimate reminder related to, and a herald of, her finitude. Giving up on either 
would be conceding to the finality and irreversibility of her ill-health. 
These introductory experiences illuminate MS related ill-health to be compounded by bodily 
interruptions which precede physical challenges. Such physical challenges affect an entire way 
of being and transform the body. It is this transformed body that is experienced through 
unpredictability in which a gradual decline and movement towards loss takes prominence. 
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What this comes to mean is that Audrey, Naira and Sonal are involuntarily required to take the 
viewpoint that the body is fragile and precious. 
 
4.2.1.2 Fatigue 
Fatigue is, of course, common enough in the seemingly healthy and not exclusive to MS. Yet, 
as in the case of the experience of the onset of MS symptoms, fatigue presents itself as a 
distinguishable experience: 
 
“That is another thing, the fatigue. The fatigue is absolutely horrendous... It’s 
horrendous. Sometimes I have a shower, I have to go in bed for three hours.” 
(Faustina) 
 
Much like Faustina, Sonal shares a similar outlook: 
 
“I've got to really strategize if I'm doing something on one day. I've got to make sure, 
I’ve kind of figured out now how tired, I can predict how tired I'm going to get 
sometimes. So, I can adjust my life accordingly. Like if I’m going out shopping one 
day, the next day, I've got to make sure I take complete rest. So, I don't go anywhere. 
Maybe for the day after that and the day before maybe going shopping.” (Sonal) 
 
Here, two noticeable features can be discerned. That is, firstly, fatigue is differentiated from 
the experience of tiredness and secondly, the distinguishable severity of fatigue. In seeking 
exploratory depth, it is interesting and important to attempt to discern what further can be 
known of this common experience. 
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“It was to the point where I mean I actually had to purchase a voice amplifier because 
I was so tired and so fatigued that I couldn't speak. No one could hear me when I tried 
to like speak or sometimes my mouth kind of felt that it was paralyzed shut because 
I was just so exhausted, and I couldn't get my words out.” (Sonal) 
 
What is striking about Sonal’s account is the insight she gives into the immediacy of her 
experience of fatigue; in that it is described as a movement toward an incapacitation of her 
choices, freedom, and ultimately, her voice. Carel (2016) made the argument that ill-health can 
take on a dualist stance. That is, as the body declines in functioning, the spirit flourishes. As 
“the body is tethered to its failing organs, the spirit rises free” (p.110). This is far from the case 
here. Sonal’s experience of fatigue soon imposes on her that sense of what she is and is not 
permitted to do and be. Fatigue constructs a new existence, an unfamiliar landscape to be 
navigated. Where autonomy and familiarity once took precedence, constraint and inadequacy 
now command movement. This oscillation between the lived and the habitual body is 
characteristic of the experience of fatigue. As Sonal wishes to speak, her command requires 
more energy than her body can deliver and within a few moments, she experiences an 
incapacitation of communication, a bodily betrayal, and a loss of control. From Sonal’s words, 
Sartre’s three orders of the body can be alluded to. Sonal recognizes her experience of fatigue 
in the first person. She is recognized by others as a physical entity with individual 
characteristics: in this instance, with limitations. She then recognises herself as seen through 
the eyes of the other. It is this outlook of the body that is so poignantly described in her 
narrative. She is left alone with her incapacitation. That is, she remains in a world of agency 
and action, yet incapable of contributing in it as she desires, as others may desire. 
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Thus far, discerned from the experiential material is the common experience of a bodily 
interruption and in particular, fatigue. Initially, the change in bodily orientation appears 
disruptive and exhaustive as it stems from an overpowering loss of bodily capacity. The body 
adopts a conflicting will of its own, beyond the control of the self. Later, the change becomes 
quotidian. If this view is taken, that is, the unique body-self unity being experienced as other-
than-me, it can be wondered whether this intimate encounter with physical orientation extends 
to psychological orientation.  
 
4.2.1.3 Psychological Distress 
Often the opening questions of a psychological assessment are ‘how do you feel?’ and ‘what 
do you feel?’ The questions exemplify an endeavour to commence the phenomenological 
reduction. The endeavour to gain entry into the subjective experience of the individual, the 
phenomenon, the thing itself.  As outlined in the previous theme, a startling array of bodily 
interruptions were experienced by Audrey. What emerges now is a paralysis.  
 
“Sorry if I get emotional but it’s just sad (. . .) It is. You don't feel like you're worth 
anything anymore. Gosh. (CRYING) (. . .) You know, you feel like you are just 
useless (. . .) So, what's the point? Why keep trying if you haven't got the support 
behind you? Sorry (. . .) It's hard. I've always thought that it was a cruel disability. It's 
so mental. Mentally controlling. That’s where the emotions come from. The physical 
you get used to. So, I can't wear heels. I like wearing heels, but oh well. So, I can’t 
run. So, I have heavy limbs. You learn to function with what you've got. (CRYING) 




This is not a paralysis of action per se but rather a paralysis of emotion and cognition. The 
latter imposes on Audrey in the sense of destructive feelings of emotional suffering and 
instability born of ceaselessness, often inexplicable, and change that characterizes existential 
anguish. Destructive feelings are comprised of worthlessness, whereby Audrey is disheartened 
with herself and with her ability to be. Existential anguish emerges as Audrey is able to tolerate 
the deterioration of her body, but the deterioration of the “mental” proves damaging. Whereby 
the existential anguish is so deep that she is unable to prevent herself from being drained of 
being. It is in this dark abyss of paralysis that Audrey’s ability to care for herself and to maintain 
her sense of being in the world that is so drastically depicted in her account. 
 
“You wonder eh? (. . .) I was in deep depression. It was for three years the depression. 
Deep depression. It takes me long, long time to accept if you can say the fact that I 
have this (. . .) But it's not nice to know, to know you have this and this is killing you 
from inside out (. . .)” (Faustina) 
 
As a phenomenon, depression can appear to be self-evident yet simultaneously elusive. Self-
evident because the depressive experience can be thought of as a universal way of being with 
one-self, with others, and the world. Elusive because depression was unmentioned as a distinct 
medical condition prior to the Third Edition of the Diagnostic and Statistical Manual of Mental 
Disorders of 1980. Yet, this mode of experiencing MS related ill-health is transformative of 
the way in which Audrey and Faustina encounter being. In the face of her experience, Audrey 
is summoned to undergo an existential examination of who she is. Her account reveals 
important elements of the individual situation and the individual life. That is, she is 
simultaneously confronted with the body-mind connection, deeply, seriously, and profoundly, 
and the customarily experience of thoughts, beliefs and emotions being altered by 
 78 
psychological distress. Whereas Faustina is shaped differently by her experience. Her inability 
to transcend the temporal barrier created by the depressive experience results in the emergence 
of an opaque and alien existence. This new existence marks a dramatic and intimate 
transformation to her life and discloses the manner in which psychological incapacity matters 
in RRMS. The transformation is most recognizable and damaging in the way in which Faustina 
is brought close to death.  
Both accounts have said something compellingly important about the way in which 
psychological distress takes over and deplete one’s will and one’s strength. As situations and 
health status change, psychological distress presents itself in relation to being-with-others:  
 
“I don't really talk about it that much. I mean, my parents know that I have spoken 
about it in full. But there is a lot of times I don't bury it and there's some days where 
I’m not feeling as good as other days in regard to mental health and so I ring 
Samaritans because it will calm me down. I don't like to say it in front of my parents. 
I don't want them to worry or anything because you know they see things on TV like 
people you know committing suicide, which I'm not at that point or anything.” (Sonal) 
 
 
Sonal describes how there are occasions in which she wishes to speak about her “mental health” 
but grapples with the possibility of causing others’ discomfort. Here, Sonal exposes a blind 
spot in her moral perspective. This is a crucial decision for her and whether she understands 
the implications of such a decision can be wondered. Yet, one thing that is clear is that she is 
silenced. Notwithstanding the natural consequences of this silencing on her relationship with 
her parents, Sonal takes comfort in deciding to contact the Samaritans. In choosing to speak to 
the Samaritans, she integrates her past into her present and recognizes that decisions such as 
these are not once in a lifetime, but rather quotidian, as circumstances, health status and 
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relationships change. There is a limitation placed on her “mental health” and a desire to 




All of the participants who contributed to the research experienced guilt. This experience of 
guilt was not a free-standing and physiologically based individual response, but rather an 
experience of guilt within a specific zone of personal relations.  
 
“You end up feeling guilty because like I'm twenty-odd now. Well nearly my mid 
twenty’s and I should be able to do these things for myself. Even when they are 
pushing me around in the wheelchair, I mean like they are in their fifties and I feel 
guilty that you know they are getting older now. They aren’t as young as they once 
were you know, not as fit as they once were. And they are having to push me around 
everywhere and they are having to do things for me. I did go to Dubai a couple years 
ago… but I felt guilty that my mom couldn’t enjoy herself because she was looking 
after me.” (Sonal) 
 
Sonal’s experience of guilt cannot be understood separately from the relationships in which it 
occurs. Her experience of guilt is in relation to those moment-by-moment choices to 
authenticate herself. For instance, as Sonal is in an objective relationship with her parents, guilt 
is dialogical in the sense that responsibility to authenticate her own existence cannot be 
separated from her responsibility to them. Thus, Sonal cannot be guilty toward herself alone 
because the function of guilt is to push herself to make reparation for the difficulties caused by 
her situation. Experiencing guilt in this way is common given that to be a human being means 
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to experience emotion. To not experience emotion would be a way of rejecting and escaping 
the matters produced by the event. Consequently, rather than placing a focus on the advantages 
of having access to a system of support, Sonal expresses guilt and concern toward her parents’ 
involvement in assisting her. This appears to constitute a source of identity disruption, which 
can be noted in the following excerpt: 
 
“I've always been a bit of a yes person. I don't like letting my managers down. I don't 
like letting work down. Especially because I've been a civil servant for so long. It's 
that kind of mentality. You know, you just buckle down and get on with things and 
so I feel guilty. I sometimes say, I've got a disability. I can't do this. Or I can't do this 
the way that I used to do it. Or the way you expect me to do it. But I need to stop 
being so afraid of sticking up for myself.” (Alexandra) 
 
Alexandra’s narrative echoes the relationality lifeworld in which she is positioned. There is an 
integration of the social experience of her body as an aberration, an affront to others and her 
body no longer being her body as she exists it. She lives with an unrecognizable body. That is, 
her experience of her body as dis-abled and her experience of the body as perceived by others. 
Eventually, her experience of guilt promotes a remedial activity, in which she minimizes guilt 
through conciliatory behaviours. These conciliatory behaviours shape and regulate her body 
whilst impeding plans and reducing actions to their impossibility.  
 
4.2.2.2 Power Imbalance 
Stories pertaining to medical practitioners who do not listen, helplessness when attempting to 
engage in healthcare services, and bureaucratic systems are familiar to many. Indeed, these 
stories presents anomalies, incongruities, and contradictions whilst arousing curiosity. Much 
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like these dimensions, Audrey describes a rather vivid representation of what it feels like to be 
on the receiving end of this encounter: 
 
“I didn't really like this GP because it was such a quick, every time I went in there he 
just kept saying ‘oh it's spasms or like a trapped nerve.’ That sort of thing. So, I just 
put up with it and said it’s a trapped nerve and then I’d go back and say trapped nerve 
and he’d give me exercises to do and I was like ‘well clearly it’s not working it must 
be something else.’ And then, this went on for months and months.” (Audrey) 
 
At the phenomenological centre of this primitive medical enterprise is Audrey, a patient, who 
has nothing but her indicators of ill-health and her need to offer; and a general practitioner, 
who has, or professes to have, the power to meet Audrey’s need. The offer of meeting a need, 
is characteristically, established on knowledge, accrued experience, and sound judgment. This 
suggests that the enterprise should involve a dialogical relationship, in which cumulative 
experiences of ill-health are understood, even in instances where the epistemic credentials of 
that perspective are less than impeccable. What transpires is far from conventional. As the 
general practitioner considers Audrey’s indicators of ill-health to be sufficient in determining 
the aetiology of her ill-health, the drastic lack of mutual understanding disregards her narrative 
to the extent that limitations are placed on the interpersonal exchange and a helplessness 
prevails. Equally, it should be carefully noticed that Audrey is willing to recognize herself as 
a patient. That is, her intention is not an implementation of defeatism. More accurately, it is an 
evaluation of what has been lost, what is no longer viable, and wanting to transcend the 
shadows of ill-health into the light of wellness.  
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“We went to the hospital and they said it was a bell’s palsy. They gave me some 
steroids and I was like ‘this is just not okay.’ And I kind of went back to the general 
practitioner and I was like ‘look, I don't know what's going on with me, you know, 
I've also started to experience numbness in my hand.’ So, they put me through an 
MRI scan, and you know, I went and had an eye test just to rule out anything optical. 
They thought there might be a brain tumour. There wasn't a brain tumour. Well, okay 
that must mean I'm fine … I thought ‘well, it's kind of been like four weeks and I 
haven't heard anything.’ Called the GP back and she said ‘oh, you know you might 
want to be prepared that it's probably MS.’ And I was like ‘well, have you got the 
MRI scan back?’ And she was like ‘no.’ And I was like ‘so on what basis are you 
saying that?’ And she couldn’t really answer my question.” (Naira).     
 
Naira equally and explicitly identifies the power imbalance between herself and the general 
practitioner. This power imbalance reformulates her body into a disenchanted, inanimate 
mechanism, suitable for scientific investigation. It is this disparity in collective interpretative 
resources that places her at a disadvantage when attempting to make sense of her indicators of 
ill-health. It is this experience that shows in a dispassionate manner the conditions as they 
actually exist in the medical enterprise. Amidst this imbalance of power, Faustina voiced a 
great deal of opinion in relation to the style of interaction:  
 
“The doctors, they say ‘go to your country and ask what that is because we cannot do 
anything about it.’ That was in a hospital in London. In the ***** hospital in London. 
I said, ‘well, my country - I live here.’ You know, so I cannot say nothing… The GP 
sent me to ***** to see Dr. ***** but they say, ‘if it's urgent then we send you for 
an MRI scan in three months – if it’s urgent.’ I said, I said; ‘don't worry, I will go to 
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my country. I will do all the exams in there because I cannot wait three months 
without seeing, you know, without knowing what is going on because no one say 
nothing to me.’ So, I went to my country. They make the scan and that was in 
February 2004. Made the scan and in there they give me the news. So, I come in the 
UK. I am living in the UK – why am I living in the UK?” (Faustina) 
 
Faustina’s narrative adds another layer to the experience of an imbalance in power. Besides the 
policies and practices of healthcare services being unjust, Faustina’s narrative is downgraded 
as a result of being unable to communicate in a direct manner her indicators of ill-health. 
Ultimately, she is only able to communicate her ill-health with those with whom she shares a 
sense of solidarity and unity. This is not to say that the primitive medical enterprise is inevitably 
and unavoidably unjust, but rather particular experiences generate injustice. Experiences on 
the other end of the spectrum are known:  
 
“So, I ended up in hospital and everything happened so quickly like in that week. I 
had like an MRI because of a lumbar puncture and all those things and although they 
couldn’t give me like officially hundred per cent, they had to wait for lumbar puncture 
results. They said ‘yeah, we're pretty sure that you've got MS.’ And then I think a 
couple months later, I had the formal diagnosis.” (Savannah) 
 
Savannah’s extract marks an overt and implicit reference to the bodily transformation which 
remains unknown until she comes face-to-face with it. That is, until she comes face-to-face 
with herself transformed. In granting a certain cogency, acceptance does not come through 
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awareness of an incremental loss of ability; but paradoxically through the experience of being 
diagnosed. 
  
“I said, ‘but what is this multiple sclerosis? I don't understand it.’ And I still remember 
the look she gave me, and I was like ‘what?’ She said, ‘I'm a multiple-sclerosis 
consultant. I specialize in multiple sclerosis. I work with people that have multiple-
sclerosis.’ I said, ‘so, you're telling me I got it?’ She said, ‘Yeah.’ I said, ‘so, when 
did you find out?’ She went, she looked at me and said, ‘when they released you from 
hospital did no one tell you?’ I said, ‘no’ and I told her they said, ‘they are going to 
refer me to you and we're going to work together to find out what it was.’ And she 
said, ‘they should have told you.’ She went, ‘they referred you to me because you 
have relapsing-remitting multiple-sclerosis.’ I couldn’t believe it. I couldn’t accept it. 
I really couldn’t.” (Audrey) 
 
Here, to be diagnosed means to be identified. The medical practitioner who diagnosed Audrey 
thereby identified her existence, her very being. This is not the same as being identified by a 
friend, family member or colleague. When identified by a friend, the cognitive experience is 
revived so that this friend becomes part of the experience, the life history. The friend exists and 
is now memorable. However, the experience of being identified by a medical practitioner is 
inextricably intertwined with selfhood, identity, and the patient’s sense of personal being. With 
this latter identification, the experience of receiving a diagnosis begins to emerge. That is, 
diagnosis marks the beginning of a particular association between the individual and the self, 
the individual and the medical practitioner, and the individual and the other. As Audrey’s 
narrative indicates, the diagnosis moment is captured by the transformation of symptoms into 
a less subjective entity. The symptoms are structured into explicatory relationships, 
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explanations, and predictions of ill-health. In a related vein, of importance is how the disparity 
in communicating the diagnosis not only causes disbelief but a period of intense felt denial.  
 
“So, I was diagnosed in my first year of university … I was just having fun with my 
friends I decided to go and open up my post. And then, I saw the letter and I read it 
and it said, ‘I can now confirm that your symptoms and stuff is due to MS after having 
a scan.’ And it was pretty hard. You know to digest that. I didn't really know that 
much about MS at the time. I was pretty young. I haven't really heard of it that much 
and so I googled it which isn't a good thing to do. When you google things you know 
it tells you the worst scenario, and I remember telling my parents about it and they 
were obviously in shock as well, and I think they hid a lot of how they thought from 
me to try and protect me because my dad I remember kept saying ‘no don't worry 
about it, you'll be fine, you're okay’ and all that sort of stuff but that didn't really help 
me because I felt like I was kind of alone in processing it.” (Sonal) 
 
Standing at this turning point of a diagnosis is a relationality which manifests itself in both 
familiarity and unfamiliarity. Familiarity in that the world lies spread out before Sonal as a 
sphere for action and her body is pure instrumentality taking the world for its domain. And 
unfamiliarity in which Sonal experiences herself under the medical gaze. The self is 
experienced as having limits just as an ordinary object has limits. It has become impaired 
through ill-health. That is, it is intruded upon, and intrudes into awareness. At the same time, 
whereas the medical practitioner sees symptoms, Sonal experiences these symptoms as answers 
to the demands of her present life situation. Another turning point is the internal experience of 
aloneness manifested by the adoption of technology. The emphasis on convenience and 
impersonal technological mechanisms serves to separate Sonal from medical practitioners’ and 
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succeeds in fostering feelings of disconnection and loneliness. There is evidence to suggest 
that Sonal’s interaction with her parents becomes increasingly dissatisfying since technology 
produces an impersonal manner of relating. That is, a mode of relating to one another in a 





Another dimension in the experience of being diagnosed is the encounter with scientific and 
medical terminology.  Participants described how symptoms were no longer a private and 
subjective experience of bodily interruption. Rather, symptoms reflected a transition toward a 
medical ontology in which universal understanding and meanings was associated.  
 
“When I was first diagnosed my parents and my younger sister were with me and I 
told them. I'm one of seven children. So, I told them I don't want anybody else to 
know until I deal with this myself. I don't want to tell anyone. So, for a few months I 
didn't confide in the rest of my family. I just kept it within the four of us that were in 
the room at the time that I was diagnosed. I think because I was in a kind of a mindset 
of denial really you know, and I wasn't sure what I would tell people anyway because 
I didn't fully understand what I was going through myself. So, for the first few months 
after I was diagnosed nothing changed. I kept on with my responsibilities and I kind 
of buried my mind in the sand as it was. Like I just carried on as if nothing had 
happened or at least other people around me couldn't notice that anything was really 
going on with me.” (Alexandra) 
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By the end of this passage, Alexandra’s experience of a diagnosis is not the overriding matter. 
The theme, rather, is her experience of secrecy. Her narrative places focus on the way she is 
granted control over those she wished not to inform of her diagnosis and how she allowed 
herself to maintain normality. To further explore this theme, it is relevant to mentioned that 
secrecy is dissimilar to lying in that the latter involves deception, whereby the former may not 
necessarily incorporate deception. Equally, secrecy is dissimilar to the practice of privacy. 
Privacy is in essence a non-relational experience, whilst secrecy at all times implicates the 
other from whom a secret is kept, or with whom a secret is shared with. With this in mind, it is 
possible to discern the experience of secrecy for Alexandra. The connectedness between 
Alexandra and the other can take the form of self-conscious emotions. As Alexandra 
experiences these self-conscious emotions, she is prevented from thinking about how her 
diagnosis is related to self-representation. Rather, she becomes motivated by her desire to 
protect others from her diagnosis in order to arrive at a satisfying self-identity. For instance, “I 
just carried on as if nothing had happened or at least other people around me couldn't notice 
that anything was really going on with me.” It is here that her passage provides an orientation 
into how secrecy alters relational possibilities. 
 
Within this context, it is necessary to explicate spatiality into the way in which this experience 
of secrecy is characterized. As the interview progressed, Alexandra shared “I was maybe either 
in my bedroom or wherever when I was on my own and then at that point, I was doing research 
and probably looking at things I shouldn't really have been looking at. You know, unhealthy 
images of MS. I was predominately looking at worst case scenarios and then upsetting myself 
even more. And then dealing with those emotions on my own and suppressing them.” It is here 
that secrecy incorporates not only an alteration to relational possibilities, but a change in 
surrounding spatiality. Just as an alteration of relational possibilities is experienced as a self-
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conscious emotional change, lived spatiality is characterized by both curtailment of spatial 
possibilities and an abrupt descent of limits onto a world previously larger, freer, more open. 
Spatiality relates to Alexandra’s immersion into the world of her “bedroom”, which she now 
navigates with challenge. Her “bedroom” intended by her body as a repository for rest, now 
takes another dimension. By maintaining the secrecy of a diagnosis, her “bedroom”, a familiar 
place she inhabits, changes her way of being. In the face of her experience, secrecy creates 
spaces in which vigilance replaces ease and uncertainty creates tension and dis-ease. What is 
striking is how Alexandra’s experience of solitude comes not only from maintaining the 
secrecy of her diagnosis and the isolation of her bedroom but an unwillingness to recognize 





“At the time I was like twenty-two and I was like, ‘you’re telling me that my 
prognosis is bad?’ He said things like, ‘if I was your sister, this is what I would tell 
you to do.’ And I was just like, ‘what do you mean if I was your sister?’ ‘What is this 
crap?’ Like it was so unprofessional. And I remember leaving and just sitting in the 
car and I was like ‘I'm going to die.’ (.) ‘I'm going to die.’ (.) I called my now husband 
and I just said, ‘this is the situation, if you want to go, you can go.’ (CRYING) And 
I don't think he really understood at the time, but he was like ‘don’t be stupid, we will 
deal with it as it comes.’ And it was just like really bad time for a really long time. 
Like for six months, I wouldn't really leave the house. I was really scared.” (Naira) 
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Underlying this passage is the movement of Naira’s suffering and solitude toward death. Here, 
diagnosis represents a threat to life. Diagnosis represents death as a structural component, a 
fulcrum point in which, diagnosis is the end of life. Diagnosis is the end of her time. The 
moment of diagnosis is the extinction of the self and the final experience of self-awareness. 
This moment set limits to her existence and to confound this inevitable vicissitude of time, she 
appears to no longer be able to be able and expresses this further in her intimate relationship. 
In doing so, she realises that death is subjectively inconceivable in that death does not happen 
to those who die, but to those who grieve. Just as no one individual cannot live another 
individual’s life, “no one can take the Other’s dying away from him” (Heidegger, 1962, p. 
284). Heidegger (1962) proposed human being-in-the-world is permanently a being-toward-
death. In other words, just as the experience of life serves as a backdrop to the meaning of 
death, the experience of death serves as a backdrop to the meaning of life. Death, of course, 
can be expressed as a philosophical matter, but it remains obvious that the concept is not purely 
theoretical but a highly subjective matter that touches each human life. Thus, in the lived 
experience of a diagnosis serving as a backdrop to death, some experience death as an urge 
toward being engulfed: 
 
“It's difficult. When you're physically fit being told that you've got this condition, and 
this is the potential outcome … I'm a control freak just generally. I plan my life. I sort 
of say ‘okay, I want to be married by the time I am this age. I want to have children 
by this age. I want to have this amount of children.’ And a lot of my plans now, in 
my mind, are unachievable or I’ve kind of changed. I've had to change my outlook 
on life and live more in the moment and I think stop taking time for granted. So that's, 
I think emotionally, it's been tough. It's been much more harder than that. I mean, I 
had really serious lows and I think the way that I kind of dealt with it was akin to the 
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grieving process so there was that lots of stages that I went through where I finally 
got to a stage of acceptance, but it took me a while to get there.” (Alexandra) 
 
At first reading, a shift in Alexandra’s intentionality can be discerned in that her sense of self 
is revised and redefined in the face of an ever-increasing bodily interruption. Not only does 
this lead to an interruption of her temporality but a dynamic process of grief emerges. But what 
is it that can be known about diagnosis, death, and grief from a phenomenological perspective? 
Death is present in health, as life and death are intimately linked. Death is also present on the 
experiential spectrum of ill-health and inevitably constructs part of the ill-health experience. 
Yet, by revealing the finitude of existential life, death and diagnosis represent an edifying 
effect. That is, the common thread uniting the narratives of Naira and Alexandra is the way 
their experiences impart courage, resoluteness, whilst nourishing their capacity for 
compassion. The narratives lay bare who each individual is beneath the attempt to displace the 
death anxiety which diagnosis has fast-tracked. Once death is conceptualised, life’s purposes 
and priorities reorganise themselves. This visceral awareness reveals a fresh new way of life, 
infinitely valuable, uncertain, and mysterious. 
 
4.2.5 Other 
4.2.5.1 Diagnosis Inconsistencies 
In general medicine, diagnosis provides an economical means of communicating precisely the 
presence of actual bodily disease or the presence of organic disorder. To make a diagnosis, the 
medical practitioner observes the body through a physical examination. This may reveal 
unusual signs, which may or may not be accompanied by subjective observations made by the 
patient. Both are often checked against laboratory test results and/or radiological reports. 
Diagnosis then becomes identification. That is, the medical practitioner attempts to identify the 
 91 
patient through diagnosis. Not only then is a patient manufactured through diagnosis, but a 
disease and/or disorder is made real and noticeable. By receiving a diagnosis, the language of 
science permeates everyday living so that an individual’s existence, experience of the world, 
and of themselves becomes scientized.  
 
“The hospital wrote to me to say that they've made a mistake and actually there were 
lesions on my brain and that I should return for a diagnosis of MS. So, I did return, 
and I asked for a second MRI because I wasn't confident in the original findings and 
because of the issues. And I was given a second MRI in August 2018, which did 
confirm new lesions within time and space.” (Alexandra) 
 
Naira provides a similar indication of the diagnosis process:  
 
“I went and saw a GP and they said it might be labyrinthitis. And I was like ‘oh crikey, 
ok, well that's come back in a really short amount of time’ and I didn't think anything 
of it.” (Naira) 
 
At an earlier stage in the interview, Alexandra described receiving an incorrect diagnosis. It 
could be speculated that receiving an incorrect diagnosis would mean to have no 
acknowledgement of her very being. Yet, the extract above shows that even with a correct 
diagnosis she experiences difficulty in redefining the new bounds for her capability and that 
she comes to understand diagnosis with a disbelief. Similarly, for Naira, diagnosis was a 
renunciation of the severity of her ill-health. During the interviews, other participants 
descriptions of receiving a diagnosis included: adopting a mode of unavailability; a 
reformulation of self-concept; the future being a source of doubt and restriction; despair 
increasing through observation of other PwMS; and neurological examinations strengthening 
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feelings of uncertainty. These dimensions indicate toward the diagnosis of RRMS being a non-
linear and continually shifting process. That is, as experiences of the body change over time, 
these experiences arise from the living flow of everyday existence. 
 
“Everything I kind of knew was taken away. Like wearing heels was … No one talks 
you through that journey. No one explains that there are certain things that you do 
naturally that you're not going to be able to and I think that's the acceptance of it 
because I loved wearing high heels. I loved partying. Couldn’t party anymore. I loved 
being sociable and now I'm just content in my own company… It changed my life 
completely and, in a sense, it just took over… I just cried. I felt lonely and I was angry 
with the world. Angry with everything. And I was depressed… I just wasn't me. I was 
fighting with everything I knew… I wasn't myself. I was a stranger in my own body.” 
(Audrey) 
 
Here, diagnosis marks a deepening erosion of Audrey’s freedom to live. A previously open 
future is now diminished due to the progressiveness and unpredictability of RRMS. Lifestyle 
undertakings lose their habitual element and turn out to be either taxing or extinct. Such 
undertakings are no longer immediate possibilities. What was previously done unthinkingly, 
without preparation and minimal effort, is now an upsetting and explicit reminder of the past 
and of a great change. Thus, not only does Audrey’s diagnosis encapsulate a restricted freedom 
to live but her desire to do so. In other words, by lacking the desire to act, then an actual 
incapacity to act becomes, paradoxically, secondary. 
 
As outlined, the experience of a diagnosis of RRMS is a profound realization of bodily 
vulnerability and finitude. Equally, it can be accurate to discern that receiving a diagnosis can 
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lead to unintended and unexpected gains such as insight, maturity, and clarity. Such gains are 
brought to the fore in the following excerpts:  
 
“You just never really know if you're going to be well enough. Also, it has, that’s one 
of the main reasons why I changed job roles. But that was the positive. Like it was 
something I wanted to do that was better for me but it did kind of stem from the fact 
that can I deliver the role I was doing to the best I could because I just was so up and 
down with being unwell. So, I really, I think it’s just been, trial and error with learning 
to just get on with things and not worrying about what it will be like. I just had to 
start being like ‘if I want do it, I'm going to plan to do it’ because you never know. I 
might be fine or I might not.” (Savannah) 
 
Naira, shares a similar sentiment: 
 
“You can't feel your hand today but you can feel the wind on your face. The sun is 
shining, someone smiled at you. Today, you're walking. Today, you can see the 
colour of the leaves… it's hard to just be like its God and God's will and that's okay… 
I found new purpose. I just started to connect with others differently and you know 
like it made me have a new appreciation for life.” (Naira) 
 
Here, diagnosis awakens both Savannah and Naira from the slumber of shallow preoccupations 
to the preciousness and fragility of life. Both begin to see things more clearly and vividly. Life 
is then not some mysterious vital force, but precisely an ongoing restabilizing process. 
Specifically, Naira’s reference to “God and God's will” reflects an Islamic discourse and a 
future orientation. This future orientation is best understood through ‘entwurf' (translated to 
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projection) (Heidegger, 1962, p.185). Here, Naira’s projection defines her character and 
identity. This, claims Heidegger, is the essence of human existence: the capability to be this or 
an alternative kind of individual, to become something, even if this does not ensue from a 
conscious decision to be this kind of individual engaged in this activity.  
 
4.3 Experiences of Disease-Modifying Treatment 
 
4.3.1 Corporeality  
4.3.1.1 Body Object  
 
Subjecting the experience of receiving a diagnosis to an analysis resulted in discerning the 
dynamic movement of the lived body into the objective body. Not only did the experience 
throw the lived body back on itself, even more distinctively, it called the lived body into 
question. With the body now brought into focus, an endeavour is undertaken as to what this 
mode of experiencing might mean. 
 
“My body ached all the time. All I wanted to do was sleep all the time. I wasn't myself. 
I was a stranger in my own body” and “you're in a body that is not yours because you 
don't have control.” (Audrey) 
 
It is this experience that exacerbates a similar type of alienation of the lived body with which 
menaces Sonal:  
 
“When I get a flare up or a relapse then I start to do the whole feeling sorry for myself 
and things like that. Then I find it harder to then, this summer I kind of flared up 
pretty badly. And so, it kind of just brought back, I don't know the feelings are like 
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‘oh, you know, I’ve got this MS thing. It’s going to happen for life. I’m this bad 
already, how’s it going to be like in the future.’” (Sonal) 
 
In this passage, the language of nosology permeates Sonal’s experience to the extent that her 
encounter with medical terminology becomes enmeshed into her ontological constitution of 
being. That said, within the confines of nosology, medical language reigns supreme and Sonal’s 
subjectivity seems the least determinative element of her health. In the midst of the experience, 
her identity as a structure which is unable to persist beyond the flow of circumstances and 
temporality is discerned through her words. That is, previous endeavours are reminders of the 
horizons of engagement and the capability of what her body could do without thought which 
are now out of bounds. This new disorientation absorbs her, destabilises avenues of 
involvement and becomes a viable source of definition of her-self. In some way, she feels 
extraneous from her lived body and appears to complement, continue, and regain a sense of 
bodily self through questioning.  
 
The common thread uniting the account of Sonal to that of Audrey is the experience of the 
lived body transitioning. Audrey introduces a palpable pain engulfed deep within the lived 
body. That is, Audrey is unable to separate herself from the pain, which is continuous over 
time and judges herself largely, or even exclusively, in terms of her ability to have autonomy 
over her body. At the same time, the unexpected feeling of a powerlessness captures the fragile 
dimension of the body. It is this powerlessness that is narrated as an unrelenting compromise 
of her lived body. Both accounts are indicative of the manner in which the lived body and 
emotions are inseparable. That is, how both elements permeate their existence, and how their 
lived body and their emotional well-being are the same matter. For both Audrey and Sonal, as 
is the case with the other participants, the lived body becomes a mechanism to repair. A 
 96 
mechanism of forging and renewing relationship with the world through an altered sense of 
embodiment.  
 
4.3.1.2 Decision Dilemma 
There is, as yet no curative treatment for MS. There is, however, DMT which can reduce 
disease progression in the relapsing phenotypes of MS (Amato et al., 2020). Studies such as 
this are adequately understood and vastly documented within the literature. Yet, it is not until 
the question of how a DMT agent is decided upon is raised that further analysis is warranted. 
In the following excerpt, Faustina provides an indication of the experience of selecting a DMT 
agent: 
 
“The damage can be enormous and cannot be repaired so you have to put in the 
balance what would you prefer; gambling that something will happen to you or put 
injections and you know you are a little bit preventing the course. It’s a very personal 
thing.” (Faustina) 
 
Faustina’s account alludes to a deeper feature of the experience of deciding upon a DMT agent 
in that she feels torn between making a rational choice regarding her ill-health and losing the 
freedom to manage an inevitable decline of her body. Other participants shared a similar 
personal experience of their decision-making process: 
 
“He (the neurologist) was talking about injections, which I didn't want to do and so 
he said, ‘luckily there is a clinical trial where there is tablet form.’ And so, I felt a lot 
happier knowing that I could take a tablet form as opposed to an injection form. I 
always knew that I wanted to take something for it. I wasn't just going to let it slide 
and just leave it.” (Sonal) 
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In the next passage, Savannah explains how she came to decide upon a DMT agent: 
 
“I'd never went for the infusion because it’s such a big decision to make on your own 
and you’re always like ‘is this the right thing…’ It was such a big step and I just, I 
guess in my head, I was being like you know ‘I don't need that. I don't need that. Like 
I'll be OK with just a tablet.’ Like I didn't want to take such a bold step when I thought 
that I could handle it or manage it with the tablet.” (Savannah)  
 
Amidst the decision-making process, both Sonal and Savannah express reservation with 
specific methods of administrating DMT. Before engaging in an analysis, it is important to 
acknowledge how modes of administering DMT have been developed from subcutaneous 
injections to intravenous infusions and now to oral tablets (Ransohoff, 2015). The results of 
which are profound. Whereas Sonal relies on the guidance of a medical practitioner, Savannah 
appraises DMT through the way she understands who she is and what she wants to be. To see 
what this might mean, it is necessary to explicate some of the dimensions characterising each 
choice. Medical practitioners have a duty to keep professional knowledge and skills up to date 
(General Medical Council, 2020). In doing so, they use this knowledge for the purposes of 
building trust and for the purposes of healing. In the experience of Sonal, this primitive medical 
enterprise allows her operational causes of concerns to be relieved. Equally, avoiding injections 
valorises her individuality in that a reawakening takes place. That is, Sonal wishes to not only 
overcome her ill-health but seeks to return her body to its normative docility.  
 
By contrast, Savannah’s experience highlights relational and emotional concerns. Initially, 
deliberating over the prospect of taking infusions gives rise to a confrontation with the isolating 
experience of a neurological disease. This disease opens Savannah up to her emotional life in 
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a way that may be purely physiological in the first instance. Yet, it is this deliberation of DMT 
agent that is indicative of a new world journey of coping. It is at this moment that discovery 
begins. Firstly, the oral tablet mode of administration is selected as it is perceived as potentially 
preserving a degree of normalcy. The upshot of this is a feeling of immediate registration of 
how the body has changed. Secondly, by eliminating the prospect of taking infusions, Savannah 
eliminates the prospect of curtailing her ability to manage freely the medications. Thus, DMT 
does not exclusively mean treatment in the sense of a reduction of disease but rather treatment 




“I love it, but I hate it. If you can understand? (Faustina).  
“Can you tell me a bit about it?” (Dipesh).  
“I love it because I think help me really help me you know, and I hate it because I 
hate the needles.” (Faustina) 
 
Faustina’s explicit account highlights a valuable dimension in discerning the experience of 
taking DMT. In specific reference to subcutaneous injection, her experience does not appear 
to resemble a choice. Rather, she is forced into a predicament with what appears to be only one 
feasible conjecture. On the one hand, injections are perceived as an obligation to the extent that 
Faustina is forced to take a DMT agent in order to be helped. The burden of which may not 
only reflect the degree of side effects and risk associated with taking an injection agent but may 
be associated to the obstacles PwRRMS are required to overcome. On the other hand, it is this 
dynamic and fragile dimension of DMT administration that has a revitalizing potential. That 
is, as injections serve as an intimate reminder of her corporeal discomfort, Faustina’s 
experiential horizon change. This process becomes important in that when confronted with the 
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discomforting DMT experience, Faustina’s response is underpinned and fuelled by a felt and 
deep sense of resilience. 
 
“The first day’s really hard core because my eye that I was already having trouble 
with just completely went black … I kept noticing, like my body was going from one 
extreme to the other. Like one minute, I was freezing cold and had so many blankets 
on me. I just couldn't stop shaking and then the next minute I was boiling hot and 
needed fans on me and stuff like that. So, the first day was really bad and then in the 
night I was quite sick and then after that kind of each day got a little better. I think 
the Tuesday and Wednesday weren't nice but because they weren't as bad as the first 
day, I handled them a bit better and then I remembered the Thursday being fine 
because I have had the steroids to start with and I think they were pretty nasty as well 
like they can do a lot of damage. The Thursday, I felt really, really good and then the 
Friday was a bit rubbish again.” (Savannah) 
 
In contrast to Faustina, Savannah’s account speaks to the idea that the DMT experience 
intensifies the awareness of the body. Specifically, Savannah’s account brings to the fore the 
everyday absence of awareness of how the body over time acquires a unique and habitual way 
of relating to its world. Now that the body’s capacity experiences alteration and compromise, 
what prevails is a pained body. This continues to be focal in Savannah’s experience as it brings 
into question the healing potential of DMT which is a separate issue from the body as an 
isolated mechanism requiring repair. 
 
Perhaps the hallmark of Savannah’s experience is the way in which it resembles Faustina’s. 
That is, the way the familiarity of the body is taken away as they become more out of step with 
their regime of corporeal control. Whilst there is an alienation, there is a connectedness to this 
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new physical condition. It is this constant interplay that represents their new world view. Not 
only is there a motivation and desire to continue with future treatment but treatment represents 
a relational dimension. That is, new and original relationships with various elements of their 
life world through their reformed sense of embodiment. With this in mind, it is yet to be seen 
if this results in overcoming the impalpability of expressing the pain which resides somewhere 
deep inside of the body which others have described: 
 
“It felt as if I've been hit by a bus that your whole body is aching. You feel bone pain 
… It's almost as if I could feel my bone marrow getting into work you know. Even 
my spine. Like the insides of my bones hurt.” (Alexandra) 
 
4.3.1.4 Reformulated Life 
 
The experiences below describe how DMT alters the influence of RRMS to the extent that life 
no longer represents the boundaries of ill-health, but rather a restabilizing process. That is, 
where once Alexandra and Naira were dragged out of the tranquil pace of day-to-day life and 
plunged into a life which failed to make any sense in the manner it previously did, DMT 
reformulates life.  
 
“I felt like I was reborn. I was a completely new person. And this is what life should 
feel like. You know, I don't really struggle. I wasn't struggling with fatigue as much 
as I was prior to having treatment. It was like I had a new lease of life.” (Alexandra) 
 
Much like Alexandra, Naira shares a similar experience: 
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“I found new purpose. I just started to connect with others differently and you know 
like it made me have a new appreciation for life.” (Naira) 
 
It would seem appropriate to inquire further as to how these textual portrayals, namely, 
‘reborn’, ‘a completely new person’, ‘a new lease of life’, and ‘a new appreciation for life’ can 
discern the experience of taking DMT. The experience of taking DMT awakens Alexandra and 
Naira from the slumber of preoccupations surrounding the uncertainty of RRMS into the 
preciousness of life. Up until that time, as RRMS closed in, it did so by depleting their 
contingency and emotional resource. Through taking DMT, both cross into a new horizon 
accompanied by cohesion and purpose. The plans of the past which once appeared saturated 
with difficulty are reconstructed. The endeavours which once provided nourishment and 
enrichment are re-engaged with. A new real value is revealed. That is, the life of an unknown 
nature and passively endured is replaced with a boundless flow of life’s everyday spontaneity. 
Where in ill-health the body dominated action (i.e., Alexandra re-planning her life due to being 
diagnosed with RRMS (see 4.4.1 Death)), now the project dominates action (i.e., navigating 
the world with her ‘new lease of life’). The new recognition that emerges allows both 
Alexandra and Naira to refuse to be limited by the incapacitation of their bodies. Thereby 
enacting their freedom as a deliberative focal point despite of their ill-health.  
 
A point of further ponderance extends to whether DMT can mitigate the existential suffering 
associated with RRMS and put an end to the perceived finitude:  
 
“The fact that I've had Lemtrada has definitely given me a sense of security because 
I feel as if I have some armour on you know to protect me from relapses … I felt like 
I had a new lease of life where I felt invincible in a way. These are things other people 
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take for granted. Being able to walk for two hours a day and still go to the gym. And 
do a full day’s work and then not feeling like you're dead at the end of the day because 
when I'm coming home at the end of the day, I'm still making myself dinner. Or 
watching something on TV and not falling asleep in the middle of whatever I am 
watching. I was socializing more. So, I noticed that before having treatment, I'll make 
excuses not to go out on the weekends with my friends because I was just too tired to 
go. I couldn't be bothered, I'd say. But really and truly it is because I was too tired. 
The thought of going out is what I couldn't be bothered about. But yeah, I was making 
more effort to socialize. I had the energy to socialize. I had the mental capacity and 
the mental energy to actually socialize with people. So, I think for me Lemtrada has 
been a godsend.” (Alexandra) 
 
By submitting this passage to an analysis, a feature that appears particularly intriguing is the 
experience of taking DMT serving as a vehicle for a new relationship with the body to be 
formed. Alexandra’s ill-health which was a condition of the past becomes the sole content of 
the moment. That is, whilst she had ceased to live with the realities of her diagnosis, DMT 
engages her into a new relationship with her body. The process begins with a recognition of 
her body’s existence. The essential efficiency of her body only seizes her attention when she 
could no longer just act from the body, but when she is required to act toward it. This process 
of objectification enables Alexandra to revalue the dimensions of her body. It is here that the 
experience of taking DMT is marked by an explicit awareness and absorption of the presence 
of the body. In her case, the body reveals itself originally as a new order. As a result, life regains 
its enchantment. It is turned into a sudden incentive to live. As the world grows dearer to 
Alexandra, steps are taken on the road toward attuning with her body. That is, the body that 
interacts with the environment, the body that is drawn together, and the body that encloses her. 
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In this new way, somewhat paradoxically, the progressive inevitably of RRMS makes life very 
much alive. And just as DMT allows for a variation of life, life comes to be understood in terms 
of the body. 
 
4.3.1.5 Complementary and Alternative Medicine 
As outlined in the previous theme, a dimension of the experience of taking DMT is that the 
body engages in a restabilizing process. It is in this process that the more insistently the body’s 
capacity is rekindled, the more revitalizing the potential for participation in life. Yet, it is in 
reference to the dynamic healing process that Naira shares an experience of healing through an 
alternative agent of treatment: 
 
“He (in reference to a work colleague) actually gave me a book on mindfulness (.) 
(TEARS). Changed my life (.) Like genuinely (. . .) Sorry (. . .) I worked through it 
and I think it helped me to learn to appreciate the small things in life again. Just small 
like ok so either you can't feel your hand today, but you can feel the wind on your 
face. The sun is shining, someone smiled at you. Today, you're walking. Today, you 
can see the colour of the leaves and it was really, it was so, you know, it literally 
saved my life. He saved my life with that book.” (Naira) 
 
Naira’s desire to use CAM stems from accepting a gift in which the preciousness of giving and 
receiving is of considerable intrigue. The act of giving a gift can extend to a plethora of 
possibilities including gifting for the purposes of gratitude or for inner satisfaction. Either way, 
it is in this manner that this ordinary intention creates an exchange. A focal experience, ‘he 
saved my life with that book.’ It is indeed that this unfolding experience is grounded by two 
different sets of insights: (i) the refashioning of a new emotionally meaningful life through a 
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reformed sense of embodiment; and (ii) alternative treatment recognizing the connection 
between the mind and body. 
 
Naira describes her reformed experience of embodiment eloquently. The meaning of life as she 
lives it and the nature of personal actions as she experiences them are refashioned through a 
process of self-transformation and self-observation. This process creates a new life view 
focused on the interconnection between the mind and the body, which is directly disciplined 
by the attention given to the physical sensations that form the life of the body and the 
continuous interconnection with the life of the mind. It is this new experience that permeates 
the affairs of her everyday life. Previously (see 4.4.1 Death) Naira’s experience of RRMS was 
characterized by a trajectory toward death. Now, her experience appears to transcend hedonic 
and eudaimonic well-being. That is, she experiences a sense of stability and composure. A state 
of equanimity. This organic occurrence evokes an understanding that is otherwise beyond 
reach. Through this untrivialized dimension, the phenomenology of this total sensation can be 
further discerned. Naira’s increased compassion for her body subsequently extends to 
embracing the nourishing gaze of the sun, the warmth of a smile, the liberty associated with 
walking, and the beauty that is the changing of the seasons. Through direct experience, her 
realization is then that life and relationships can be experienced as pleasurable, meaningful, 
and full of intrinsic existence. 
 
Audrey shares her experience of taking an alternative agent of treatment: 
 
“The deactivator has changed my life and it sounds so big making that statement but 
it's true. Before it, I was very content to sit in the house be depressive and not do 
anything and try to do something every so often like work wise. But that allowed the 
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negative thoughts to take over and say, “I'm not good enough”. The activator now has 
allowed me to be more active for starters. It's allowed me to sleep. It's allowed a lot 
of symptoms to be forgotten about because they're not happening anymore. My eyes 
stopped spinning. My speech stopped slurring as often. My legs stop being as heavy 
as they were, the weirdest thing is that I used to have numb feet, I don't have numb 
feet no more. I knocked my little toe, the other day and felt it (LAUGHTER). It's 
giving me a chance to go to the gym, to be more active. It’s allowed me to look up 
straighter. It's allowed me to have positive visions amongst the dark visions.” 
(Audrey) 
 
Audrey’s excerpt points to fundamental life feelings that are very much tied up in the bodily 
experience. What is striking about this embodied interweaving of life and body is that Audrey 
initially experienced this engagement as melancholic, inconsequential, and without purpose. 
Further, Audrey’s reference to her ‘symptoms’ is indicative of an epistemological 
conceptualisation of the body grounded on anatomical, physiological, and biochemical 
characteristics. Yet, by selecting an herbal ‘deactivator’ (taken in capsule form and consisting 
of milk thistle, green tea, ashwagandha, bacopa, and turmeric) as an agent of treatment, a 
departure from this restorative medicine is represented. Of this sort yields a specific alteration. 
Audrey’s body is validated, respected, and enlightened. It is now that her body can be managed 
at various levels and degrees within, or tangential to, life’s encounters. Of note is the specific 
ways in which Audrey is enabled to both establish new relationships to the world and to 
rekindle old relationships in new ways. The nature of how Audrey grows, how she frees herself 
from ill-health suggests that the alternative agent has a more pressing relevance in that she 
rediscovers and restores her body's connection to life. Not only does this agent facilitate the 
emotional side of re-embodiment but fosters a recognition between the mind and body.  
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Whereas the experience of DMT is characterized by the lived body becoming a mechanism to 
repaired, that is, a mechanism for reforming relationship with the world through an altered 
sense of embodiment; CAM medicine alters; corporeal identity, that is, the taken-for-granted 
awareness of the world, and the relations with life.  
 
4.3.2 Temporality  
4.3.2.1 Future Orientated 
 
Similar to the exploration of receiving a diagnosis (see 4.4 Temporality), consideration is given 
to the experience of taking DMT in the context of both temporal and experiential time.  
 
“The idea of having to inject myself once a week or twice a week and having flu like 
symptoms because of the injections for the next twenty or thirty years of my life and 
it not really meaning anything in the end was a waste of my time and energy. You 
know, that was how I feel about it. So, I looked at Lemtrada because it's something 
that will cause definitely causes a permanent change and that the clinical trials are 
quite promising at least for about fifty per cent of people. And it's something that you, 
ideally you can do twice and then that’s you forever, hopefully.” (Alexandra) 
 
Savannah shares the following outlook: 
 
“The second-round next year that potentially could be for life. So, if unless like some 
people have to have a top up but that to me is a massive pro because as opposed to 
the tablets where I would be having to take them for the rest of my life, they don't 
really know the long-term effect of them. It’s quite nice to know that there might be 
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an end in sight, not to be like cured or anything, but at least to be off medication.” 
(Savannah) 
 
These passages specify time not being viewed as a succession of seconds, minutes, and hours, 
but rather as a network of intentionality. As Alexandra and Savannah live in an aura of ill-
health, their excerpts present a perception of wanting to overcome the incoherence of the 
present. For instance, enduring the physical demands of impaired embodiment grounds 
Alexandra in the present moment before the future is thought of. That is, free of DMT. 
 
Perhaps the most poignant description of an awareness of time occurred in the context of ‘waste 
of my time’. This experience is a cyclical time which unfolds in a chronology of injection 
administration with intervals of further mounted illness. Time does not mean days and months 
and years. Rather, time resembles a symphony, a crescendo of symptoms, unforgiving 
interludes of relapses, and the existence of a trudging determination. Thus, Alexandra’s 
experience is based on both the distant and immediate future. Although the latter represented 
uncertainty and unpredictability, there is a realization of at least some choice in it. That is, 
whilst the inevitable limited nature of her existence is acknowledged, she presents a perspective 
of how her time can be given new meaning. It is here that the treatment selection process is 
permeated a temporal dimension. 
 
By contrast, Savannah’s time is characterized by the present being transposed into an imagined 
future. She is at a standstill, or at least by deliberating DMT, her time is re-divided, re-ordered, 
and re-arranged. She is compelled to make choices that serve to affect her perception of the 
passage of time. This perception is debilitating in the sense that time itself becomes a precious 
commodity, and the more she attempts to hold on to it, the faster she experiences it as going. 
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Given the nature of her diagnosis, the future assumes an inherently problematic quality. In 
thinking of projects, she can never be sure what her physical status will be at some future point 
in time meaning that her experience of time is focused on the thing she seeks rather than time 
itself. The truism, ‘not to be like cured or anything’ takes on a whole new meaning in that the 
future contributes to personal meaning. In particular, her sense of what is possible in her life.  
 
In summary, it is true that this chapter explored the inner lives of Audrey, Alexandra, Faustina, 
Naira, Savannah, and Sonal. It is also true that this was not the sole intention. Researchers are 
unable to ‘know’ their participants uniquely. Uniquely, perhaps in the way a medical 
practitioner ‘knows’ his or her patient. A researchers’ subject is not the participant. Rather, the 
subject is that phenomenon. That is, the experience of being diagnosed with RRMS and the 
experience of taking DMT. Audrey’s descriptions are an example of these phenomena. So are 
the experiences borrowed from the other participants. Once borrowed, these experiential 
accounts are regarded, for all intents and purposes, as epistemologically fictious.  
 
It is hoped that this chapter has constructed an inquiry that made the experience of being 
diagnosed with RRMS and the experience of taking DMT recognizable to the reader. In this 
endeavour lies the possibility of becoming more sensitive to the experiences of the participants. 













This chapter, as is the case with discussion chapters, characterizes what has gone before and 
consolidates the findings discerned from the experience of a diagnosis of relapsing-remitting 
multiple sclerosis (RRMS) and the experience of taking disease-modifying treatment (DMT). 
Within this context, a focus is placed on linking the reported findings to the previous literature. 
Equal, consideration is given to the discerned themes and their ability to answer each of the 
two research questions. Next, the chapter will move on to discussing the implications of this 
thesis. The result of which indicates that research, theory and clinical practice related to people 
with RRMS (PwRRMS) is best thought of as a dynamic equilibrium where all components 
weigh in. At this point, the chapter examines the limitations of this thesis. In light of which, a 
perspective on avenues for future research is outlined. Finally, a concluding statement is 
presented which is reflective of this thesis marking another step in understanding how 
PwRRMS experience challenges before, during and after a diagnosis of RRMS. 
  
5.1 Findings related to the First Research Question 
 
The question as to how individual’s experience a diagnosis of RRMS must include the 
associated complexity. According to the reviewed literature, this complexity should 
fundamentally acknowledge that symptomatology can vary greatly for each individual (see 
Crayton & Rossman, 2006; Newland, et al., 2016) and recognize the multifaceted nature of 
physical impairment (see Burke, 2019; Isakkson & Ahlström, 2006; Pretorius & Joubert, 2014; 
Toombs, 2001). Both dimensions of which were confirmed by this thesis (see 4.2.1.1 Bodily 
 110 
Interruption and 4.2.1.2 Fatigue). Fatigue, a heavily reported symptom (see Capone et al., 2019; 
Krupp, 2003; Leocani et al., 2008; Newton et al., 2016; Smith et al., 2013; Tur, 2016), was 
noticeable in many of this thesis’ participant narratives. In this respect, the applicable accounts 
provided a framework to discern the relationship between symptomatology and daily life whilst 
confirming the unpredictable and complex nature of RRMS. Such understanding equally 
highlights how the unique experience, presentation, and intensity of symptoms influence 
psychological well-being. 
 
Within the theme of Psychological Distress (see 4.2.1.3), it was clear that some participants 
experienced vulnerability in relation to their symptoms which a diagnosis did not diminish, for 
a few, the feeling was intensified. It is in this respect, as it was described, that the moment of 
psychological distress was the moment when participants felt as though the meaning of life had 
disappeared and they no longer had a place in the world. The literature is clear that the 
experience of psychological distress is not uncommon as studies have cast a light on how the 
intricacies of a diagnosis can transform an individual’s being-in-the-world and what their world 
becomes (see Al-Sharman et al., 2018; Beshears, 2010; Burke, 2019). Similar to a previous 
study (see Issakson & Alhstrom, 2006), this thesis acknowledged natural human responses, 
namely, uncertainty, trepidation, and anxiety to unexperienced symptoms until an explanation 
was obtained. Yet dissimilarly, it is noteworthy to highlight that this thesis discerned what has, 
as yet been largely unexplored, namely, the nature in which the experience of receiving a 
diagnosis of RRMS is associated to a ‘deep depression’ and the need to understand, address, 
and treat this disorder separately from RRMS. On the one hand, it is worth drawing attention 
to how this disorder limits an individual’s ability to experience wonder, gratitude, and elation 
for levels of activity they can undertake within the confines of a diagnosis of RRMS. On the 
other hand, while certain symptoms of depression overlap with those of RRMS, an increased 
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focus is required to identify and establish the appropriate treatment for the former and not 
interpreting this form of distress as an inevitable consequence of the RRMS progression. It is 
in this respect that an active treatment approach may be beneficial for improving mood as well 
as reducing the fatigue associated to both conditions. 
 
Unsurprisingly, there is a vast body of knowledge (see Al-Sharman, 2017; Burke, 2019; 
Malcomson et al., 2008) emphasising how receiving a diagnosis of RRMS resulted in immense 
emotional turmoil. Indeed, it was evident that for participants in these studies the reality of a 
diagnosis was fraught with uncertainty owing not least to the unpredictable nature of RRMS. 
The literature has indicated that common emotional responses varied between fear and 
devastation which often changed during and after diagnosis. However, in stark contrast to 
previous researchers’ (see Al-Sharman, 2017; Beshears, 2010; Burke, 2019), this thesis’ 
themes of Diagnosis Inconsistencies (see 4.2.5.1) and Power Imbalance (see 4.2.2.2) presented 
an alternative insight into the manner in which some participants experienced diagnosis within 
the primitive medical enterprise. Although at times this was reflective of an epistemic injustice 
and at other times suggestive of a disenchanted breakdown in the dialogical relationship, the 
language of science permeated individual existence so that the experience of the world and of 
oneself became scientized. It was here that such experiences of a diagnosis of RRMS was 
compounded by a drastic felt sense of disillusion, helplessness and disbelief. 
 
Diagnosis Inconsistencies (see 4.2.5.1) acknowledged the challenges associated to making a 
diagnosis which has been long recognised and well documented (see 1.1.5 Diagnosis). It can 
be said that some medical practitioners experience difficulty in associating the early symptoms 
to RRMS, that they may be unaware that a lack of prompt intervention may preclude relapse 
and/or that postponing an accurate diagnostic could potentially be problematical. It is worth 
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drawing attention to the significance of this matter. Diagnosis Inconsistencies in the large part 
expressed how misdiagnosis increased morbidity, created inadequate treatment plans and may 
have delayed the treatment of other potentially curable pathologies. From an economic lens, it 
is important to hold in mind the influence of a misdiagnosis and the treatment of misdiagnosed 
individuals, especially in developing nations. From a theoretical and clinical lens, although 
decades of research have culminated in a more rapid diagnosis of RRMS, there remains a need 
for researchers to model and decipher ways to prevent misdiagnosis. Researchers may be able 
to fulfil this need by ascertaining whether the McDonald Criteria (2017) is being applied 
correctly in clinical practice. This would mean exploring whether clinical or previous events 
are being substantiated by objective corroborative evidence and whether the radiological 
criteria are being applied appropriately. Equally, in cases of diagnosing difficulty, either a 
second opinion from a neuro-radiologist would be recommended or a cerebrospinal fluid and 
serum oligoclonal bands assay could be performed. In essence, attempts should be made to 
achieve an equilibrium between diagnostic certainty and a timely diagnosis. 
 
Multiple studies (see Al-Sharman, 2017; Beshears, 2010; Burke, 2019; Issakson & Alhstrom, 
2006; Pretorius & Joubert, 2014; Toombs, 2001), including this one, support the view that for 
many individuals, a diagnosis of RRMS fosters experiences of uncertainty. However, this 
thesis was a point of departure from which three original themes, namely, Guilt (see 4.2.2.1), 
Secrecy (see 4.2.3.1), and Death (see 4.2.4.1) built upon the prevailing nature and degree of 
uncertainty whilst contributing to answering the first research question. Continuing to examine 
these three themes has tremendous potential for developing an understanding of the experience 
of receiving a diagnosis within the continuum of pre- and post-diagnosis.  
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A complexity associated to the experience of receiving a diagnosis of RRMS was that of death 
(see 4.2.4.1 Death). Within the findings, for some participants, the experience of diagnosis 
represented the ending of life. That is, diagnosis was a mainspring for conceptualisations of 
death and the reconfiguration of existence. Surprisingly, there is little, if any literature relating 
to how this unmitigated challenge, this transcending of the advent of physical death is 
understood in clinical practice. Therefore, the participant accounts stand as invaluable 
interpretations which contribute substantially to understanding the packages of care required 
for individuals who receive a diagnosis of RRMS. It would be of importance for healthcare 
professionals (HCP) who encounter individuals with suspected or newly diagnosed RRMS to 
keep in mind that individuals may have incorporated inaccurate conceptualisations of the 
disease. And so, initial intervention(s) could be based around providing a thorough 
understanding of the autoimmune disease. What is meant by ‘thorough’ is a level of 
understanding that limits PwRRMS engaging in internet searches to find answers. Whilst other 
studies (see Beshears, 2010; Burke, 2019) have reported on the commonality and the 
experiences of PwRRMS internet searching the prognosis of their condition, it remains 
important to address any inaccuracies and uncertainties early on as it can influence treatment 
decision making and treatment compliance. 
 
In a somewhat surprising theme, implicit in the participants accounts, was a reverberating sense 
of secrecy (see 4.2.3.1 Secrecy). The nature of which requires further grounding. Whilst it is 
pertinent to take note of how symptomology was no longer a private experience of bodily 
interruption but rather a transition into a medical ontology; the experience of being diagnosed 
came with the message that participants sought to maintain control over those who knew of the 
diagnosis. In other words, secrecy did not lock away the experience deeply inside of an 
individual that she could not see, rather that she is seldom, if ever, in the right position to see 
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it. It is this exposure to, and the at times guilt (see 4.2.2.1 Guilt), that encouraged such privacy. 
Yet, the remarkable thing here is that this realm of secrecy goes one step further by suggesting 
that PwRRMS engage in a personal attempt to create and maintain a progressive narrative of 
life in the face of a diagnosis. Alternatively stated, the solitary experience of receiving a 
diagnosis becomes opaque whilst PwRRMS engage in numerous attempts to find their way 
back into the normalcy of life. Thus, for some, the experience of receiving a diagnosis is a 
personal and multifaceted undertaking and not a one-step process. 
 
Within the realm of Guilt (see 4.2.2.1), the lived experience of receiving a diagnosis of RRMS 
was not a free-standing individual response, but rather an experience within a specific zone of 
personal relations. This finding was unlike that reported in previous literature as it was now 
described by participants when reflecting upon the social experience of the body as an 
aberration to others and the body no longer being the entity as they experience it. In fact, the 
value of discerning how participants described living with an unrecognizable body, that is, a 
body that was dis-abled and the experience of this body as perceived by others bared strongly 
on how previous literature conceptualised the theme of Guilt. Isakkson and Ahlström (2006), 
in their study of PwMS, captured how guilt in combination to depression, sadness, and shame 
was understood as the body being an object devoid of subjectivity. This conceptualisation was 
replicated in a previous study of individuals with a progressive phenotype of MS (see Burke, 
2019). In addition, previous literature has acknowledged how unfamiliarity amongst caregivers 
of PwMS gave rise to feelings of guilt (see Beshears, 2010, Boeije, et al., 2003; Cheung & 
Hocking, 2004; Grytten & Maseide, 2005). It is in regard to this divergence that the presented 
theme of Guilt is a matter of significant importance for answering the first research question 
and making an original contribution to the literature.  
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5.2 Findings related to the Second Research Question 
In attempting to chart PwRRMS experiences of taking DMT, in large part, surrendering control 
to a medical terminology was not compatible with participants personal narratives of ill-health. 
Although there remains a difficulty in locating a formal point of occurrence, in the context of 
the second research question, the theme Body Object (see 4.3.1.1) provides a useful point of 
reference. This theme elaborated some ideas about the relationship between the language of 
nosology and the ontological constitution of being. That said, for all of the participants, their 
bodies were described as being subjected to reductionist and rational standards which became 
a source of definition. This strengthened the degree to which personal meanings were 
structured from health into ill-health, and the degree to which ill-health negotiated life. 
Researchers (see Fawcett & Lucas, 2005; Finlay, 2003) have provided similar findings.  
 
Many studies have sought to provide a framework with which to understand how PwMS 
attempt to gain control over the unpredictable nature of the disease and the corresponding 
negotiation of life (see Johnson et al., 2006; Lowden et al., 2014; Miller & Jezewski, 2001, 
2006; van Capelle et al., 2017; van Reenen et al., 2019). The theme Decision Dilemma (see 
4.3.1.2) discerned the corollary of personal attempts to create an overall self-vitality embodied 
as a rich matrix of meaning within the world. This process began with deciding on a DMT 
agent which did not exclusively mean treatment in the sense of a reduction of disease symptoms 
but rather treatment which maintained a progressive narrative of life. Though personal and 
socially valued dimensions played a central role in the DMT selection process, many 
participants described a palpable pain (see 4.3.1.3 Pain) engulfed deep within the 
experimentational and transient experience of taking DMT. That is, some participants were 
unable to separate themselves from the associated pain experience which captured the fragile 
dimension of the body. It was this powerlessness that was narrated as an unrelenting 
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compromise of corporeality. Nonetheless, the body was given an identity which provided an 
opportunity to embrace the body as a mechanism to repair. A mechanism of forging and 
renewing relationships with life through an altered sense of embodiment.  
 
When it came to renewing relationships with life, a crucial dimension was the perceived 
influence of the future (see 4.3.1.4 Reformulated Life and 4.3.3.1 Future Orientated). Perhaps 
the most poignant manner in which to describe this dimension is to highlight how DMT 
impacted RRMS - to the extent that life no longer represented the boundaries of ill-health, but 
rather a restabilizing process. For many, taking DMT meant enduring the physical strains of a 
diminished embodiment in the present moment before viewing the open possibilities for a new 
future. That is, reintegrating temporal experiences, and, concomitantly, experiencing an ability 
to exist as a center of intentionality capable of a more cohesive sense of personal organization.  
 
Other studies have cited similar findings. For instance, Van Capelle et al. (2017) reported the 
theme “hope of delaying the progression of the disease” (p.4) as a reference to the increased 
importance of the future in the DMT selection process. In agreement, van Reenen et al. (2019) 
reported the theme “living in the now” (p.9) which referred to:  
 
“certain activities and liberties are lost, and satisfaction needs to be found elsewhere. 
What has been lost has been replaced by something else, something that might not 
have been there without having MS: the urge to live in the now and to enjoy life as 
much as possible and for as long as possible.” (p.10). 
 
What this meant is that for PwRRMS, whilst fighting with the uncertainty and unpredictability 
of an autoimmune disease, DMT represented an inherent meaning. That is, the experience of 
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taking DMT represented a transition into the horizon of the future. A future that structured life 
according to goals and undertakings. A future that could never erase the experiences and the 
lost opportunities associated to ill-health but could create its own temporality. Such an active 
process view could be associated to the following DMT agents; Alemtuzumab (Lemtradaâ), 
Dimethyl Fumarate (Tecfideraâ), Ocrelizumab (Ocrevusâ) (this thesis), Interferon Beta 1a 
(Avonexâ), Glatiramer Acetate (Copaxoneâ), Fingolimod (Gilenyaâ) (van Capelle et al., 
2017), and Teriflunomide (Aubagioâ) (Van Reenen et al., 2019).  
 
Perhaps the most intriguing finding in specific reference to the second research question is the 
manner in which PwRRMS combine treatment (see 4.3.1.5 Complementary and Alternative 
Medicine). Within this original theme, a light was cast on taking DMT – a light that was 
missing within the current body of knowledge. It is worth recognizing that participants often 
adopted alternative treatment strategies which marked a significant deviation from commonly 
researched alternative agents of treatment (see 1.1.6 Treatment). This does not necessarily 
denote definitive conclusions regarding interventions. Rather, this speaks volumes about how 
the continuing mystery regarding MS pathophysiology is interfered from the lived experience 
of PwRRMS. To the reader, combining DMT and CAM can present as unorthodox. However, 
effectiveness may be derived from the placebo effect alone and, unless extremely or potentially 
harmful, such an intervention should not be written-off. Though definite conclusions about this 
treatment regimen remain premature at present, the combination of treatment discerned various 
dynamics that are likely to play a role in the treatment selection process. It may well be that 
PwRRMS combine treatment because the degree of clinical benefit and the optimal dosage of 
DMT remains uncertain or that there remains much to understand about which process is initial 
triggered: cyto-degeneration (inside-out) or a primary autoimmune attack (outside-in). Either 
way, by recognizing and understanding how and why PwRRMS combine DMT and CAM can 
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hopefully enable a better understanding of the components involved in the disease process. For 
this reason, further investigations are required to consider the relative consistent use of 
alternative agents as a means for the possibility of prevention, and potentially even the 
treatment of RRMS (see 5.6 Recommendations for Future Research). 
 
5.3 Implications of this research 
This thesis has plausible implications for theoretical and empirical research. For instance, the 
literature related to RRMS and DMT has relied heavily on quantitative approaches of inquiry 
to arrive at findings subsequently applied to PwRRMS. The findings gleaned from this thesis 
indicate toward the qualitative method of inquiry being a valuable approach to understanding 
how DMT agents exert their effect on PwRRMS (see 4.3.1.4 Reformulated Life). At various 
points during the analysis, it was clear that no form of treatment substantially improved the 
degenerative disease process in RRMS. Although this should come as no surprise, it is worth 
recognizing that whilst disease heterogeneity will persist in presenting challenges to clinicians 
treating RRMS, pursuing further phenomenological inquiries would be of merit. The reasons 
for which are as follows.  
 
The findings of this thesis point to an overarching need to understand the interplay between 
RRMS and DMT in greater depth. With that said, it may well be that researchers would not 
have to seek a detailed exploration if PwRRMS could be treated with DMT that was easier to 
administer and better tolerated. As this is not currently the case, researchers should pay more 
attention to phenomenological inquiries in order to step closer to identifying treatments that 
can promote an improved quality of life and ultimately lead to the prevention of 
neurodegeneration. Advancing these understandings would prove clinically relevant, as the 
interplay between RRMS and DMT would be more systematically studied.  
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With respect to this thesis’ findings, it is argued that the value of researching the experience of 
taking DMT has been demonstrated. Whilst Kalb et al. (2015) argue that “the last 20 years have 
provided a significant number of treatment options that improve prognosis and quality of life 
for people with MS” (p.39), this thesis has taken this argument further by identifying salient 
aspects of taking and combining DMT and CAM. Future research in this area should develop 
these arguments further and to the point that the principles of evidence based DMT practice 
can be applied to CAM treatment. For instance, Wingerchuk and Carter (2014) understand the 
widely accepted DMT treatment process as either an escalation or an induction approach. The 
escalation approach comprises of an initiation of a moderately effective yet highly safe DMT 
agent and then a change to a DMT agent characterized as highly effective yet exhibiting an 
increased safety risk in the event of an unsatisfactory response to the former. The induction 
approach is based on the desire of obtaining a rapid remission of a very active MS. Thus, 
treatment comprises of an initiation of a highly effective DMT agent for a defined time period 
after which either observation or a lower risk maintenance treatment is initiated. Whilst both 
of these approaches are valuable in guiding treatment for PwMS, there remains a paucity of 
evidence regarding CAM treatment strategies. Perhaps the paucity of such knowledge stems 
from the complexity associated to investigating the effects of CAM on PwMS and/or the 
financial commitments involved in unequivocally assessing efficacy. Nonetheless, studies 
should be undertaken. A way of undertaking such studies is by duplicating this thesis with other 
samples, including other phenotypes of MS, and attempting to gain a more extensive 
understanding of CAM usage patterns and decision making. At the same time, of value would 
be assessing CAM treatments scientifically, even if there remains no methodological and 
practical consensus.  
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Whilst the abovementioned implications are valuable to theoretical and empirical research, 
implications for clinical practice are plausible. In specific reference to the call for an integration 
of counselling psychology and neuropsychology (see Goss, 2015a; 2015b; Rizq, 2007), an 
introductory step could include a review of the standards for the accreditation of doctoral 
programmes in counselling psychology to establish whether sufficient training is being 
provided on neuropsychology. What is meant by ‘sufficient’ is a minimum level of proficiency 
as opposed to a fully specialised training – as there is already a pathway for practitioners to 
become fully qualified as neuropsychologists (see the Qualification in Clinical 
Neuropsychology). This level of proficiency would include a delicate amalgamation of both 
counselling psychology’s blend of scientific, humanistic, and reflective models of working and 
neuropsychological assessments and psychometrics. It is believed that this blend can generally 
complement the phenomenological core of counselling psychology practice with the argument 
also being made that counselling psychologists are well placed to deliver neuropsychological 
assessments and psychometrics in a relational and reflective manner (see Fairfax, 2007).  
 
Another way in which the two disciplines can be brought together is through interdisciplinary 
research. If counselling psychologists engage in interdisciplinary research with either 
neuropsychologists and/or neuroscientists what can emerge is a unique integration which 
develops novel ways to further understand both neurological disorders and psychological 
distress. Opening the channels of research would not necessarily mean an abandonment of 
distinctive professional identities or the respective overriding commitment to the practitioner 
and client relationship. Rather this potentially rich tapestry of shared language, in effect, a 
recognition of the biopsychosocial model would acknowledge the differing language of each 
discipline whilst bringing a softer and more approachable set of meaning to neuroscientific 
findings. Integrating in this way could help counselling psychology continue to move forward 
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as a scientific and empirical field of psychology whilst strengthening the scientist-practitioner 
element of its identity. Another method of integration could be aligned to the pluralistic 
framework as proposed by Cooper and McLeod (2011). 
 
Based upon the light cast on the experience of receiving a diagnosis of RRMS and taking DMT 
– a light that was missing within the current body of literature - it is worth recognizing that 
these implications which once taken into consideration can be advantageous to the packages of 
care for PwRRMS. For instance, clinicians should strive to develop a holistic understanding of 
PwRRMS due to the unique pathogenesis in each individual (see 4.2.1.1 Bodily Interruption). 
Equally, whilst thinking about treatment regimen and treatment compliance which can be based 
on a diverse range of unique psychological, biological, and social elements, it seems reasonable 
for clinicians to deliberate the experiences discerned from this thesis and to collaborate in the 
treatment decision making process especially when in reference to CAM. 
 
With this in mind, it would be essential for practice to be based on an evidence base specific 
to the RRMS population. A simple Google Scholar search of ‘CAM’ and ‘RRMS’ yields 8,780 
results which indicates toward a degree of intrigue in CAM treatment options for the RRMS 
population. Yet, due to studies of CAM treatment being confounded by challenges, namely, 
small participant samples, reverse causality, complications in quantifying endpoints and an 
absence of an appropriate biomarker of improvement, drawing meaningful treatment efficacy 
conclusions can be difficult. And so, in the interim as high-quality evidence is developed, 
clinicians should acknowledge the contemplation of CAM use as representing an 
interrelationship between the mind, body, and soul and as an indication toward a low level of 
trust in the effectiveness of taking DMT. It may well be that DMT agents can be highly 
effective, but they are not panaceas.  
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It is worth recognizing that clinical practice may well benefit from patient–clinician discussions 
and recommendations surrounding CAM treatment. This collaboration would be based on 
PwRRMS expressing an interest in complementary treatment or informing of complementary 
treatment use to clinicians which studies (see Apel-Neu & Zettl, 2008; Pucci et al., 2003; 
Schwarz et al., 2008; Stoll et al., 2012) including this one, found does not often happen. 
However, it is imperative that these discussions take place with the reasons being as follow. 
Efforts to discuss, educate and inform should begin by allowing adequate time and adjusting 
content to the needs of each PwRRMS. Perhaps most importantly, the need for this implication 
stems from the need to exercise appropriate levels of clinical vigilance for those who seek 
alternative strategies to manage the disease holistically. On a similar line, the frequency of use 
clearly warrants discussions around the safety and possible complications of CAM use in 
combination with DMT. In addition, the belief that CAM treatment is harmless should not be 
ignored. As per this thesis findings, the nature of the collaboration being proposed could 
potentially overcome the disagreements often experienced within the primitive medical 
enterprise (see 4.2.2.2 Power Imbalance and 4.3.1.2 Decision Dilemma). This is very much 
consistent with the attempts that should be made to intensify efforts to understand the 
prevalence of CAM use and CAM treatment not only to enable clinicians to be up-to-date, open 
minded, and clinically cautious when making decisions pertaining to DMT and CAM 
treatment. But to also collaborate with PwRRMS in making informed choices regarding the 
multi-dimensional elements of their healthcare. 
 
5.4 Limitations of this research 
Two distinct limitations can be attributed to this inquiry. Firstly, given that the recruited sample 
consisted of females solely, the recruitment of males could have discerned themes other than 
those presented. Although this thesis has highlighted the female preponderance in MS (see 
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1.1.3 Prevalence and Epidemiology), future researchers may overcome this limitation by taking 
cognisance of this thesis recruitment methods whilst exploring other recruitment avenues. Such 
as, recruiting collaboratively with third parties (i.e., MS societies and/or neurological hospitals) 
or directly recruiting members of MS societies. Secondly, the inclusion criterion extended to 
any individual who had received a diagnosis of RRMS which meant that the time frame 
between the day of the diagnosis and the day of the interview in some cases was several years 
(see 3.6.4 Participants). This can be regarded as a limitation because given that the participant 
narratives were generated retrospectively, those narratives may have been affected by the 
participants’ ability to accurately recollect experiences. This may be of particular pertinence 
given the cognitive impairment associated with MS (see 1.1.2 Pathophysiology, Symptoms and 
Classifications). A way of future studies overcoming this limitation is by adding to the 
inclusion criteria the requirement of potential participants scoring suitably on either the 
Screening Examination for Cognitive Impairment (Beatty, et al., 1995), the Mini Mental State 
Examination (Cockrell, et al., 2002), or the MS Neuropsychological Screening Questionnaire 
(Nauta, et al., 2019). Equally, with these two limitations in mind, the reported themes may not 
be transferable to PwRRMS who are at a different stage of the RRMS disease course.  
 
5.5 Recommendations for future research 
A core question raised (see 5.2 Findings related to the Second Research Question) is whether 
it is possible to improve treatment outcomes for PwRRMS by integrating DMT and CAM 
treatment. To facilitate clarity, this thesis supports the utilisation of CAM. Such support is built 
on the foundation that a proportion of participants from this inquiry used CAM at least once 
during their journey with the disease. For this reason, an answer to the question of attitudes 
toward CAM is that PwRRMS generally do consider alternative forms of treatment. Within 
such a consideration lies the view that the healing process is not just a passive response to 
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RRMS and the opinions of medical professionals but rather is a dynamic, active, and 
autonomous process. With this in mind, researching different combinations of DMT and CAM 
should be considered to assess the real value of an integrated approach for the treatment of 
RRMS. This line of inquiry may also enhance insights into those who commence DMT and 
then either stop, switch, or supplement their treatment regimen which may guide future 
packages of care.  
 
Notwithstanding the abovementioned limitations, researchers should take cognisance of this 
inquiry and explore the following avenue as it can be a fruitful path for future research. A 
uniqueness of this thesis is that it has taken a preliminary stride in discerning the experience of 
taking different DMT agents in a single inquiry. With this in mind, the inquiry has shown that 
not only is this approach underused but the experience of RRMS affecting DMT decision 
making requires further attention. Thus, replicating this inquiry with samples stratified by 
gender, ethnicity, and geographic location may contribute valuable insights and further 
illuminate the meaning of the phenomenon. It is in this respect that this line of research can be 
enhanced further by either repeating semi-structured interviews through a longitudinal study 
design or by augmenting subjective accounts in combination to objective measurements to 
yield further knowledge.  
 
Finally, a note on reporting. As discussed (see 2.0 Literature Review), past researchers have 
not clearly reported the recruited participant(s) phenotype of MS. Therefore, moving forward 
for the purposes of accuracy, it is important that all future studies clearly state the recruited 
participants phenotype of MS as it will prevent findings being perceived as generalisable across 
all of the phenotypes of MS. 
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5.6 Final Thoughts 
By no means does this thesis claim to comprehensively address the identified gap in the body 
of knowledge. It does, however, confirm that individuals experience a variety of challenges 
before, during and after a diagnosis of RRMS and provides a progressive step in understanding 
why PwRRMS supplement DMT with CAM treatment. Whilst previous investigations into this 
latter phenomenon have tended to focus on the efficacy of the respective forms of treatment, it 
has been suggested herein that due to the complex nature of RRMS, treatment decision making 
is challenging and multifaceted. With this in mind, will this inquiry transform the current 
methods of treating RRMS? Most likely not in the short term. Primarily due to the role of CAM 
in the treatment of RRMS yet to be substantiated. However, over the longer term, and in the 
context of the growing popularity of taking CAM, there may well be more emphasis placed on 
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(.) Short pause 
(...) Long pause (more than 3 seconds)  
[. . . ]  Material omitted to ensure confidentiality and/or text extracted due to poor  
 quality of recording. 
 
Transcript 
Dipesh: Can we start by talking about your relapsing remitting multiple sclerosis, can you tell 
me about being diagnosed and your experience of coming to terms with the condition? 
Alexandra: OK, so I had my first known relapse, erm in 2015, January 2015 it was in my right 
eye. At the time I went to um an A&E department in London. Um that specialize in eyes and 
they had said that it could potentially be MS but given that I was experiencing a viral, signs of 
a viral infection at the time and was under some stress at work, they suggested, also suggested 
that it could have been the symptom or the outcome of a viral infection. So, where I was very 
physically fit. I was very active. I just completely dismissed the idea of having MS. And 
actually, refused having an MRI scan at the time. I was young and dumb; I like to tell people. 
I was very naive. So anyway, I went away, and my optic neuritis cleared up within about a 
month. Two years later. I had Botox injections to my forehead which is something that I do for 
cosmetic reasons and the following day I woke up with double vision, so my initial instinct 
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was that it was my double vision was caused by the Botox, but again, I went back to the eye 
hospital and was offered an MRI and at this point I took it. My journey to diagnosis was actually 
quite complicated because at the time I was told that the MRI scan was clear. That there was 
no abnormalities on my brain and that potentially my vision problems, although they were 
unusual could have been explained either by my viral infection two years prior or the Botox at 
that point. And then six months later, the hospital wrote to me to say that they've made a 
mistake and actually there were lesions on my brain and that I should return for a diagnosis of 
MS. So, I did return, and I asked for a second MRI because I wasn't confident in the original 
findings and because of the issues. And I was given a second MRI in August 2018, which did 
confirm new lesions within time and space. But within the time frame of me waiting, having 
the initial, so I went back between June and from June to August, I think I was in an emotional 
turmoil. Uhm, the thing is, I only knew one person with MS in my life and that was the mother 
of a friend of mine and she is bed bound and she cannot speak. So, the only exposure that I had 
to this condition was quite a severe case, so I think emotionally I was catastrophizing. It's 
difficult. When you're physically fit being told that you've got this condition, and this is the 
potential outcome. Uhm, when I think I'm someone I don't know if this applies to a lot of 
people. But I'm someone, I'm a control freak just generally. I plan my life, I sort of say “OK, I 
want to be married by the time I am this age. I want to have children by this age. I want to have 
this amount of children and a lot of my plans and now, in my mind, unachievable or I’ve kind 
of changed, I've had to change my outlook on life and live more in the moment and I think stop 
taking time for granted, and for granted.  So that's, I think emotionally it's been tough. It's been 
much more harder than that. I mean, I had really serious low’s and I think the way that I kind 
of dealt with it was akin to the grieving process so there was that lots of stages that I went 
through where I finally got to a stage of acceptance, but it took me awhile to get there, but sorry 
am I talking too much? 
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Dipesh: No not at all. It’s fine.  
Alexandra: OK.  
Dipesh: Can I just ask you a couple of questions? Do you remember roughly when you were 
diagnosed with MS? 
Alexandra: That would have been in Aug 2018, so after I had my technically my second MRI 
scan, I went into the hospital around that time for a follow up appointment and was diagnosed 
then with relapsing remitting MS.   
Dipesh: And what were your symptoms at the time? You mentioned the double vision? Did 
you notice anything else? 
Alexandra: So, from, I had to double vision which was in June 2017 bearing in mind there was 
quite some time from then to my official diagnosis because of the error at the hospital but when 
they wrote to me to say that they've made the mistake and invited me back in, I didn't go back 
in until June 2018 and then from June to August when I was waiting for my MRI scan, I did 
experience a third relapse which was numbness and tingling in my left leg. I speculated with 
my consultant that maybe the stress of the shock diagnosis brought on this 3rd relapse because 
the stress of a diagnosis, in some cases can bring on another relapse for MS patients. Especially 
because it was something that I kind of put to bed and I wasn't expecting to hear any more on 
the issue and then to get a letter out of the blue, particularly because it was a stressful time in 
life for me anyway because I received a letter in May 2018, and it was the same time that I 
bought my first home. So, my speculation is that where I had applied for critical illness and life 
insurance and given the insurance company permission to contact the hospitals. I kind of 
speculated maybe that's what kind of uncovered the mistake. Maybe that’s why it triggered the 
hospital to look at my case records again and then write to me but that is simply my speculation. 
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I've got obviously no proof of that. So, you can imagine first time homeowner, my place needed 
a lot of renovation and a lot of which are going to do myself and then I'm diagnosed with MS 
Uhm. You know, you are kind of life gets turned upside down. So yeah. 
Dipesh: One of the next questions is about the impact. You mentioned your life got turned 
upside down. But before we go into that bit and the second question, I wanted to ask you if you 
knew much about multiple sclerosis or even relapsing-remitting multiple sclerosis?  
Alexandra: Not really. I mean, I'd had, as I say, I had a friend of mine whose mom, she's got a 
secondary progressive MS, but I didn't know the distinction. I only know the distinctions 
between the different types of a MS now, so I just knew multiple sclerosis is something that 
was disabling I've met. In my line of work, I deal with members of the public on a day to day. 
I have a caseload of my own. I've got clients of my own and I deal with their families at times, 
so I've met people with MS and kind of know of them having MS but not understanding what 
impact that had on their life or what their symptoms were. So really and truly, my one, my 
main source or my main example was my friend’s mother, who as I say is unfortunately quite 
badly affected by the disease.  
Dipesh: And how are you managing your condition? 
Alexandra: Before I was diagnosed? 
Dipesh: Once you are diagnosed and your initial treatment? 
Alexandra: Well before I was diagnosed, I didn't know so I guess I was just managing fatigue 
and whatever symptoms I had. Like everybody else like drinking coffee and just taking it on 
the chin like British people do (LAUGHTER). We all say we are tired all the time, so you know 
when you're feeling tired and everybody else is feeling tired, they think you are normal but 
 184 
when I was diagnosed from June so let’s say, I went back to the hospital in June 2018, was 
provisionally told I had MS, but I didn't accept the diagnosis until I had my second MRI scan 
in August 2018. And when I went back and I was officially diagnosed, I had already done some 
research so what I had done was looked at the available DMT's and I was adamant that I was 
going to have Lemtrada. I didn't want anything else so when I went to my follow up 
appointment in August. I said to my consultant that is what I wanted and thankfully, he agreed, 
and this was before the EMA warning came in, so I was very lucky to be given Lemtrada as a 
first line therapy. So, I didn't have Lemtrada until November 2018, so there was a couple of 
months in between August and November where I knew I had MS and I wasn't being treated, 
but what I did take was a high dose of vitamin D's. So, I take 20,000 units of Vitamin D a day. 
So, going back to me being a control freak as you can see. I've done my own research and I've 
looked at what alternative therapies are also good for MS so not just I'm not just treating myself 
medically but also looking at vitamins and also diet and lifestyle. So, I've now gone vegan, but 
prior, I only recently became vegan about month ago, but prior to that I went on the keto diet, 
which I started almost instinctively after I was diagnosed. Sorry excuse me. But not keto that 
includes dairy basically I was paleo keto so dairy free gluten free. All the free from’s, I adopted 
(LAUGHTER). So, yeah, I've tried to treat this holistically. Holistically that’s how I’ve tried 
to manage it.  
Dipesh: The second question was around how relapsing remitting multiple sclerosis impacted 
your life? So, you touched upon at that time buying a new property and your property needing 
a lot of regeneration work also, but I was wondering if we could unpack that a little bit more? 
Alexandra: Well, if I think back, um because now I've had Lemtrada. Sorry. Let me let me 
rephrase this, if I think back to before I was diagnosed. I was in hindsight, quite clearly unwell. 
Um in the sense that I was very fatigued, and I was very weak, you know in mind and body I 
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would say. But I didn't know any different so, as I’ve given you example where I would go to 
work, and people would ask me ‘how are you this morning?’ And I'd ‘say you know what, I'm 
so exhausted’. And where the next person you know sat next to me would say exactly the same 
thing ‘oh yeah me too, I didn’t get any sleep last night, kids kept me up’. I just assumed that 
the way I was feeling was common. And I shouldn't complain because you know it's not right 
to complain. You just need to get on with it. And also, culturally I'm Greek Cypriot I don't 
know if I can say that but I'm also the oldest daughter in London for my family. So, I care for 
my grandmother and I look after my parents, but I can't be sick. You know, I just have to get 
on with life and just keep my head down and, and, and do what I can to help my family. So 
that was me then but then I had Lemtrada and yes going through Lemtrada itself is difficult. 
It's difficult. It's quite an intense medication to take. But actually, once you're past the phase of 
recovery from having the treatment, I felt like I could fly. Like my fatigue was lifted I felt like 
I was reborn, but I was a completely new person, and this is what life should feel like 
(LAUGHTER). I'm you know, I don't really struggle, I wasn't struggling with fatigue as much 
as I was prior to having treatment. It was like I had a new lease of life basically. But I can't 
take that for granted because um there are times when I do struggle so if I haven't had a good 
night sleep. I know that I need to, you know the whole spoon thing. So, I need to know where 
to prioritize my energy and most of the time prioritizing my energy is getting to work and doing 
what I can, or you know more than what I can normally at work because my work is quite 
stressful. And then coming home, hopefully get into the gym and by the time I've done that, 
it's bedtime for me. I can't manage much more but I think touch wood but I'm pretty lucky if I 
compare myself to my counterparts who have MS. So, I really don't try to complain. I tried to 
keep this positive as I can. 
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Dipesh: You mentioned that you are the elder sister and you also look after your grandmother. 
So, how did being diagnosed with relapsing remitting multiple sclerosis impact those around 
you? And you're responsibilities to others? 
Alexandra: Well, when I was first diagnosed my parents and my younger sister were with me 
and I told them. I'm one of seven children. So, I told them I don't want anybody else to know 
until I deal with this myself. I don't want to tell anyone. So, for a few months I didn't confide 
in the rest of my family. I just kept it within the four of us that were in the room at the time that 
I was diagnosed. I think because I was in a, in a, in a kind of a mindset of denial really you 
know, and I wasn't sure what I would tell people anyway because I didn't fully understand what 
was going through myself. So, for the first few months after I was diagnosed nothing changed, 
I kept on with my responsibilities and I kind of buried my mind in the sand as it was. Like I 
just carried on as if nothing had happened or at least other people around me couldn't notice 
that anything was really going on with me, but then in the evenings I was maybe either in my 
bedroom or wherever when I was on my own and then at that point, I was doing research and 
probably looking at things I shouldn't really have been looking at. You know, unhealthy images 
of MS. I was predominately looking at worst case scenarios and then upsetting myself even 
more. And then dealing with those emotions on my own and suppressing them. So, I kind of 
shut myself off from everyone else. But once I did tell my brothers and the rest of my family. 
Most people were very supportive. I think, they were all afraid of what Lemtrada was and what 
the risks were because I basically told them in preparation for me having treatment because 
things were then going to change in terms of me being able to continue to look after my 
grandmother whilst I was recovering and also being able to baby sit for my brothers because 
they all have children and I also babysit so, uhm I had to kind of say, I won't be able to be 
around the kids for a little while and these are the reasons why and I think they were concerned 
that this is a fairly new medication and maybe the risks with too great and that I should maybe 
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see things out and see how the MS affects me before I do anything drastic. But for the most 
part people were very supportive, uhm I just had to be quite assertive about my choices and I 
had to be confident in the decision that I made in the research that I have done and be able to I 
guess reassure my family that actually my decision was the right one and I was comfortable 
with the risks that were involved. But yeah, for the most part, everyone was supportive.  
Dipesh: You touched upon work as well… 
Alexandra: Yeah. 
Dipesh: How has relapse remitting multiple sclerosis impacted your work? 
Alexandra: Well, how does my work impact on my MS (SHARED LAUGHTER). I think, 
whilst I was going through my diagnosis, I confided in my manager. I'd say fairly late, later on 
in the process I confided in my manager. Uhm, he is brilliant. You know, he's very supportive, 
he would allow me to take hospital appointments on the on-work’s time. And let me go home 
early sometimes if I was feeling particularly low. Particularly because I think he could see that 
I haven't told any of my colleagues and kind of knew what I was going through and I'm the 
type of person that will make up the work anyway, so, uhm, I work, I don't know if, I, I don't 
know if I can say… well I'm a civil servant so as you can imagine high caseloads, high stress. 
We work well over the amount of hours that we are contracted to work so if there were days 
that I was off like I was able to go home early the following day I'd be working you know more 
than the eight- or nine-hour day anyway. I think work can on the one hand be useful because 
whilst I was struggling with the emotional impact of the diagnosis work, work was a necessary 
distraction. It was something to kind of take my mind off of things and also it gives me purpose, 
a sense of purpose. But also, on the other hand, where work is so mentally draining, I felt like 
I was going home, um already quite, already drained. Sorry to use the same word. I was already 
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mentally drained but then I was you know basically screwing myself over again because I'd 
spend hours researching online so my brain had no time to relax no time to shut off. And I was 
just basically running myself into the ground with work and then my own personal research 
and I was exhausted like totally exhausted. Now since I've had the Lemtrada, so I've been quite 
lucky, my GP supported mean having twelve weeks off every time I've had infusions because 
of the nature of the work that I do, I go into prisons as well. So, I'm working with a population 
that are likely to have infections. So, where I have a low immune system, I've been signed off 
for the initial twelve weeks where your immune system is re populating. Although, it won't re 
populate to the full extent, your B-Cells will repopulate a little bit in the twelve weeks. And 
when I returned to work, I mean, it's been, it's been really good. Um, there are measures in 
place to protect me. They can't always guarantee that they'll work the way that they meant to. 
So, to give you an example, my caseload is supposed to be capped at 100%. But there are times 
where I've gone over that because it is a civil service and we're short staffed. But generally, I 
do feel that my manager is somebody that I can approach, and I can say to him that I'm 
struggling, and he will make adjustments for me. When there are times where I'm particularly 
feeling under stress, I notice that I will feel as if I’m vibrating. Uhm, I describe it to people as 
if I feel a bit giddy like, it's, it's like there are, now I can't even really explain it, but like all the 
nerves in my body are kind of excited if that makes sense and then I will feel the pins and 
needles in my left leg. So, I know that I'm under stress and the stress is causing physical, it’s 
manifesting physically. And when I am particularly tired, uhm, I will have some blurred vision 
in my in my right eye in particular. So, what I will do then is I will hopefully if I can stop 
working, take a break. But I can't lie to you, I think in the current job that I am in, I don't think 
it's something that's sustainable for somebody who has a condition that is impacted by stress. 
It's something that I've, I've managed to keep doing but for how long I really can't tell you. 
Because you can shrug off blurred vision or pins and needles in your leg but if my symptoms 
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were to get worse. You can no longer ignore those you know. You have to, you have to at one 
point sit down and say to yourself right, “is this really worth me risking a deterioration in my 
health over a pay-check?” Which is not why I do the job. I do the job because I love the job 
and I love my clients but somebody else could do my job and hopefully that person will be 
better at it because they won't be compromised by something like MS. 
Dipesh: So, when you ask yourself that question about your symptoms and the stress and is it 
worth having a pay-check, it seems as though you know that there's maybe someone else that 
could potentially do your job, but I guess you still go back? You mentioned that you're signed 
off work for a while, but you would go back to work? 
Alexandra: I will, I will be going back to work. Although work don't know this but I'm actually 
in the process of, I’m looking for other jobs. But the trouble is, it's very hard to, I think for 
anyone who, I’ve trained specifically to do my job, so I've got a degree and I've also got a 
graduate diploma, so I'm qualified for the role that I do. And I'm unfortunately not qualified 
for much else. You know that's just the way society works these days, so if I wanted to have 
another graduate job at the same sort of pay, I'd have to retrain. I'd have to go back to university. 
So, I'm kind of in a bit of predicament about what I would do about work. I either accept a pay 
cut and work somewhere else. Hopefully somewhere low stress but then I'd have the added 
stress of maybe financial issues. So, it's, it's a catch twenty-two uhm. I would like to try to do 
my job or something in line with my job for as long as I can. And I think the solution bar me 
retraining and finding something completely different, the solution is me being a stronger 
advocate for myself and having better more defined boundaries and sticking to those 
boundaries and maybe, maybe I don't like to say this but starting grievances if managers don't 
comply with the safeguards are put in place to protect me at work. Because it's all well and 
good the excuse being but we're short staffed, we don't have anybody else to give the work too. 
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But actually, if you carry on giving me the work, I may go off sick and then you'll be down 
another member of staff. So, you need to hopefully put things in place to stop me from doing 
that and knowing that I have MS chances are I’m more likely to go off sick than the next person. 
So, let’s try and work together so that I can be, so I can work the best of my abilities and for as 
long as possible. But that's something that I've struggled to do because I've always been a bit 
of a yes person. I don't like letting my managers down. I don't let him work down, especially 
because I've been a civil servant for so long. It's that kind of mentality. You know you just 
buckle down and get on with things and so I feel guilty, sometimes say, I've got disability, I 
can't do this, or can't do this the way that I used to do it or the way you expect me to do it, but 
I need to stop being so afraid of sticking up for myself at work. 
Dipesh: So, the next question was pertaining to your understanding of DMT's. You mentioned 
that you've done a lot of research… 
Alexandra: Yes. 
Dipesh: So, I wanted to know what you what you thought DMT were designed to do? How do 
you think they would benefit someone with MS? Also, you mentioned that you were adamant 
that you wanted Lemtrada and you had a consultant which was sympathetic towards that. So, 
I guess, I wanted to also know also perhaps why Lemtrada and not another DMT like Tecfidera, 
for example?  
Alexandra: OK, so at the time, this was 2018 when I was looking at treatments for MS. My 
first line of thought was stem cell replacement therapy. Because I, I was, I was really 
catastrophizing at the time and I was thinking quite drastically but obviously that's not given 
under the NHS unless you’ve had Lemtrada and unless I was willing to do a fundraiser my 
parents couldn't afford to pay for me to have stem cell placement therapy unless they were to 
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sell their house and again that would have been extreme measures for anyone to go through or 
go down when you just been diagnosed with MS and you don't even know what the course of, 
or what your disease, what course of your disease will take. So, I was looking at what was the 
next best and it was either Lemtrada, or Ocrevus. Because Ocrevus was just bought out in 2018 
as far as I remember and because Ocrevus was fairly new, I looked at Lemtrada instead. But I 
think even if Ocrevus hadn't been new I would have been, I think I would have been pulled 
more towards Lemtrada because of the it's, it's a stronger drug in the sense that it causes 
permanent damage or a permanent change I should say to your immune system. Now the reason 
why wanted to go so hard hitting, and this might be controversial, I mean, you could, you could 
challenge me. I'm open to being challenged. But as far as I'm concerned, the other DMT's that 
are available on the market, do not really have a significant effect on the progression of MS. 
They may control relapses or so we believe. We believe that they might control relapses 
amounts but in terms of disability outcomes I couldn't see any other DMT having a significant 
impact on disability outcomes. So, what I mean by that is, somebody who doesn't take 
medication, what happens to them when they reach the age of 60 in comparison to somebody 
who does take a beta interferon and then when they when they reach 60 years old, both might 
still be using a walking stick. So, for me, I, if you do kind of a cost benefit analysis, the idea of 
having to inject myself once a week or twice a week and having flu like symptoms because of 
the injections for the next 20 or 30 years of my life and it not really meaning anything in the 
end was a waste of my time and energy. You know, that was how I feel about it. So, I looked 
at Lemtrada because it's something that will cause it definitely causes a permanent change that 
the clinical trials are quite promising at least for about 50% of people. And it's something that 
you, ideally you can do twice and then that’s you forever, hopefully. Uhm, you never have to 
think about having MS again. And I would hope that even though the clinical trials are I think 
only about 10 years on, there is data from trials done in the 90s, so people with MS at that time, 
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there is still evidence of a change their immune system so the lasting impact of Lemtrada is 
something that I was particularly impressed. But I don't know if impressed is the right word 
because there are other lasting changes that Lemtrada can bring about you know negative side 
effects that aren't necessarily something that you want. But I was willing to take the risk. If 
you're going to take any medication, I think one take something that will definitely make a 
difference. Otherwise, there's no point. Yeah, that's it actually. Just, something that will make 
a difference or there's no point. So, for me, it was okay Lemtrada carries a lot of risks but it's 
the only one that can really make a difference other than Ocrevus so it's either that or nothing. 
And you face MS alone. 
Dipesh: Did you say that you took Lemtrada in infusion form? 
Alexandra: Yes. 
Dipesh: And what was your experience of doing that? 
Alexandra: So, in my first year. I only had, so it's five days of infusions and I had steroids for 
3 days, the first three days. First, three days will be easiest because of the steroids that was 
given as well as antihistamines, you given antihistamines and steroids. Aside from having an 
infusion related rash at the time, uhm I felt pretty good. It wasn't until my fourth and fifth day 
where I had the maximum number of steroids that I was entitled to, uhm so I did my fourth and 
fifth day without any steroids. It was those days that I found I felt the roughest and by the fifth 
day, my, my heart rate had actually dropped quite low and I was in and out of consciousness 
I'd say, for the whole day. So, I was closely monitored on the fifth day because of that. Uhm, I 
struggled with the recovery for Lemtrada the first time around in particular. Uhm, I was 
basically, knocked off my feet. This time around, I only had three days of infusions, which is 
typical for Lemtrada. It’s always, after your first round, only ever three days that you do in the 
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follow-up years. Its standard is two years, but if you need a third or fourth or fifth round, you 
can have. So, because it was only three days this year, I had steroids on either day. So, I felt 
really good actually. For the most part I felt quite good. My main difficulties were fatigue and 
some stomach upset so I had some stomach troubles. But generally, it wasn't as bad as my first 
round. The recovery has been difficult. As well, but again probably not as bad maybe because 
I knew what to expect so I was better prepared. Uhm, yeah. 
Dipesh: When you say the recovery was difficult, would you be able to tell me what you mean? 
Alexandra: OK, so in my first year, I'd say, the first week - I was in bed. I could barely get up. 
It felt as if I've been hit by a bus that your whole body is aching. You feel bone pain. But 
through understanding what takes place with Lemtrada, you know it's not something that, it’s 
not a decision you can make lightly. If this is a drug that you want, its intense. It eradicates 
your T and B cells so in order for your body to replace those it will do so from your bone 
marrow, so bone pain is actually fairly common or at least should be expected after you've had 
some kind of chemotherapy like this. Where, it's almost as if I could feel my bone marrow 
getting into work you know. (LAUGHTER) Even my spine like the insides of my bones hurt. 
That's how bad it was. So, I was bed bound for a little while and my lymph nodes was swollen 
on my neck but again, I'm guessing my lymphocytes were dying and whatever was happening 
in my body was happening, in the right place. Uhm, so I was fatigued for about for the twelve 
weeks, I'd say I was suffering with fatigue. So, what that meant for me was, uhm normal day, 
normal day to day activities were harder. I needed to take naps in order to get through a long 
day. I was very sensitive to heat. So, I would have hot flashes like somebody may be 
experiencing menopause might have. My skin would even feel hot to the touch. Uhm, I would 
experience UTI’s more so than the average person. Infections. Like I have diarrhoea often if I 
ate something that was maybe questionable. But for example, you have to be you have to follow 
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a listeria diet, which you have to be very careful. Even fruits and vegetables. Make sure that 
they are thoroughly washed so if I went to somebody's house for dinner, I might eat something 
thinking it would be okay but actually it would give me an upset stomach so, uhm, you have to 
be much more careful about where you eat, where you go. Uhm, I couldn't really be around my 
brother’s children, because again children, they are a hub for bacteria and, uhm, I had to isolate 
myself a lot. At least keep myself kind of away from groups of people so not only you kind of 
experiencing all of these issues, but you're doing it on your own because you can't really mix, 
too much with too many equals. So, over the Christmas period, I guess it was quite hard for 
me. This time around, I've had similar symptoms uhm, but I think an added symptom that I 
never felt before was hoarseness in my voice. I found it; I had some difficulty breathing when 
I had my infusions this time around. And it kind of affected the sound of my voice for about a 
week or so. When I returned home but that's gone now, so. Hopefully it stays gone. 
Dipesh: After you've had the infusions? Because you earlier on mentioned that the treatment 
made you feel like on top of the world, I was wondering if you can tell me a little bit more 
about how you feel after you've had the treatment? 
Alexandra: OK. So, once I had my first round of Lemtrada, once I started to feel a little bit 
better, obviously, it's not going to be easy, I say this to people that are expecting to have the 
treatment. It's not easy at first, but once you start to recover, I felt like, Uhm, I've I started going 
to the gym, which is something that I couldn't really do before. I never did before, and I felt 
like I had a lot more energy. I was walking to work. Walking back from work, which is forty-
five minutes there and forty-five minutes back and still going to the gym. So, I had bounds of 
energy. Uhm, I was at the Duracell rabbit. Now, I don't know, this could be my thyroid, I mean, 
I don't know it could be. I could have an overactive thyroid. Or I could have had an overactive 
thyroid at that time, but that's something that is being measured by the hospital that I am under. 
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But for me, I felt like I had a new lease of life where, uhm, I felt invincible in a way. And these 
are things other people take for granted being able to walk for two hours a day and still go to 
the gym and do a full day’s work and then not feeling like you're dead at the end of the day 
because when I'm coming home at the end of the day, I'm still making myself dinner. Or, 
watching something on TV and not falling asleep in the middle of whatever I am watching. 
Uhm, I was socializing more. So, I noticed that before having treatment, I'll make excuses not 
to go out on the weekends with my friends because I was just too tired to go. I couldn't be 
bothered, I'd say. But really, and truly it is because I was too tired. The thought of going out is 
what I couldn't be bothered about. Uhm, but yeah, I was making more effort to socialize. I had 
the energy to socialize. I had the mental capacity and the mental energy to actually socialize 
with people. So, I think for me Lemtrada has been a godsend. Uhm, but I don't take for granted 
that some people have had serious side effects of the drug and I'm not out of the woods, you 
know. I could potentially develop a serious side effect. So, it's something that I need to be 
mindful of. Uhm, but fingers crossed for me - I'll stay healthy. 
Dipesh: You mentioned Lemtrada has had a really positive impact on yourself holistically, you 
mentioned earlier that you’ve made changes to your diet also. So, you incorporated a ketogenic 
diet, which is elevated in its fats and you've made amendments to your working patterns as 
well. So, I guess I'm wondering how would you be able to know if it was just the Lemtrada or 
other elements that helped?  
Alexandra: Very difficult to say. So, I don't try to, uhm, not to pinpoint at any one thing. Uhm, 
I think all of them combined have made a difference. It's actually. It's a scary thought 
sometimes because I've, I've recently changed my diet again. So, there’s not enough research, 
I think on the impact of diet and MS. There is some. There's definitely some research. Uhm, 
but there's not enough. So, I find that a lot of people with their MS that I've spoken to, are 
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reluctant to make dietary changes because where it's not it's not proven maybe they don't really 
want to muddy the waters or do anything that might actually turn out to be a hindrance 
themselves or irrelevant really in the long run. Whereas for me, it was something that I felt like 
was, just as important as the medication because I don't need a piece of paper or an article to 
tell me that eating organic and eating more fruits and vegetables and eating less processed 
foods is going to be better for my body. It's, I think, not only is the actual behaviour and the 
process of eating better food better for my body, but also the idea of being able to control some 
of the aspects of my health is also good for me mentally. So, it's kind of an allrounder in the 
sense that I felt better in myself physically. But also, better about my choices. I respect myself 
more. Uhm, I've proven to myself that I care about myself enough to make these changes. And 
I'm very disciplined. So, I've learned so much about myself in the past year and a half. Uhm, 
I'm actually proud of the person I've shown I can be and how I've stuck with these changes. 
Sorry I went on the big there. 
Dipesh: No not at all. It is really interesting when you said that you have learned a lot about 
yourself. You touched upon earlier, you mentioned being a bit more boundaried with your time 
and your capabilities at work and also in your private life in terms of looking after your brother's 
children. But I guess, I'm wondering what else have you learnt about yourself? 
Alexandra:  I think that it’s a really good question. I think, before I was most certainly unhappy 
in my life before I realized I had a MS. And I was stuck in a rut in a sense, I was just literally 
going to work and coming home. And I guess expecting some kind of miracle moment where 
things will fall into place. I would meet a partner. We would get married. Have kids and live 
happily ever after you know. Whereas now, my perspective on life has changed that if you 
want something you have to go out and work for things. Stop taking life for granted. But that's 
easier said than done obviously. It’s knowing what do I actually want? And what type of partner 
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do I want in light of my new diagnosis. You know, it has to be somebody who's open minded. 
Somebody who's caring, supportive. Who is going to be able to fathom all of my dietary 
restrictions and the amount of vitamins that I take every morning and the essential oils that 
have burning in the house and this is got to’ be someone that I mean, this person might, not 
necessarily be realistic, but the point is I'm figuring out who I am, what I need, and actually 
taking the action to go out and get it. So, that means being more confident and I've always been 
somebody who can talk the talk but, actually, now, I've tried to put myself in situations where 
I'm not necessarily the most comfortable, but I’m forcing myself to make new connections with 
people. So, I will go to random seminars where I don't know anyone, but just to make friends 
and maybe learn something new. I've started a YouTube channel discussing my MS. I've made 
connections with people online. And I’ve started an Instagram page and everything. So, I think 
for me, I'm still learning who I am. But I think who I am is, someone, I'm proud of her, she's 
on a journey. She's not perfect. Uhm, but she's not so bad. Uhm, I have to stop being so negative 
sometimes. I’m a bit of too much of an inner critic and I'm learning to love myself more. This 
sounds all cheesy but it's very important I think because people with MS particular the people 
I've met online, uhm, they can be quite hard on themselves. Uhm, and they have a negative 
outlook on life, and I think that actually might have an impact on their physical impairments 
because when you've got a negative outlook, you're less likely to want to go out and get out. 
So, you're less likely to exercise and then when that happens and if it happens continuously 
then you're going to have more muscle atrophy and all of these things. So, you need to, there 
has to be an incentive for you to want to get out and that has to be I love myself. I want myself 
out there in the world, exposing myself to other people. I realize that I'm important in spite of 
having MS. Or maybe because I have MS. Uhm, yeah. Sorry (Laughter). 
Dipesh: I'm really glad you shared that because it was part of the next question. I wanted to ask 
you which is more about your experience of not only MS and DMTs, but I guess one of the 
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things I was wondering was, what has been the most challenging thing for you? Or a 
challenging part of the journey, so far? 
Alexandra: Easy question. The uncertainty. Uhm. That and the not knowing and not being able 
to know, you know what, what's going to happen in thirty years. Uhm, so I know that there's 
been times where I've said to my consultant “am I going to be disabled in 25 years?” And he 
would look at me and say, “no of course not.” But nobody can answer those questions for you. 
And where I'm somebody who as I said before, I like to know things. I'm, I'm quite controlling. 
I'd like to understand things and pick at things and analyse things. So, the idea of not knowing 
and struggling with that uncertainty has really taken its toll on my mind at some point and my 
mind will wonder and I'll start to imagine worst case scenarios. But the way that I've kind of, 
stented myself, I’ve got a mantra that I have developed that is tomorrow is an illusion. Uhm, I 
think for me in particular, uhm, and culturally as well, the, the ideal of life is you get married 
and you have children. And you raise those children and you be a good mother and then when 
those children have children, you'll be a good grandmother. And for me, I think about being a 
burden on my children or a burden on my grandchildren so, I have to, I have to bear in mind 
that nothing in life is ever promised. And that there are no guarantees anyway, so even if I 
didn't have MS, I could get into a serious car accident and that might disable me anyway. Uhm, 
or, I might have MS, but I’m hit by bus and I die. You know, I'm very mobile when I die, but 
I die anyway, so, nobody knows what the future will hold. You can have an idea or a fantasy 
about what that might entail but actually you need to live more in the moment, uhm, I think 
that's been the hardest thing for me to kind of understand, is take risks now and stop thinking 
so much about five years’ time, ten years’ time, and live for now.  
Dipesh: Would you say that part of this way of thinking has been due to the benefits of taking 
DMTs? Or where would you attribute this way of thinking from? 
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Alexandra: Uhm, I can't lie. The fact that I've had Lemtrada has definitely given me a sense of 
security because I feel as if I have some armour on you know to protect me from relapses. 
Uhm, and I think if I was taking a less effective DMT. I don't think I feel that way. I only feel 
this way because I'm very sure of the benefits of Lemtrada. So, for sure before I had Lemtrada, 
remember if we go back, I was diagnosed in August. I didn't have Lemtrada until November. 
From August to November, I was almost driving myself insane with the fact, with the idea that 
I was unmedicated. And I was walking around, you know, maybe going to encounter my next, 
relapse and this one was going to be a big one. And I haven't given myself any medication, so 
how is that going to protect myself or prevent anything from happening? So, I think props go 
to people who are diagnosed with MS and they are comfortable going ahead without any 
medication and just taking life as it comes. They are so secure in mindset you know, but I'm 
not secure enough to do that. So, for me as I've said Lemtrada kind of it's like I'm wearing my 
armour and then all the other additional things that I do to hopefully protect myself long term.  
Dipesh: And when you mention the additional things you mean like the diet and things like 
that? 
Alexandra: Yes.  
Dipesh: I don't know if you're aware, a couple of months ago, I think it was in November, the 
NICE guidelines published a paper talking about the effectiveness of taking CDB oil for 
spasticity in multiple sclerosis. So, I was wondering what your thoughts were about taking 
additional forms of treatment to enhance recovery and your journey with MS? 
Alexandra: I would be open to it, I've looked at the impact of it. Part of my research... 
(participant receives a telephone call). 
Alexandra: Sorry. 
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Dipesh: You were saying about CDB. 
Alexandra: Yes, I'm so I looked into that as well. Uhm, I see the benefits. I, also, I don't do it 
regularly, but I have smoked cannabis when I've felt particularly, uhm, there was one moment 
that I recall it was between August and November 2018, when I was waiting for treatment and 
I hadn't told anyone at work what was going on yet and I was really under a lot of stress and I 
felt like my whole body was physically shaking from the vibrations. Internal vibrations. And a 
friend of mine smoke’s cannabis, so I rang her up and I asked her if I could go to her house. I 
took a little bit with me, brought it home. Rolled it. Smoked it. And the effect was almost 
immediate in terms of calming my nerves and I was pretty much symptom free for the moment 
I was under the influence of cannabis. For me personally, it's something that I can enjoy 
socially. Uhm, but I would struggle with it being something that I take on a daily basis. Maybe 
in the mornings because I don't know how I would function at work if it caused, if these are 
CDB oils without the THC element, then I can, I would be happy to take something like that 
on a daily basis because that wouldn't cause the, I don't know what to call it, the high effect. 
But then at the same time, I also have my own opinions. Based on research that I've read on 
the effectiveness of CDB oil without the THC element. So, I don't know if I would take the 
CDB unless I knew that without the THC it would still be having a positive impact on me 
because I think the THC also has a part to play in that I don't know if you know, but there is 
somebody, he's a celebrity called Montel Williams and he is a talk show host in America. He 
has MS. He's in his 60s and he still walking and talking is very mobile and he credits most of 
his good health to cannabis and this is when I first came across the whole cannabis and MS, 
uhm, relationship. And he's actually brought out his own cannabis products in America. So, I 
think in America it is something that they've been they've kind of known for a long time and 
people have been self-medicating with cannabis is fairly new over here in the UK. Well, it's 
not actually people don't medicate with cannabis officially in the UK, but you can go to Holland 
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and Barret and buy CDB. But it's not high-quality CDB. So, the types you'll get in America is 
going to be much better, but I've never used those so I, I can't say what they like.   
Dipesh: Final question. What would you say to an individual with relapsing-remitting multiple-
sclerosis who is about to commence DMT? 
Alexandra: I would say, uhm, don't listen to your consultant. Uhm, in the sense that do your 
own research be your own advocate because if I hadn't had known what DMT I wanted and 
was sure of my choice, I don't know if it would have been offered to me as the first port of call. 
Maybe I would have been offered one of the ABC's, which is what I hear a lot of my MS 
counterparts are offered as first line therapies, which is all well and good. I see, I see the 
argument for being offered, uhm, like less dangerous DMT's. But, as I've told you before, I 
don't see the long-term benefits of taking those medications so for me, it's a waste of time. So, 
I would probably be a bit of a pessimist I'd say to somebody who's just been diagnosed. I would 
say look at the most more intensive drugs and consider those if you can't consider those side 
effects, I won't even bother looking at the other DMTs. But if you need to take another DMT, 
then I would do so in conjunction with lifestyle changes, including you know regular exercise, 
dietary changes, you know, I don't necessarily want to recommend that they become vegan 
because that's a personal choice of mine but cut out processed foods make sure your plates, 
you know are full of more vegetables and try and choose organic if you can. Take vitamin-D 
because that itself has been proven to have a significant effect on relapse rates so that is 
something that doesn't have a negative impact on the body. There are no serious side effects 
from taking vitamin D past 60,000 units per day so if you can take 10,000 units, 20,000 units 
do so. And other vitamins that you might need. Meditate or pray or whatever it is that you can 
set yourself daily. You know trying to reduce stress from your life and all of those elements 
combined should hopefully help you because I think, I don't want to, sorry, I know this isn't 
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the purpose of your research, but I don't want to be the type of person advocates only DMT's. 
I think, medicine isn't going to help you if you can't rid yourself with the root cause of the 
problem and the root cause for a lot of people with MS could be bad lifestyle and stress, so you 
need to kind of help people in all parts of their life for positive outcomes. 
Dipesh: Correct me if I'm wrong, but I guess, it sounds as though when you see the consultant, 
they see you as someone with MS and then they are saying “okay, let's give you a DMT which 
can solve the MS.” But what you are doing is going away looking at yourself holistically and 
thinking can I make changes to my diet, maybe pray more, maybe put oils on around the house, 
and then you're doing your research. But it seems that you're not perhaps getting that kind of 
advice or not having those discussions with your consultant. Would that be fair to say?  
Alexandra: That is fair to say. My consultant, so I remember when my first consultant I had as 
my case was being transferred from my original hospital to my MS Hospital, he had told me 
that 10,000 units of vitamin-D a day was dangerous. And then I showed him the paper that said 
that it wasn't and there were some trainees in the room with him, some students at the time who 
were all nodding in agreement with me because they had also seen that paper. So, if I had 
trusted his word at that time, it would have been false information or it wouldn’t have been, I 
wouldn’t say false, because he obviously read a paper, at some point in his life, but I'm saying 
he didn't have the up-to-date relevant information. And then with my new consultant who I get 
on greatly with like his brilliant is very open minded. However, I think there is uhm, I think 
most consultants, this is an assumption of mine, I think most are reluctant to advise on diet 
because there isn't enough evidence, so they don't want to necessarily recommend something 
or put their name on something. So, most have recommended to me, that I have spoken to a 
Mediterranean diet. Now Mediterranean diet can mean a lot of things, it's very vague. But 
generally, when I've spoken to my consultant about my diet, he is very supportive. He doesn't 
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dismiss the lifestyle changes that I've made and actually commends me at times to say, “you 
know, I can see that you're doing really well, you've lost weight, you look healthy, you know, 
you don't look like a patient of mine.” But, generally, consultants, I don't think are given the 
autonomy or the authority to advise on these issues. Uhm, which is a shame because MS 
Management isn't simply medication It's a number of things. 
Dipesh: OK. Thank You for agreeing to take part in the interview, before we end is there 
anything else, you'd like to add, or anything that you may feel it's important? 
Alexandra: Just quickly I just wanted to say that I think there's a lot of disparity across the UK 
in terms of like if I compare my experience in a very well established hospital in London to 
people that I've met online in, in hospitals outside of London, not everybody is offered the 
same type of treatment or the same service and I think that's quite disheartening because again 
I'm in a cohort people that's very fortunate surely because of my geography and where I live 
and so I think what, what might, what, what might be important is if you look at DMT rates 
across the UK and seeing, sorry and then seeing where the DMTs are taken up more frequently 
and maybe not so frequently and thinking about why that might be and is that because of the 
quality of care or maybe the lack of information? I mean, I don't know.  
Dipesh: Ok. So maybe from your experience of speaking to other people with MS, there's like 
a disparity between the treatment people are getting perhaps in London, for example, to up 
North.  
Alexandra: I know for certain that and the local hospital to where I live doesn't actually, it's 
not, set up to deliver Lemtrada. So, if you wanted to have Lemtrada, if you were a patient at 
the hospital, your case would need to be transferred to another hospital and to another 
consultant. So, some people are reluctant to change hospitals because they built up good 
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relationships with their consultants and they don't want to leave. People don't like change. 
People don't like having to go into central London if they live on the outskirts of London. So, 
making services, maybe more uniform as well across hospitals. Yeah, that's my two pence 
(Laughter) I won’t say anymore.  
Dipesh: Thank You. Anything else? 
Alexandra: No Thank You. 
Dipesh: Thank You. 
Alexandra: Thank You. 
 
